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ABSTRACT 
 
Transient expression is fast becoming a widely used platform for the rapid expression 
of pharmaceutical proteins in plants. In order to fully exploit the high-level expression 
achieved from the Cowpea Mosaic Virus-based HyperTrans (CPMV-HT) transient 
expression system, the pEAQ vector series was developed. These vectors allow for easy 
and quick direct restriction cloning or high-throughput Gateway cloning into the CPMV-
HT system. They are tailored for high-level transient expression through incorporation of a 
suppressor of gene silencing and gene of interest on the same T-DNA. Furthermore, the T-
DNA region can accommodate multiple expression cassettes to ensure same-cell 
coexpression of multiple proteins. The pEAQ vectors are now a widely used toolbox for 
plant transient expression.  
The pEAQ vectors have been used for the expression and assembly of virus-like 
particles (VLPs) of Hepatitis B core (HBcAg) and Bluetongue virus (BTV) in plants. The 
widely used epitope carrier HBcAg can be efficiently expressed using this system. The use 
of dimeric, tandem HBcAg (tHBcAg) constructs alleviates the steric constraints usually 
encountered upon display of large foreign polypeptides on the outer surface of HBcAg. 
Assembled tHBcAg particles displaying functional green fluorescent protein have been 
produced and purified to enable structural analysis. The expression of tHBcAg constructs 
for the display of two different, medically relevant polypeptides has also been achieved. 
Efficient, high-level expression and assembly of the four main structural proteins of 
BTV using the pEAQ vectors has allowed for purification of high-quality VLP preparations 
for use in immunogenicity studies. Relative protein expression levels were modulated by 
codon optimization or selective use of the HT leader sequence. The heteromultimeric BTV 
VLP represents the most complex VLP to have been expressed in plants to date. This 
technology has also been used to produce Bluetongue VLPs encapsidating different 
fluorescent proteins – a useful tool for the study of BTV infection. 
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1 GENERAL INTRODUCTION 
A virus-like particle (VLP) is a scaffold which resembles its parent virus in structure and 
antigenicity, while lacking the viral genome. VLPs are often able to invade host cells and 
are recognized by the immune system, however the lack of a functional genome renders 
them unable to replicate and cause infection. Such particles have recently found 
commercial application as inherently safe and efficacious vaccines, and are being 
developed for a wide range of applications ranging from basic research of viral life cycle 
and structure, to their use as bionanoparticles in targeted drug delivery. However, the 
high cost of producing VLPs in cell culture systems presents a major hurdle in the 
economical use of VLP technology. 
The topic of this thesis is the production of VLPs using the plant-based Cowpea Mosaic 
Virus (CPMV) expression system. In particular, tandem Hepatitis B and Bluetongue Virus 
particles have been produced using a tailor-made vector system for easy and quick 
transient expression of multiple proteins in Nicotiana benthamiana leaves.  
In this section, a general introduction to VLPs, plant-based expression systems, and the 
CPMV system in particular will be provided. For ease of reference, the background 
information specifically associated with vector development, Hepatitis B and Bluetongue 
Virus will be provided at the beginning of Chapters 3, 4 and 5, respectively.  
 
1.1 VIRUS-LIKE PARTICLES 
1.1.1 VIRAL VACCINES: COMPARISON OF EXISTING TECHNOLOGIES 
In 1797, Edward Jenner used material from a fresh cowpox lesion to inoculate a small 
boy, who then proved to be fully protected from later infection by the more severe 
disease, smallpox (Riedel, 2005). This was the first example of the use of a mild virus to 
induce protective immunity against a deadly virus, a process which Jenner termed 
“vaccination.” Until its worldwide eradication in 1988, smallpox vaccines were still based 
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on Jenner’s principle and used another Orthopoxvirus (Vaccinia Virus) to induce protective 
immunity against the disease agent Variola Virus (Fenner, 1988).  
Live vaccines, modelled on this early smallpox vaccine, are still used widely. As the 
name suggests, such vaccines are based on live virus strains which are known to cause 
only a mild form of the disease, such as closely related but less virulent viruses (live, 
heterologous vaccines) or attenuated strains of the disease causing virus. These 
attenuated viruses are prepared by serial passage of the virus in cell culture, and the 
molecular basis for attenuation is often poorly understood (WHO, 2010a). When 
inoculated into the host during vaccination, the attenuated virus is limited in its 
pathogenicity but still able to replicate. The immune system is stimulated as though this 
was a natural infection, but the reduced virulence of the vaccine strain allows the body to 
easily overcome the disease. Live attenuated vaccines can be extremely effective, often 
requiring only a single dose to achieve protective immunity, and stimulating both cell-
mediated and humoral immune responses. However, there is a high risk of adverse effects 
owing to underattenuation, reversion to a more severe form (Martin et al., 2004; Minor et 
al., 1986), as well as unexpectedly severe responses in some immunocompromised 
individuals.  
Non-replicating virus vaccines, such as inactivated (killed) virus and subunit vaccines, 
are potentially safer, albeit less effective than live-attenuated vaccines. The safety of these 
vaccines lies in their inability to replicate, due to a lack or disruption of the viral genome. 
However, the full complement of viral antigens is often not in the correct conformation, 
damaged, or not present, thus affecting the immunogenicity of these vaccines. 
Inactivated virus vaccines are prepared by growing live virus in cell culture or egg 
systems, followed by inactivation to render the virus unable to replicate. This inactivation 
can be achieved by the use of UV irradiation, heat, or more commonly through the use of 
chemicals such as binary ethylenimine (Bahnemann, 1976; Dr. Mercedes Mourino, Fort 
Dodge Animal Health, personal communication). Each batch must be thoroughly tested 
for complete inactivation to ensure safety, but treatments must be mild enough to retain 
the immunogenicity of the vaccine. Effective immunity is achieved through a series of 
booster immunizations. A comparison of the discussed vaccine types is provided in Table 
1.1. 
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Table 1.1: Comparison of virus vaccine technologies. 
Characteristics Live-attenuated Inactivated Subunit Virus-like particle 
     
Able to replicate yes no no no 
Native virus structure yes yes no yes 
Contains viral genome yes yes no no 
Efficacy high medium low medium 
Doses required one multiple multiple multiple 
Amount required low medium high medium 
Batch safety testing 
required 
yes yes no no 
Risks 
Underattenuation, reversion, 
opportunistic pathogens 
Incomplete inactivation; batch 
variability, opportunistic 
pathogens 
Protease degradation, stability stability 
Commercial examples 
Oral Polio Vaccine – 
attenuated by serial passage 
in non-human cell lines1 
Inactivated Polio Vaccine (IPV) 
– formaldehyde inactivated2 
Recombivax (Merck) – 
Hepatitis B surface antigen 
from yeast 
Gardasil3 (Merck), Cervarix4 
(GlaxoSmithKline) – Human 
Papillomavirus L1 VLPs from 
yeast / insect cells 
1(WHO, 2010b); 2 (Venters et al., 2004); 3(Monie et al., 2007); 4(Monie et al., 2008) 
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Subunit vaccines can provide an inherently safe alternative to the traditional vaccines 
discussed above. As the name suggests, these vaccines consist of only a small portion of 
the virus, often the main immunogenicity determinant. As such, these vaccines are non-
replicative and cannot cause disease. Recombinant subunit vaccines are viral proteins, 
glycoproteins, or portions thereof, which are expressed to high level in heterologous 
protein expression systems, such as yeast, insect cells or bacteria. The safety of these 
vaccines comes at the cost of efficacy as well as the speed and price of production.  
Virus-like particles can have the efficacy of an inactivated vaccine with the safety of a 
subunit vaccine (Roy and Noad, 2008). As explained above, VLPs consist of the main 
structural components of a virus, but lack the viral genome. These particles resemble the 
parent virus in size and structure, and present the viral epitopes in the correct 
conformation, allowing them to be recognized by the immune system which raises an 
effective response. However, the empty particles are not able to replicate and therefore 
cannot cause disease. VLPs of a diverse range of viruses have been produced in a range of 
expression systems for use as vaccines. Chimaeric VLP vaccines have been developed 
which allow the display of many copies of a foreign epitope on their surface. These will be 
discussed in greater detail in the next section. 
In addition to the proven vaccine technologies discussed above, some other 
experimental vaccine strategies have recently emerged. It is possible to induce an 
immune response against a viral pathogen by injecting cells with plasmid DNA containing 
the gene of a viral protein, which is expressed by the cellular machinery (Raz et al., 1994; 
Wolff et al., 1990). Portions of the expressed protein are then presentated by the major 
histocompatibilty complex on the surface of the host cell, a process which also occurs 
upon phagocytosis or internalization of traditional vaccines (reviewed by Gurunathan et 
al., 2000). Research efforts have focussed on the development of novel vectors for the 
targeted delivery of DNA vaccines to cells. It has been shown that particles in the range of 
40 nm in diameter provide the optimal size for uptake and delivery of DNA vaccines 
(Minigo et al., 2007). In addition to delivery by way of biodegradable nanoparticles, 
heterologous viruses have also been used as carriers of DNA vaccines (Sutter and Moss, 
1992; Sutter et al., 1994; Xiang et al., 2010). 
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1.1.2 VLP EXPRESSION: THE STORY SO FAR 
A wide variety of different viruses have been used as templates for the production of 
VLPs: animal and plant viruses, rod-shaped and icosahedral viruses, enveloped and non-
enveloped viruses. Viruses have small genomes which are encapsidated by tightly 
packed, symmetric protein shells of defined three-dimensional shape and size. These viral 
capsids often consist of only one (as in the case of Hepatitis B cores) or few structural 
proteins which assemble in a regular array, thereby forming a stable particle. In the case 
of enveloped viruses, the capsids become encased in host cell membrane by budding, 
and display other viral and host proteins on the outside. The assembly of structural 
proteins into VLPs is often not dependent on the presence of the viral genome or other 
elements of the virus. In fact, some VLPs even assemble in vitro (Morikawa et al., 1999; 
Rose et al., 1993). While VLPs of animal viruses can be used as vaccines in their own right 
(discussed here), plant virus-like particles can function as vaccines when foreign epitopes 
are displayed on their surface, and have found wide use in bionanotechnology (discussed 
in the next two sections). 
Virus-like particles have been expressed in all commonly used heterologous protein 
expression systems. Early recombinant VLPs were expressed in prokaryotic systems (E.coli; 
Cohen and Richmond, 1982) and cell-free systems have also been successfully used 
(Bundy et al., 2008). However, eukaryotic systems have been most commonly utilized in 
the production of VLPs. Yeast (S.cerevisiae) has been employed to produce enveloped 
VLPs of Hepatitis B surface antigen (Valenzuela et al., 1982). Insect cells, particularly with 
the use of baculovirus expression vectors, have been adopted as the most widely used 
VLP production platform, with examples ranging from complex triple-shelled Rotavirus-
like particles to enveloped Simian Immunodeficiency Virus particles (Crawford et al., 1994; 
Delchambre et al., 1989; Roy and Noad, 2008). Yeast and insect cells are currently used in 
the production of the first commercially available VLP vaccines (Merck’s Gardasil and 
GlaxoSmithKline’s Cervarix), which consists of the major structural component of Human 
Papillomavirus (HPV). Virus-like particles have also been successfully expressed in 
mammalian cell lines, such as Chinese Hamster Ovary (CHO) cells (Hobman et al., 1994), 
and in plants (reviewed by Santi et al., 2006). The benefits and drawbacks of the most 
important current VLP production platforms are summarized in Table 1.2. Examples of 
VLPs expressed in plants are provided in Table 1.3.  
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Table 1.2: Comparison of the most commonly used (VLP) expression systems. 
 Prokaryotic Eukaryotic 
 Bacteria Yeast Insect cell Plants (transient) 
     
Representative 
species 
Escherichia coli Pichia pastoris Spodoptera frugiperda 
Nicotiana 
benthamiana 
Growth Fermentation Fermentation Cell culture Glasshouse 
Speed of 
development 
Fast Slow Slow Fast 
Yielda High High Medium Medium 
Protein folding + ++ +++ +++ 
Mammalian 
Glycosylation b 
- + ++ ++ 
Disulfide bonds no yes yes Yes 
Advantages 
Low cost, fast and 
easy development, 
continuous batch 
fermentation 
Eukaryotic 
processing, 
Relatively low cost, 
continuous batch 
fermentation 
Near mammalian 
processing, easy 
development of 
baculoviruses 
Post-translational 
processing, speed 
of development, 
low cost scalability 
Disadvantages 
Lack of processing, 
poor folding, 
insolubility 
Selection of high 
expressing strains 
Continuous 
fermentation not 
possible; high cost 
Continuous 
production not 
possible, 
downstream 
processing 
Information presented here was largely gathered from a review by Yin et al (2007). 
a) Yield is highly protein dependent, and some proteins may be more compatible with specific expression 
systems 
b) Mammalian glycosylation is more important in antibody production than VLP production. Efforts to alter 
expression systems to allow for mammalian glycosylation are ongoing for all mentioned eukaryotic systems  
 
Many of the VLPs produced to date have been shown to be effective immunogens 
(reviewed by Roy and Noad, 2008). Not only have VLPs been shown to protect against the 
viral pathogen from which they are derived, some have been shown to offer cross-
protection against other related strains and serotypes, as in the case of influenza VLPs 
(Quan et al., 2007). In some cases it is possible to produce chimaeric VLPs, which are 
comprised of the structural proteins of different serotypes. For example, it has been 
shown that the core proteins of many Reoviridae are sufficiently structurally conserved to 
allow assembly of the outer shell structural proteins of other serotypes to produce 
chimaeric VLPs (Kim et al., 2002; Loudon et al., 1991). Additionally, the stable structure of 
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VLPs makes some of them amenable to insertion of foreign antigens for display on the 
particle’s surface. Epitope display is further discussed in the following section.  
 
Table 1.3: Examples of plant-produced virus-like particles  
Virus Proteins Shape Envelope Reference 
     
Influenza 1 Vesicular Yes (D'Aoust et al., 2010; D'Aoust et al., 2008) 
Hepatitis B (HBcAg) 1 Icosahedral No (Mechtcheriakova et al., 2006) 
Norwalk Virus 1 Icosahedral No (Mason et al., 1996) 
Hepatitis B (HBsAg) 1 Vesicular Yes (Mason et al., 1992) 
Rotavirus 2 Icosahedral No (Saldaña et al., 2006) 
Human Papillomavirus 1 Icosahedral No (Warzecha et al., 2003) 
 
 
1.1.3 EPITOPE DISPLAY 
In 1987, it was reported that the immunogenicity of a 19 amino acid (aa) peptide of 
Foot and Mouth Disease Virus (FMDV) was enhanced 500-fold by fusion of the peptide to 
Hepatitis core antigen (HBcAg; Clarke et al.). Today, it is generally accepted that the 
display of an epitope on a large carrier moiety such as a VLP increases its immunogenicity. 
This is due to the high density of foreign epitopes displayed on a compact structure, and 
may also be due to a more native conformation of the epitope (Brown et al., 1991). 
Though HBcAg remains one of the most commonly used carriers for epitope display (see 
section 4.1.3), many other VLPs have been developed for this purpose (see Table 1.3).  
Attempts have been made to create chimaeric virus particles which display foreign 
epitopes while retaining their ability to infect and replicate in their native host. An early 
example of this strategy was the replacement of an antigenic site of Poliovirus type 1 with 
a similar site from type 3, thereby producing a chimaeric particle (Burke et al., 1988). It was 
soon recognized that this strategy could be used to insert sequences of entirely unrelated 
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pathogens, such as Human Immunodeficiency Virus (HIV), to raise neutralizing antibodies 
against the foreign pathogen (Evans et al., 1989).  
Another notable example of replicating chimaeric virus particles is the use of the plant 
virus CPMV to display epitopes of FMDV and other antigens in the βB -βC loop of its small 
coat protein (Porta et al., 1994; Usha et al., 1993). These immunogenic particles were 
shown to be able to infect cowpea plants and accumulate to a high titre, thereby 
theoretically allowing easy scale up of production. However, it was found that some 
insertions were lost after several rounds of passage (Taylor et al., 1999). Also, the size of 
the insert was limited to 30 amino acids with larger inserts limiting virus spread and 
increasing the likelihood of deletions (Porta et al., 2003). Today, with the advent of more 
efficient expression systems (e.g. CPMV-HT, as discussed in section 1.3.) there is no longer 
a need to produce viable virus, thus allowing the development of empty CPMV-like 
particles (Sainsbury and Lomonossoff, 2008; Saunders et al., 2009). Such VLPs tolerate the 
display of much larger epitopes and even whole functional proteins (Drs. Keith Saunders 
and Paolo Lenzi, personal communication).  
In addition to the display of foreign epitopes on the outside of VLPs, immune 
responses have been raised to heterologous antigens displayed on the inside of VLPs or 
on other non-structural viral proteins. The large size of the internal cavity of Reoviridae 
particles is amenable to the encapsidation of foreign peptides and proteins as large as 
GFP, some of which have been shown to elicit an immune response (Charpilienne et al., 
2001; Kar et al., 2005; Tanaka et al., 1995). The non-structural protein NS1 of Bluetongue 
Virus (BTV) forms stable tubular structures in infected cells. NS1 fusion proteins have been 
shown to assemble into long tubules displaying the epitope, and these particles are 
efficient immunogens (Ghosh et al., 2002b; Mikhailov et al., 1996).  
The fusion of foreign peptides to VLPs is not restricted to applications in vaccine 
development. For example, the display of half of a heteromeric coiled-coil protein on the 
inside of Cowpea Chlorotic Mottle Virus allows for the controlled assembly of VLPs with 
non-covalently linked cargo molecules on the inside of the particles (Minten et al., 2009). 
Also, cell attachment motifs displayed on the surface of VLPs allows the particles to be 
targeted to specific cells or tissues. Both of these examples of peptide display can be 
particularly useful in bionanotechnological and medical applications, as discussed below.  
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1.1.4 BIONANOTECHNOLOGY 
In the past decade, viruses and in particular VLPs have found increasing use in the 
rapidly expanding field of bionanotechnology. Recent developments in this field have 
been reviewed by Soto and Ratna (2010). As previously mentioned, VLPs are being 
developed as carriers for the targeted delivery of drugs to specific organ types. VLPs can 
be loaded with molecules either by in vitro particle assembly in the presence of the 
substance, or by diffusion of the material through the pores of the particle (Comellas-
Aragonès et al., 2007; Douglas and Young, 1998). The outside of the particle can then be 
decorated genetically through fusion of targeting motifs, or by chemical modification to 
display antibody fragments (Frolova et al., 2010; Soto et al., 2008).  
Some other bionanotechnological applications of VLPs include: (1) their use as 
scaffolds for the production of metallic particles and nanowires for use as nano-scale 
conductors in electronics (Lee et al., 2006; Radloff et al., 2005); (2) their use as cages for 
the production of metallic nanoparticles of defined size, giving them special spectral 
properties (Aljabali et al., 2010; Mr. Alaa Aljabali, personal communication); (3) their 
coupling to solid surfaces for use as sensors (Steinmetz et al., 2006); (4) their coupling to 
fluorescent proteins, dyes and quantum dots for amplification of assay signals or live cell 
imaging (Brunel et al., 2010; Steinmetz, 2010). However, these applications are beyond 
the scope of the work described in this thesis.  
 
1.2 MOLECULAR FARMING: PLANT-BASED EXPRESSION SYSTEMS 
“Molecular farming” is a collective term for the production of commercially relevant 
protein products in plants and animals. In stark contrast to cell culture systems, the use of 
farm animals and crop plants potentially allows some common farming practices and 
infrastructure to be employed, thereby giving these systems a feasible advantage in 
terms of production costs. Being eukaryotic, both animal and plant cells are capable of 
folding and post-translational modification of complex protein products, providing an 
advantage over prokaryotic expression systems.  
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Research efforts in animal molecular farming have focussed mainly on the expression 
of foreign proteins in mammary glands for secretion within milk (Houdebine, 2000; 
Simons et al., 1987). Some of the many proteins produced in this way include virus-
neutralizing antibodies (Castilla et al., 1998), spider silk protein (Xu et al., 2007), and 
human fibrinogen, which is a complex of three different proteins (Prunkard et al., 1996). 
The major technical drawbacks of animal molecular farming as a production system 
include the time and effort involved in the generation of the transgenic animals, as well as 
the risk of contamination with opportunistic pathogens and prions (reviewed by 
Houdebine, 2000). A lack of public acceptance due to ethical objections also presents a 
major hurdle.  
Plant molecular farming became a reality in 1989 with the first production of 
recombinant antibody in transgenic tobacco (Hiatt et al., 1989). In the past 20 years, the 
field has developed rapidly, with ever more researchers and companies adopting the 
technology. To date, antibodies have been the pharmaceutical most commonly produced 
using plant-based systems (Ma et al., 1995), but a host of other products have been 
expressed, including human serum albumin (Sijmons et al., 1990), biodegradable plastics 
(Nawrath et al., 1994) and subunit vaccines, many of which are based on VLPs (see Table 
1.3).  
In this section, I will introduce the technological developments in the field of plant-
based pharmaceutical production, with a special emphasis on the technologies used in 
this body of work. Additional plant-based pharmaceutical production platforms including 
those based on moss (Decker and Reski, 2007), algae (Griesbeck et al., 2006), plant cell 
culture (Doran, 2000), root secretion systems (Sivakumar, 2006) and transplastomic plants 
(Daniell, 2006) will not be discussed further in this thesis. 
 
1.2.1 STABLE INTEGRATION 
The first plant-made pharmaceuticals were produced by stable integration of a 
constitutively expressed transgene into the genomes of tobacco and potato (Hiatt et al., 
1989; Sijmons et al., 1990). Individual plant cells can be transformed with a construct 
consisting of an expression cassette for a heterologous gene of interest (GOI) as well as a 
selectable marker gene (Bevan et al., 1983). By sequential growth on hormone-containing 
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selection media, calli can be grown from the transformed cells, followed by rooting and 
regeneration of whole transgenic plants.  
Though many other techniques exist, transgene integration is today most commonly 
achieved through Agrobacterium tumefaciens-mediated transformation (Rao et al., 2009). 
The crown-gall disease-causing elements of the bacterial tumour-inducing (Ti) plasmids 
have been removed, and key virulence genes transferred to another plasmid (Hoekema et 
al., 1983). This has enabled the development of relatively small binary vectors which are 
compatible with Agrobacterium-mediated T-DNA transfer (Bevan, 1984). These binary 
vectors can be propagated in E. coli and A. tumefaciens, and allow for easy integration of a 
GOI into a multiple-cloning site within the T-DNA left and right borders (A more detailed 
introduction to binary vectors is found in section 3.1). By cloning the GOI within the 
context of a subcellular localization signal or a tissue-specific promoter or an inducible 
promoter, the expression of foreign proteins can be targeted both spatially and 
temporally in transformed plants (Cramer et al., 1999; El Amrani et al., 2004; Moore et al., 
2006).  
Stable integration is still used for the production of pharmaceutical proteins today and 
offers key advantages such as easy scale-up through sowing of seed, and may well 
present fewer regulatory approval hurdles due to the existing regulatory framework for 
GM crops (Gilbert, 2009; Spök et al., 2008). However, the slow and cumbersome 
regeneration of homozygous, high-expressing lines, as well as the generally low yield of 
recombinant protein, and problems with silencing or loss of the transgene have been the 
main reasons for the fast adoption of transient expression technology (Rybicki, 2010).  
 
1.2.2 TRANSIENT EXPRESSION 
In 1989, the expression of a ß-D-Glucoronidase (GUS) reporter using Agrobacterium-
mediated transformation was investigated with the finding that transient expression of 
the gene occurred with 1000-fold higher frequency than stable integration (Janssen and 
Gardner, 1989). This led to the first use of agro-infiltration technology for the transient 
expression of foreign genes in leaf tissue (Kapila et al., 1997; Vaquero et al., 1999).  
Manual syringe agro-infiltration is a simple and low-tech method to achieve transient 
expression in leaf tissue, which was previously achieved by particle bombardment (Klein 
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et al., 1987) and microinjection methods (Neuhaus and Spangenberg, 1990). After 
growing an A. tumefaciens culture to a high density in liquid culture, the cells are pelleted 
and resuspended in a buffered infiltration solution. This bacterial suspension is then 
injected into the intercellular spaces of the leaf tissue by way of a blunt-ended syringe 
sealed around a small wound in the leaf surface. The suspension efficiently floods around 
all leaf cells, allowing the bacteria to attach and transfer the transgene-containing T-DNA 
into the plant cells. The morphology of Nicotiana benthamiana leaves makes them 
particularly easy to infiltrate in this way. By inducing the Agrobacteria within the 
infiltration solution with acetosyringone, a natural plant hormone released during wound 
response, T-DNA transfer efficiency can be further boosted to attain expression in nearly 
100% of the leaf tissue (Sheikholeslam and Weeks, 1987).  
Transient expression by way of agro-infiltration is an easy method to test the efficiency 
of a construct of interest in a laboratory setting. As with stable integration, subcellular 
targeting signals can be used to localize heterologous protein to the ER, chloroplast, 
vacuole, periplasmic space, etc. Good expression levels can usually be achieved in seven 
days or less thereby allowing for fast evaluation of a new construct (Marillonnet et al., 
2004; Sainsbury et al., 2009). The superior yields achieved with transient expression, and 
the speed with which expression can be obtained, have made it a commercially viable 
alternative to transgenic plants (Rybicki, 2010).  
For scale-up of transient expression systems, it has been necessary to find an 
alternative to manual injection of infiltration solution into each leaf. Vacuum infiltration 
allows whole plants to be infiltrated in several seconds (Kapila et al., 1997). The aerial 
parts of the plant are submerged in the Agrobacterium solution and negative pressure 
applied. Thereby, the air which naturally fills the intercellular spaces seeps out of the 
leaves and is replaced by the surrounding bacterial solution. For commercial applications, 
vacuum systems have been fully automated to further reduce the cost of production of 
pharmaceutical proteins using transient expression.  
 
1.2.3 GENE SILENCING SUPPRESSION 
During the development of transgenic plants, it was often found that expression levels 
could suddenly drop despite the continued presence of the transgene (Flavell, 1994). In 
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addition to the known problems of transgene loss or movement through recombination, 
post-transcriptional gene silencing (PTGS) was identified as a plant defence mechanism 
against pathogens which can greatly reduce the expression levels of heterologous genes 
by way of targeted cleavage of a transcript or changes in chromatin structure 
(Baulcombe, 2004; Matzke et al., 2009). Plant gene silencing has been reviewed in the 
aforementioned publications and will not be discussed further here. 
Many plant viruses encode proteins which act as suppressors of gene silencing, 
thereby allowing the virus to overcome the host’s defence system of PTGS (Ratcliff et al., 
1997; Voinnet et al., 1999). These have been harnessed in the field of plant biotechnology 
to suppress the silencing of heterologous genes, thereby greatly increasing the 
expression levels of proteins of interest. The silencing suppressor used throughout this 
project is P19 of Tomato Bushy Stunt Virus. Upon infection, the viral genome along with 
any transgenes serves as a template for RNA-dependent RNA polymerase (RdRp), 
producing double-stranded RNA (dsRNA). This dsRNA is cleaved into small dsRNA 
fragments by a dicer-like protein. P19 has been shown to suppress silencing by binding to 
these 21 and 25 nucleotide dsRNA fragments, thereby blocking their recruitment by the 
silencing machinery (Silhavy et al., 2002). Without bound small interfering RNA, the RNA-
induced silencing complex cannot be directed to specifically cleave viral transcripts, 
allowing the virus to overcome this host defence mechanism. In the case of transient 
transgene expression, co-expression of P19 can boost GOI expression levels at least 50-
fold (Voinnet et al., 2003). This is often achieved by co-infiltration of an Agrobacterium 
strain containing a P19 expression cassette.   
 
1.2.4 MULTIPLE PROTEIN EXPRESSION 
Like other eukaryotic expression platforms, plants are able to fold and post-
translationally modify heterologous proteins, making them ideal for the production of 
complex protein products. Correct folding of foreign proteins in vivo provides the 
possibility of co-expression of multiple proteins to achieve assembly of heteromeric 
complexes such as functional enzymes, antibodies or VLPs.  
Multiple protein expression in transgenic plants can be achieved by sexual crossing of 
transgenics, co-transformation or re-transformation, followed by back-crossing to obtain 
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lines homozygous for all inserted genes (Dafny-Yelin and Tzfira, 2007). By following a 
strategy of sequential crossing of homozygous lines expressing the four components of 
secretory antibodies, heavy chain, light chain, J chain and secretory component, it has 
been possible to produce transgenic Nicotiana tabacum plants expressing functional 
secretory antibody at levels exceeding 200 mg / kg fresh weight tissue (FWT; Ma et al., 
1995). Another notable example of these strategies is Golden Rice, where the three genes 
of the carotenoid biosynthetic pathway were transformed into rice plants by co-
transformation with two Agrobacterium strains (Ye et al., 2000). Problems with expression 
efficiency in stable transgenics are often due to copy number, site of integration, and re-
arrangement, loss or silencing of the transgene, making stable integration a cumbersome 
and often unreliable means of co-expressing multiple proteins (Naqvi et al., 2009).  
An elegant strategy to circumvent some of the problems of multigene expression in 
transgenic plants has been the linking of transgenes. Such linking can be achieved by 
cloning of adjacent promoter-containing expression cassettes, insertion of internal 
ribosome entry sites (IRES) between open reading frames (Toth et al., 2001), or in-frame 
fusion of genes to form a polyprotein (Halpin et al., 1999). The linking of multiple genes in 
one expression construct allows for easier regeneration of homozygous lines and ensures 
that copy number and chromatin position do not affect the relative expression levels of 
the proteins. Co-expression of proteins at near equimolar ratios can be achieved using the 
polyprotein approach. Cleavage of the polyprotein to release the mature polypeptides is 
achieved either by design of protease cleavage sites in the linker sequences (Bedoya et al., 
2010) , or by linking the proteins with a self-cleaving peptide such as the 2A sequence of 
FMDV (Halpin et al., 1999). 
Multi-gene transient expression by agro-infiltration was first used to express antibody 
heavy and light chains to recover recombinant IgG (Vaquero et al., 1999). This was 
achieved by co-infiltration with a solution containing two Agrobacterium strains, both of 
which transferred their T-DNA into leaf cells thereby allowing co-expression of the heavy 
and light chains and assembly of a functional antibody. Though transient co-expression 
by co-infiltration is a fast and simple method to express multiple proteins in plants, it is 
highly dependent on the efficiency of T-DNA transfer. The copy number of the different T-
DNAs transferred to each cell is random, thereby causing varying ratios of heterologous 
proteins to be expressed in individual cells (see section 3.3.6). This problem can be 
avoided by employing the polyprotein expression strategies mentioned above, or by 
simply cloning multiple expression cassettes onto the same T-DNA – a strategy 
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successfully used in this project to co-express up to five proteins of interest (see Chapters 
3 and 6).  
Co-expression of a suppressor of gene silencing is routinely achieved by co-infiltration 
with a separate Agrobacterium strain. Therefore, to achieve high-level expression of two 
genes of interest (GOI), at least three Agrobacterium clones must be co-infiltrated. The 
resulting infiltration solution can be very dense, making it difficult to manually infiltrate 
leaf tissue and causing increased stress on the plant as well as an increase in 
contaminating Agrobacterium proteins in downstream processing. The co-expression of 
multiple genes and a suppressor of gene silencing from a single T-DNA construct would 
thus be superior to co-infiltration.  
 
1.3 PLANT VIRAL VECTORS AND THE CPMV-BASED EXPRESSION SYSTEMS 
1.3.1 FULL VIRAL VECTORS 
Parallel to the use of Agrobacterium-mediated expression, plant viral vectors have 
been developed as an alternative transient heterologous protein expression technology 
(reviewed by Gleba et al., 2004; Lico et al., 2008). Early viral vectors were mainly based on 
the full genome of a virus which included an introduced heterologous gene sequence 
(Gopinath et al., 2000; Porta and Lomonossoff, 1996). Expression of the GOI was obtained 
by local inoculation of plant tissue. This resulted in the development of symptoms of viral 
infection and systemic spread of the recombinant virus throughout the tissue, in addition 
to the high-level expression of the GOI during viral replication. Infectious virus can be 
harvested and used to infect more tissue for easy scale-up of expression.  
Despite the obvious benefits of high expression levels and ease of application, the 
drawbacks of full viral vectors have led many researchers and industry to back away from 
their use. In the case of icosahedral viruses, the size of the viral genome is limited by the 
internal dimensions of the capsid structure, thereby imposing strict limitations on the size 
of the inserted heterologous gene. Inserted genes are also susceptible to genetic drift as 
well as loss by recombination. Most importantly, the production of recombinant 
infectious viruses presents serious bio-containment issues (Gleba et al., 2004). 
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In the case of co-expression of multiple proteins to achieve assembly of heteromeric 
protein complexes such as antibodies or VLPs, the use of full viral vectors based on 
monopartite viruses presents the problem of viral exclusion. Using potyvirus vectors 
expressing different fluorescent proteins, Dietrich and Maiss found that co-infection with 
two differently labelled viruses resulted in leaf areas that were infected with one or the 
other virus, and only rarely with both (Dietrich and Maiss, 2003). This exclusion presents a 
problem when the expression of a functional heteromeric protein depends on efficient 
co-expression of all subunits within the same cell. In the same study, it was shown that 
the use of two synergistic plant virus vectors can overcome the problem of exclusion, a 
strategy later used for the expression of functional IgG (Section 1.3.2; Giritch et al., 2006). 
In an effort to maintain the high expression levels achieved with viral vectors while 
tackling the problems associated with the generation of infectious recombinant virus, 
several deconstructed viral vectors have been developed. 
 
1.3.2 DECONSTRUCTED VIRAL VECTORS 
The inherent limitations of the full viral vector approach discussed above have been 
addressed by the development of deconstructed viral vectors (Figure 1.1). Genes essential 
for virus replication, assembly and movement can be supplied in trans to maintain the 
viral infection cycle. Several key proteins are encoded by many RNA viruses currently used 
in plant biotechnology: (1) a viral polymerase capable of amplifying the viral genome; (2) 
the structural protein(s) necessary for viral capsid assembly; (3) a protease capable of 
cleaving viral polypeptides into functional units; (4) a movement protein essential for the 
cell-to-cell and systemic movement of the virus; (5) a suppressor of gene silencing. For 
viral vectors in which some elements of the viral infection cycle are not necessary for 
efficient transgene expression, another approach has been the deletion of parts of the 
viral genome.  
One of the first deconstructed viral vector approaches has been the movement of 
essential viral genes to the host genome (Mor et al., 2003). The viral vector itself thereby 
becomes smaller and more amenable to cloning of larger inserts. Crucially, the vector can 
only function properly when used in conjunction with the appropriate transgenic host 
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Figure 1.1: Examples of full virus and deconstructed virus vector systems. 
(A) Full virus vector based on TMV cDNA with an inserted gene of interest. (B) Deconstructed BeYDV 
vector with an inducible replicase cassette in the host genome. (C) Deconstruced CPMV vector with a GOI-
containing RNA-2 present in the transgenic host plant. (D) TMV-based MagnICON system relying on in 
planta recombination of two elements of a deconstructed virus genome. (E) Deleted CPMV vector system 
where genes for movement and coat proteins have been removed. Pol, polymerase; MP, movement 
protein; CP, coat protein; Rep, replicase; ProC, protease co-factor; Hel, helicase; Pro, protease; L; large coat 
protein; S, small coat protein; Recomb., recombinase. 
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plant which supplies the missing viral proteins. This provides a possible solution to the 
bio-containment problem of using a full viral vector.  
Another notable approach is the splitting of the viral genome into two parts which 
must be independently supplied to a plant cell via Agrobacterium co-infiltration. The 
widely used magnICON system uses a deconstructed Tobacco Mosaic Virus (TMV) vector 
which has been split into a 5’- and a 3’-module (Gleba et al., 2005; Marillonnet et al., 2004). 
Each module contains viral genes and/or a heterologous gene of interest, as well as site-
specific recombination sites. By co-infiltrating with three Agrobacterium strains to transfer 
the two modules as well as a construct encoding a recombinase enzyme, the TMV vector 
is assembled in each plant cell and allows for extremely high levels of recombinant 
protein production (up to 5 g / kg FWT reported). Conveniently, the modularity of the 
system allows for different combinations of modules to be used to allow or restrict cell-to-
cell and systemic movement.  
A modified magnICON system has been used to express functional IgG from a 
deconstructed viral vector. The problem of virus exclusion discussed above (Section 1.3.1) 
also applies to the use of deconstructed vectors based on monopartite viruses. This 
problem was overcome by the use of two non-competing viral vectors, TMV and Potato 
Virus X (PVX) to achieve efficient co-expression of heavy and light chains (Giritch et al., 
2006). However, this strategy involved the co-infiltration of six separate Agrobacterium 
constructs, making it heavily reliant on dense infiltration solutions and efficient T-DNA 
transfer of each construct to each cell. 
With the development of vacuum infiltration methods discussed above (Section 1.2.2), 
large-scale transient production of foreign proteins from viral vectors is no longer 
dependent on systemic spread. Thus, it is possible to delete the movement protein and 
coat proteins of the viral vector, leaving only the machinery necessary for high-level 
replication of the genome. An example of this is the Bean Yellow Dwarf Virus (BeYDV)-
based vector system developed by researchers in the group of Dr. Hugh Mason at the 
Biodesign Institue, Arizona. The BeYDV vector consists of the replicase as well as the long 
and short intergenic regions necessary for amplification of the viral genome (Huang et al., 
2009). Heterologous genes inserted in this vector are expressed at high levels of up to 0.8 
g / kg within four days, without movement of the vector.  
Deleted viral vectors that are not reliant on virus assembly and movement overcome 
the inherent limits on transgene size imposed by the vector capsid and genome. Such 
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deleted vectors are also not subject to the problems of transgene deletion and reversion 
to wild type, often encountered after serial passaging of full virus vectors (Kearney et al., 
1993; Rabindran and Dawson, 2001). However, these vectors are heavily reliant on high 
levels of replication for efficient expression of the transgene. Replication of viral genomes, 
particularly those of RNA viruses, has been shown to be subject to a high mutation rate 
due to the low fidelity of RdRp (Drake and Holland, 1999). While essential viral genes of 
full viral vectors are subjected to selection pressures and deleterious mutations are 
selected against, in the case of a heterologous gene mutations can accumulate. This can 
result in the expression of truncated products or inactive forms of the protein of interest, 
which can be a particular problem in the heavily regulated field of biopharmaceutical 
production. 
For the CPMV-HT system introduced below, it has been possible to delete all viral 
genes, leaving only the untranslated regions (UTR) of the viral genome which allow for 
hyper-translation of the gene of interest (Cañizares et al., 2006; Sainsbury and 
Lomonossoff, 2008). 
 
1.3.3 COWPEA MOSAIC VIRUS-BASED EXPRESSION SYSTEMS 
Cowpea Mosaic Virus is the type member of the genus Comovirus, family Comoviridae. 
CPMV is an icosahedral, bipartite virus with a genome consisting of self-replicating RNA-1 
which encodes, amongst others, the viral polymerase and proteinase, and RNA-2 which 
encodes the movement protein as well as the large and small coat proteins which are 
expressed as a propeptide (Figure 1.2 A). As well as its natural host cowpea (Vigna 
unguiculata), the virus is also capable of infecting the Nicotiana benthamiana, a fast-
growing, highly susceptible variety widely used in plant biotechnology and employed in 
this study (Goodin et al., 2008).  
1.3.3.1 Full CPMV viral vector 
Early CPMV-based expression systems followed the full viral vector approach discussed 
above (Section 1.3.1) and focussed entirely on the smaller RNA-2. The marker green 
fluorescent protein (GFP) was inserted between the movement protein and large coat 
protein, or downstream of the small coat protein (Gopinath et al., 2000). Release of the 
marker protein was achieved by inclusion of a protease cleavage site or FMDV 2A 
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sequence flanking GFP (MxGFPy; Figure 1.2 B). Though this approach was effective and 
produced GFP at levels of 1-2% of total soluble protein, the produced marker protein 
contained remnants of the flanking cleavage sites. The least modified GFP was obtained 
with a construct in which the N-terminus of the marker protein was fused to the C-
terminus of the small coat protein via the FMDV 2A linker (CPMV/S-2A-GFP; Figure 1.2 B), 
which leaves only one residual proline at the N-terminus of the heterologous protein after 
cleavage (Gopinath et al., 2000; Ryan and Drew, 1994). This early CPMV vector was used 
successfully for the transient expression of Hepatitis B cores and other pharmaceutically 
relevant proteins (Mechtcheriakova et al., 2006; Monger et al., 2006). However, the full 
virus vector approach has inherent limitations of transgene loss and biocontainment 
issues, as discussed above. It was also found that while co-expression of two GOI from 
separate RNA-2 constructs results in efficient co-expression within agro-infiltrated tissue, 
systemic spread of the full viral vectors resulted in segregation and virus exclusion as seen 
for monopartite viral vectors (section 1.3.1; Sainsbury et al., 2008). 
1.3.3.2 Deconstructed and deleted CPMV viral vectors 
A deconstructed CPMV vector system was developed in 2006 after the observation 
that viral infection could be induced in otherwise healthy RNA-2 transgenic plants after 
agro-infiltration with an RNA-1 construct (Liu et al., 2004). By transforming plants with the 
aforementioned CPMV/S-2A-GFP construct, healthy plants could be recovered in which 
the expression of GFP could be induced by agro-infiltration with RNA-1 (Cañizares et al., 
2006). However, this approach was slow due to the production of transgenic plants, and 
induction of expression still resulted in the production of infectious CPMV particles.  
The problem of bio-containment was addressed by the development of an expression 
system based on deleted RNA-2 (delRNA-2), in which the movement protein and coat 
proteins of CPMV were removed (Figure 1.2 C; Cañizares et al., 2006). The only viral 
elements flanking the gene of interest in this system are the 5’- and 3’-UTRs of RNA-2, 
which had previously been shown to be essential for replication by RNA-1-encoded 
machinery. The gene silencing suppression function previously provided by the CPMV 
small coat protein could be replaced by supplying a suppressor of gene silencing, HcPro, 
in trans. It was further found that good expression levels could be achieved from delRNA-
2 constructs in the absence of RNA-1, when co-infiltrated with a suppressor of gene 
silencing. Such constructs were used routinely when I started this project in 2007, and 
have been successfully used to express fluorescent marker proteins, IgG and hepatitis B  
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Figure 1.2: Evolution of the CPMV polypeptide expression system. 
(A) Schematic representation of the CPMV genome. (B) RNA-2 constructs used in the full viral vector 
system of Gopinath et al, 2000. The foreign sequence (GFP) was flanked by protease or FMDV 2A cleavage 
sites. (C) delRNA-2 construct developed by Cañizares et al, 2006, where GFP replaces the viral genes of 
RNA-2. (D) CPMV-HT construct where the in-frame start codon at position 161 as well as the AUG at 
position 115 were removed (Sainsbury and Lomonossoff, 2008). (E) Schematic representation of the 5’ 
UTR of CPMV RNA-2, indicating the position of open reading frames. ProC, proteinase co-factor; Pro, 
proteinase; MP, movement protein; L, large coat protein; S, small coat protein; P, protease cleavage site; 
2A, FMDV 2A self-cleaving polypeptide.  Figures modified from Sainsbury et al, 2010. 
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cores and empty CPMV-like particles (Sainsbury and Lomonossoff, 2008; Saunders et al., 
2009).  
 
1.3.3.3 HyperTrans: CPMV-HT 
With the finding that replication by RNA-1 is not necessary for good expression from 
the delRNA-2 constructs, efforts were made to investigate whether the 5’UTR of RNA-2 
could be altered to simplify cloning. The start codon of the viral movement protein, or the 
heterologous protein in the case of delRNA-2, is at position 512 of the RNA-2 sequence 
(Figure 1.2 E). Upstream of this site are two further start codons at positions 115 and 161, 
the latter of which is in-frame with the start codon at 512. Previous mutational studies 
with full virus had revealed that removal of these start codons, or frame-shifting, was 
detrimental to virus replication (Holness et al., 1989; van Bokhoven et al., 1993). 
It was subsequently investigated whether the maintenance of this exact 5’-UTR was 
still needed for heterologous protein expression from delRNA-2 (Sainsbury and 
Lomonossoff, 2008). Rather than being detrimental, it was found that the removal of the 
start codons at 115 and particularly 161 increased foreign protein expression by at least 
10-fold. Since mRNA levels were not affected, this increase is thought to be caused by 
more efficient translation, i.e. “hyper-translation.” 
The expression system based on the mutated 5’-UTR of RNA-2 is called CPMV-HT (or 
HyperTrans) and was used throughout most of this body of work (Figure 1.2 D). Being a 
deleted viral vector, agro-infiltration of a CPMV-HT construct does not result in systemic 
spread or production of infectious viral particles, thereby making the system safe in terms 
of biocontainment, and removing the limitations of transgene size imposed by 
encapsidation of the viral genome. The lack of contaminating CPMV particles is 
particularly beneficial for the production of heterologous VLP produced using the system. 
Efficient transgene expression is achieved by hyper-translation rather than viral vector 
replication, thereby reducing the risk of transgene loss, genetic drift and high mutation 
rates associated with replicating viral vectors. Multiple GOI can be expressed from 
separate RNA-2 constructs by co-infiltration, showing that the system is not subject to the 
viral exclusion phenomenon of other viral vectors (Sainsbury et al., 2008). These benefits 
make the CPMV-HT system particularly suitable for the expression of complex 
heteromeric VLP, as attempted in this project. 
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1.4 AIMS OF THIS PROJECT 
The overall aim of this project was to push the boundaries of VLP expression in plants 
in general, through use of the CPMV expression systems. In particular, I chose to express 
two very different VLPs, one simple and one complex: (1) Tandem Hepatitis B cores are 
relatively simple particles consisting of 120 copies of a single subunit and have the 
potential to be used as carriers of large heterologous polypeptides; (2) Bluetongue Virus-
like particles are large, highly complex structures consisting of 1440 subunits of four 
different structural proteins. Both of these VLPs have potential uses as vaccines as well as 
tools in research and nanotechnology.  
To enable the expression of such complex heteromeric structures, the development of 
a vector series for fast cloning and efficient co-expression of multiple GOI was seen as a 
necessary first goal.  
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2 GENERAL MATERIALS AND METHODS 
In general, standard molecular biological techniques were performed as described by 
Sambrook (1989) or according to the manufacturers instructions where specific reagents 
were used. General materials and methods relating to the work described in this thesis are 
described below. Specific materials and techniques relating to key experiments are 
introduced in the relevant chapters.  
2.1 MEDIA, BUFFERS AND SOLUTIONS 
The recipes for bacterial growth media, buffers and solutions used for molecular 
cloning and protein analysis experiments are listed in Table 2.1. 
Table 2.1: Media, buffers and solutions used for molecular biology experiments. 
Name Recipe 
  
Luria Bertani (LB) 10 g/l tryptone, 5 g/l yeast extract, 10 g/l NaCl adjusted to pH 7.0 
LB agar as LB, with 10 g/l Lab M No.1 agar added 
ELISA Block Buffer 5% (w/v) dry milk, 0.05% (v/v) Tween-20, in PBS 
βME-LDS sample buffer 
(3x; LDS-SB) 
750 µl 4x LDS sample buffer (Invitrogen), 250 µl β-mercaptoethanol 
MMA 10 mM MES buffer, pH 5.6; 10 mM MgCl2; 100 μM acetosyringone 
Phosphate-buffered 
saline (PBS) 
140 mM NaCl, 15 mM KH2PO4, 80 mM Na2HPO4, 27 mM KCl 
SOC 20 g/l tryptone, 5 g/l yeast extract, 0.58 g/l NaCl, 0.19 g/l KCl, 2.03 g/l 
MgCl2, 2.46 g/l magnesium sulphate 7-hydrate, 3.6 g glucose 
SNAPid Block Buffer 1% (w/v) casein, 1% (w/v) bovine serum albumin, 0.1% Tween-20, in PBS 
1 x TBE 10.8 g/l Tris-HCl, 5.5 g/l boric acid, 2 mM EDTA 
Western Blot Transfer 
buffer 
3.03 g/l Tris-HCl, 14.4 g/l glycine, 20% (v/v) methanol 
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2.2 MOLECULAR CLONING TECHNIQUES 
General techniques used for molecular cloning are described below. Details of specific 
cloning strategies can be found in Section 2 of each results chapter.  
 
2.2.1 ISOLATION / PURIFICATION OF PLASMID DNA AND DNA FRAGMENTS 
Plasmid DNA was prepared using the QIAgen MiniPrep Kit, as per the manufacturer’s 
instructions. DNA fragment purification was perfomed using QIAgen PCR Purification Kit 
or QIAgen Gel Extraction Kit, according to the instructions. DNA was stored at -20°C.  
 
2.2.2 POLYMERASE CHAIN REACTION (PCR) 
Amplifications of DNA fragments for subsequent cloning were carried out using the 
proofreading polymerase Phusion (Roche) and the supplied buffer according to the 
following protocol. The lowest melting temperature of the two primers was used as the 
annealing temperature (XX).  
 
Recipe 50  μl  Cycles   
5x HF buffer  10 μl  98°C  2  min 
10 mM dNTPs  1 μl  98°C 30  sec 
DNA template 1 μl  XX°C 30  sec 
10 μM forward primer 2 μl  72°C 25 sec/kb 
10 μM reverse primer 2 μl  72°C 5 min 
Phusion polymerase 0.5 μl     
dH2O 33.5 μl     
  
Amplifications of DNA fragments for subsequent analysis by agarose gel 
electrophoresis (e.g. Colony PCR) were performed using GoTaq polymerase (Promega) 
and the supplied buffer. The annealing temperature was chosen to be 2°C lower than the 
lower of the two primer melting temperatures.   
25 x 
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Recipe 20 μl  Cycles   
5x GoTaq buffer  4 μl  98°C  2  min 
25 mM MgCl2 1.2 μl  98°C 30  sec 
10 mM dNTPs  0.4 μl  XX°C 30  sec 
DNA template                1 μl  72°C 1 min/kb 
10 μM forward primer 0.4 μl  72°C 5 min 
10 μM reverse primer 0.4 μl     
GoTaq polymerase 0.1 μl     
dH2O 12.5 μl     
 
2.2.3 RESTRICTION ENDONUCLEASE DIGESTION 
Restriction enzymes were obtained from New England Biolabs (NEB), Roche or 
Invitrogen. Restriction digests were carried out in the appropriate 1x NEBuffer (NEB), as 
recommended by the NEB Double Digest Finder tool:  
http://www.neb.com/nebecomm/DoubleDigestCalculator.asp.  
 
2.2.4 DNA MODIFICATION 
As required, DNA fragments were manipulated to facilitate certain cloning strategies. 
 
i. Blunting of DNA ends was achieved by treatment with DNA Polymerase I Klenow 
fragment (NEB) supplemented with dNTPs, resulting in removal of 3’ overhangs 
and filling in of 5’ overhangs. 
ii. Blunting and 5’-phosphorylation of inserts was achieved with a Quick Blunting Kit 
(NEB) consisting of T4 DNA polymerase and T4 polynucleotide kinase. 
iii. Dephosphorylation of vector backbones to prevent self-ligation was performed 
using Calf Intestinal Alkaline Phosphatase (CIP; NEB) or Shrimp Alkaline 
Phosphatase (SAP; USB Affymetrix).  
 
 
30 x 
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2.2.5 DNA LIGATION 
DNA ligations were carried out using NEB T4 DNA ligase. Prior to ligation, purified DNA 
fragments were quantified using a NanoVue spectrophotometer (GE Healthcare), and a 
vector : insert molar ratio of 1 : 3 was calculated for reactions not exceeding 100 ng total 
DNA. Ligations were carried out at room temperature for one hour, or 16°C overnight.  
 
2.2.6 SITE-DIRECTED MUTAGENESIS 
Site-directed mutagenesis was performed to change individual nucleotides in order to 
introduce or remove restriction sites. Mutagenic primers were designed according to the 
guidelines of the Quick Change Site-directed Mutagenesis Kit Instruction Manual 
(Stratagene). Mutagenesis reactions were set up as follows, and included Pfu Turbo 
polymerase (Stratagene). Annealing temperature and extension time were chosen 
specifically for each primer set and DNA template employed. 
Recipe 50 μl  Cycles   
10x Pfu Turbo buffer  5 μl  95°C  2  min 
DMSO 3 ul  95°C 30  sec 
10 mM dNTPs  1 μl  XX°C 30  sec 
DNA template  1 μl  68°C 1 min/kb 
10 μM forward primer 2 μl  72°C 5 min 
10 μM reverse primer 2 μl     
Pfu Turbo polymerase 1 μl     
dH2O 36 μl     
 
Reactions were treated with DpnI to cleave the parental DNA template, followed by 
transformation into E. coli. 
 
2.2.7 GATEWAY® CLONING 
Genes of interest were amplified using a set of primers allowing end-tailoring of 
bacteriophage λ attachement B (attB) sites (Figure 2.1). The BP clonase II enzyme 
(Invitrogen) allowed directional recombination to transfer the PCR fragment into 
30 x 
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pDONR207, the “donor vector” backbone. Successful recombinants (called “entry clones,” 
pENTR…) were selected for by plating on LB agar with 7 μg/ml gentamycin. This newly 
created entry clone contained the GOI, flanked by attL sites. The subsequent LR reaction, 
facilitated by LR clonase II (Invitrogen), allowed the transfer of the GOI into a destination 
vector (pDEST…), thereby producing a so-called “expression clone.” Both the donor 
vector and the destination vector contain a cytotoxic ccdB gene cassette which is 
removed upon recombination, thereby negatively selecting transformants which did not 
recombine successfully.  
 
Figure 2.1: Schematic representation of Gateway cloning and Gateway vectors for 
subcloning of CPMV expression cassettes. 
Gateway cloning involves sequential recombination reactions to transfer a gene of interest 
(GOI) into an expression clone. Recombination side products are indicated on right.  
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2.2.8 DNA SEQUENCING 
All sequencing reactions were prepared using BigDye Terminator v3.1 (Applied 
Biosystems) according to the manufacturers instructions. Sequencing was carried out by 
Genome Enterprise Ltd.  
 
2.2.9 AGAROSE GEL ELECTROPHORESIS 
Agarose gel electrophoresis was used for analysis of PCR products and restriction 
fragments, as well as gel purification. Generally, 0.8% (w/v) agarose dissolved in 1 x 
Tris/Borate/EDTA (TBE) buffer was used to resolve DNA fragments larger than 500 bp. 
Smaller fragments were resolved in 1% or 2% (w/v) agarose gels, as required. 
 
2.2.10 TRANSFORMATION OF COMPETENT CELLS 
The strains of E. coli used in this work are detailed in Table 2.2.  
 
Table 2.2: E.coli strains used in this work. 
Strain Genotype 
  
DH5α 
F- φ80dlacZΔM15 Δ(lacZYA-argF) U169 recA1 endA1 hsdR17 (rk-, mk
+) phoA 
supE44 λ- thi-1 gyrA96 relA1 
TOP10 
F- mcrA Δ(mrr -hsdRMS-mcrBC) φ80lacZΔM15 ΔlacX74 deoR recA1 araΔ139 
Δ(ara-leu)7697 galU galK rpsL (StrR) endA1 nupG 
Invitrogen 
OneShot ccdB 
Survival 2 T1R 
F- mcrA Δ(mrr-hsdRMS-mcrBC) φ80lacZΔM15 ΔlacX74 recA1 araΔ139 Δ(ara-
leu)7697 galU galK rpsL (StrR) endA1 nupG fhuA::IS2 
 
 
Chemically competent E. coli were transformed by heat-shock and allowed to recover 
in SOC media for one hour at 37°C in a shaking incubator before plating on LB agar plates 
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containing the appropriate antibiotic(s). The concentrations of antibiotics used in this 
study are detailed in Table 2.3. 
 
 
Table 2.3: Working concentrations of antibiotics used. 
Antibiotic Working concentration 
  
Carbenicillin 100 μg / ml 
Chloramphenicol 34 μg / ml 
Gentamycin 7 μg / ml 
Kanamycin 50 μg / ml 
Rifampicin 50 μg / ml 
 
 
2.3 CLONING VECTORS 
In a period of continued development of cloning vectors to facilitate the use of the 
CPMV-HT expression system, standard cloning procedures were periodically changed to 
allow the use of new vectors. The main vectors used in this study are briefly introduced 
below. Details of their construction and use are found in Chapter 3.  
 
2.3.1 PM81-FSC2 
pM81-FSC2 (Sainsbury and Lomonossoff, 2008) is a 4882 bp small, high-copy plasmid 
containing the basic CPMV expression cassette: a gene of interest flanked by 5’- and 3’-
untranslated regions of CPMV RNA-2, driven by a 35S promoter and nos terminator. The in 
situ GOI can be easily replaced by restriction cloning using NruI and XhoI. However, for use 
with the delRNA-2 system for which it was designed, due care must be paid to the 
maintenance of the GOI start codon at position 512 of the RNA-2 sequence (Cañizares et 
al., 2006).   
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2.3.2 PBINPLUS 
The binary vector pBINPLUS is a modified version of the classic plant expression vector 
pBIN19 (Bevan, 1984; van Engelen et al., 1995). The Agrobacterium Ti-plasmid left and 
right borders flank a T-DNA region containing a selection marker and a multiple-cloning 
site (MCS). Unique eight base-pair restriction sites AscI and PacI allow easy subcloning of 
CPMV expression cassettes from pM81-FSC2 to pBINPLUS. 
 
2.3.3 PENTR-ET2 AND PDEST-BINPLUS 
pENTR-ET2 is a Gateway-compatible alternative to pM81-FSC2 (see section 3.3.1). It 
contains the same CPMV expression cassette with unique restriction sites for replacement 
of the GOI, but includes attL sites. These sites allow for easier subcloning by site-specific 
recombination into the binary vector by LR reaction. 
pDEST-BINPLUS is a Gateway destination vector in which the MCS of pBINPLUS is 
replaced with attR sites flanking a cytotoxic ccdB gene and resistance gene (Section 3.3.1). 
This can be used in LR reactions with pENTR-ET2-based plasmids to transfer CPMV 
expression cassettes into the binary vector T-DNA region.  
 
2.3.4 PEAQ VECTOR SERIES 
The pEAQ vector series consists of small binary vectors with T-DNA regions tailored for 
specific plant-expression purposes. These vectors are discussed in detail in Chapter 3.  
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2.4 TRANSIENT EXPRESSION OF PROTEINS IN NICOTIANA BENTHAMIANA 
2.4.1 TRANSFORMATION OF AGROBACTERIUM TUMEFACIENS 
In this work, binary vectors carrying expression constructs flanked by T-DNA borders 
were transformed into electrocompetent Agrobacterium tumefaciens strain LBA4404 
(Hoekema et al., 1983). After electroporation at 2.5 kV, SOC media was immediately added 
and the cells left to recover for one hour at 28°C. Cells were then plated on LB agar 
containing 50 μg/ml rifampicin and 50 μg/ml kanamycin.  
 
2.4.2 PLANT GROWTH CONDITIONS  
Nicotiana benthamiana plants were grown in glasshouses maintained at 25°C and 
watered daily. Supplemental lighting was provided to maintain 16 hours of daylight in the 
winter months (October – April, inclusive). Plants were used for transient expression 
studies 3-4 weeks after pricking out. 
 
2.4.3 AGROINFILTRATION 
For transient expression, inoculated liquid cultures of A. tumefaciens strains were 
grown at 28°C in a shaking incubator for 24 hours in LB medium containing the 
appropriate antibiotics. The optical density at 600nm wavelength (OD600) was measured 
(typically reaching OD600 of approximately 5) and used to calculate the volume of culture 
(X) needed to make an overall inoculum of OD600 = 0.4 (unless otherwise specified), 
according to the following equation.  
 
The determined volume of culture was centrifuged at 4000 x g for 5 minutes to pellet 
the bacteria. After decanting, the pellet was resuspended in the desired volume of MMA 
to yield an inoculum of OD600 = 0.4.  
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Co-infiltration of multiple construct was achieved by mixing the required amounts of 
the cultures prior to pelleting. After resuspension in MMA, the resulting infiltration 
suspension had an OD600 of n  0.4, where n is the number of different constructs to be 
co-infiltrated. 
Small-scale experiments were designed to allow sampling from at least three separate 
leaves per construct. This was done to minimize the variability of expression levels 
observed from leaves of different age.  
 
2.4.4 HARVESTING 
Leaf tissue was harvested six days post infiltration (dpi) using the following techniques, 
unless otherwise specified.  
Small-scale sampling was done by excising three leaf discs from three separate leaves 
of the same plant, using a cork borer of 11 mm diameter. Samples of this size 
corresponded to approximately 100 mg of healthy leaf tissue. Leaf veins were avoided 
where possible. Leaf discs were placed in 2 ml screw-cap tubes and either analyzed 
immediately or stored at -20°C. 
Large-scale sampling was done by removing any large veins and non-infiltrated tissue, 
and recording the leaf sample weight. Leaves were then either extracted immediately in 
three volumes of a protein extraction buffer (Table 2.4), or stored at 20°C. 
 
2.4.5 CONFOCAL MICROSCOPY 
Unless otherwise specified, a Leica SP2 inverted confocal microscope was used to 
visualize fluorescent protein expression in N. benthamiana leaf tissue. Leaf fragments of 
approximately 25 mm2 were excised from infiltrated tissue at 1 cm distance from the point 
of injection. Fragments were mounted on coverslips by floating the underside of the leaf 
portion on a water droplet, and then taking care to avoid trapped air while mounting 
onto a glass slide. The leaf underside was thus viewed by the microscope. Specific 
parameters used for the visualization of EYFP, ECFP and EGFP are detailed in Chapter 3.   
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Table 2.4: Protein extraction buffers used. 
Name Recipe 
  
BTV extraction buffer 
(BTV ExB) 
20 mM Tris-HCl , pH 8.4; 140 mM NaCl; 1 mM EDTA; 0.1% (w/v) sodium 
deoxycholate;  Complete Protease Inhibitor Cocktail (Roche, add fresh) 
BTV VLP extraction 
buffer 
50 mM Bicine, pH 8.4; 20 mM NaCl, 0.1 % (w/v) NLS sodium salt; 1 mM DTT 
(add fresh);  Complete Protease Inhibitor Cocktail (Roche, add fresh) 
BTV CLP extraction 
buffer 
50 mM Bicine, pH 8.4; 140 mM NaCl, 0.1 % (w/v) NLS sodium salt; 1 mM 
DTT (add fresh);  Complete Protease Inhibitor Cocktail (Roche, add fresh) 
Extraction Buffer (ExB) 50 mM Tris-HCl , pH 7.25; 150 mM NaCl; 2 mM EDTA; 0.1% (v/v) Triton X-
100; 1 mM DTT (add fresh), Complete Protease Inhibitor Cocktail (Roche, 
add fresh) 
HB Extraction Buffer 1 
(HBexB1) 
10 mM Tris-HCl pH 8.4, 120 mM NaCl, 1 mM EDTA, 0.75% (w/v) Sodium 
deoxycholate, 1 mM DTT (add fresh), Complete Protease Inhibitor Cocktail 
(Roche, add fresh) 
Low-salt SSB 50 mM Bicine, pH 8.4; 20 mM NaCl, 0.5 % (v/v) NP-40; 10 % glycerol; 1 mM 
DTT (add fresh);  Complete Protease Inhibitor Cocktail (Roche, add fresh) 
Smith Stabilization 
buffer (SSB) 
50 mM Bicine, pH 8.4; 140 mM NaCl, 0.5 % (v/v) NP-40; 10 % glycerol; 1 mM 
DTT (add fresh);  Complete Protease Inhibitor Cocktail (Roche, add fresh) 
  
 
 
2.4.6 PHOTOGRAPHY 
Photography was used to document detrimental effects of certain constructs on leaf 
tissue, and to visualize fluorescent protein in leaf tissue and density gradients. Excitation 
of fluorescent proteins was achieved using Blak-Ray lamps (Ultra-Violet Product Ltd). 
Unless otherwise specified, all photographs were taken by Mr. Andrew Davis.  
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2.5 PROTEIN ANALYSIS 
2.5.1 PROTEIN EXTRACTION 
Small-scale samples were extracted by adding a ¼-inch ceramic bead (MP Biomedicals) 
and 300 μl of an appropriate extraction buffer, unless otherwise specified. Leaf tissue was 
homogenized using a FastPrep machine (MP Biomedicals) at speed setting 5.0 for 40 
seconds. Large-scale samples were extracted by adding 3 volumes of an appropriate 
extraction buffer and blending in a WARING blender until homogeneous (approximately 
40 seconds). Large cell debris was removed by squeezing the homogenate through one 
layer of Miracloth (Merck).  
The composition of the protein extraction buffers used in this project are given in 
Table 2.4.  
 
2.5.2 POLYACRYLAMIDE GEL ELECTROPHORESIS (PAGE) 
Invitrogen’s NuPAGE Bis-Tris Mini gels of 12% or 4-12% (w/v) acrylamide were used 
throughout this study, as indicated. Gels were run in NuPAGE MOPS buffer, supplemented 
with NuPAGE Antioxidant in the internal chamber, according to the manufacturer’s 
instructions. For reducing, denaturing polyacrylamide gel electrophoresis (PAGE), two 
volumes of sample were mixed with one volume of 3x LDS βME sample buffer  (LDS-SB) 
and boiled at 100°C for 5 minutes. The two protein standards used were SeeBlue Plus 2 
(Invitrogen) and Broad Range Prestained Protein Marker (New England Biolabs).  
2.5.3 COOMASSIE BLUE STAINING 
After PAGE, protein bands in gels were visualized by addition of 20 ml InstantBlue 
Coomassie blue-based protein stain (Expedeon) and staining for at least one hour. Gels 
were destained in water for at least 30 minutes before imaging. 
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2.5.4 MASS SPECTROMETRY 
When necessary, protein bands of interest from Coomassie blue-stained PAGE gels 
were identified by Mass Spectrometry, performed by the John Innes Centre Proteomics 
facility. 
 
2.5.5 WESTERN BLOTTING AND IMMUNODETECTION 
Western blotting was performed exclusively as a wet transfer to Polyvinylidene 
fluoride (PVDF) membrane. Briefly, the transfer cassette was assembled with the gel and 
pre-wet PVDF membrane sandwiched between layers of filter paper and sponges. 
Proteins were electroblotted for 1 hour at 100V, whilst maintaining a constant cooling by 
ice bath.  
Generally, immunodetection was carried out using the SNAPid system (Millipore), 
which allows fast binding of antibodies and washing by applying a vacuum. Membranes 
were blocked with SNAPid blocking buffer, which was also used to dilute antibody 
solutions. The manufacturer’s instructions were followed. The antibodies used in this 
study are listed in Table 2.5.  
Immobilon Chemiluminescent HRP substrate (Millipore) was used to detect bound 
secondary HRP-conjugated antibody. The emitted luminescence was detected with 
Hyperfilm (Amersham).  
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Table 2.5: Antibodies used in this study. 
Antibody Antigen Supplier 
   
anti-rabbit-HRP conjugate Rabbit IgG Amersham Bioscience 
anti-mouse-HRP conjugate Mouse IgG Promega 
His-Tag Monoclonal 
Antibody 
Penta-His tag Novagen 
Living Colors A.v. 
peptide antibody 
GFP-based fluorescent proteins 
(EGFP,ECFP, EYFP, etc.) 
Clontech 
Monoclonal Hepatitis B 
Virus Core Antigen 
antibody (10E11) 
HBcAg (aa 1-10) Abcam 
Polyclonal Hepatitis B 
Virus Core Antigen 
Antibody 
HBcAg AbD Serotec 
Polyclonal anti BTV-10 core BTV-10 VP7, BTV-10 VP3 courtesy of Polly Roy 
Polyclonal anti VP5 GP638 BTV-10 VP5 courtesy of Polly Roy 
Polyclonal anti-NS1 BTV-10 NS1 courtesy of Polly Roy 
anti-BTV-1 VP5 BTV-1 VP5 Institute for Animal Health 
anti-guinea pig Alexa Fluor Guinea pig IgG Molecular Probes 
 
 
 
2.5.6 QUANTIFICATION 
2.5.6.1 UV irradiation of leaves 
To qualitatively show the expression of constructs containing GFP, leaves were 
irradiated with a hand-held Blak-Ray UV lamp (Ultra-Violet Product Ltd.).  
 
2.5.6.2 Bradford assay 
To quantify the total protein content of samples, an assay using Bradford reagent 
(Sigma) was performed. A bovine serum albumin standard curve was prepared using 
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solutions of known concentration, ranging from 3.1 to 150 µg/ml in PBS. Protein samples 
were diluted in PBS to fall within this range (1:50 dilution of plant extracts). Triplicate 
samples were mixed with Bradford reagent according to the manufacturer’s instructions, 
and absorbance at 595 nm was read using a SectraMAX Plus 96-well plate reader.  
2.5.6.3 Enzyme-linked Immunosorbent Assay (ELISA) 
Direct ELISA was used to quantify Hepatitis B core antigen expression in this study with 
a protocol modified from Huang et al. (2006). Briefly, 96-well ELISA plates were coated in 
duplicate with diluted samples and a dilution series of a quantified recombinant HBcAg 
reference (AbD Serotec). Wells were subsequently blocked with blocking buffer, and the 
bound HBcAg was detected with polyclonal anti-HBcAg antibody. The primary antibody 
was detected with anti-rabbit-HRP conjugate. TMB substrate (SIGMA) was used to elicit a 
colour reaction, which was stopped with 1 M sulphuric acid upon perceived saturation of 
the standard curve. Colour reactions were quantified by a multi-well plate reader at 450 
nm. Subtraction of negative control leaf extract reactions allowed quantification of HBcAg 
levels in extracts by comparison to the linear regression of the standard curve and back-
calculation of the dilution factors. Replicates were averaged. 
2.5.6.4 GFP Fluorescence Assay 
GFP fluorescence was used as a means of quantifying the functional GFP present in 
protein extracts using a method modified after Richards et al. (2003). Dilutions of plant 
extracts (1:100 in 0.1 M Na2CO3) were loaded onto black 96-well plates in triplicate. 
Recombinant EGFP (Clontech) was used to prepare a standard curve in diluted negative 
control extract. A SPECTRAmax multi-well fluorimeter was used to excite samples at 395 
nm wavelength and to read the emission at 509 nm. After subtraction of negative control 
values, amounts of GFP present in each sample could be calculated by comparison of the 
emission values with the linear regression of the standard curve. Replicates were 
averaged. 
2.5.6.5 A280 
Purified protein samples were quantified using a NanoDrop spectrophotometer 
(Thermo Scientific) by measuring the absorbance at 280 nm wavelength.   
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2.6 VLP PURIFICATION 
2.6.1 DENSITY GRADIENT CENTRIFUGATION 
For the purification of VLPs, density gradients were formed by injecting solutions of 
increasing density into the bottom of an ultracentrifuge tube, thereby forming a step 
gradient with defined density boundaries. The gradient was then overlayed with plant 
extract. After ultracentrifugation, fractions were collected by piercing the bottom of the 
tube.  
Density gradient materials used include sucrose, iodixanol (Optiprep) and glycerol. A 
concentrated solution (60% w/v of sucrose, or 50% v/v of iodixanol or glycerol) was 
prepared in such a way to ensure a 1x buffer concentration. This concentrated stock was 
then used to make further dilutions in 1x buffer, thus ensuring a constant buffer and salt 
concentration throughout the gradient. 
Specific density gradient media compositions and ultracentrifugation parameters were 
dependent on the properties of the particles to be purified. These are described in more 
detail in Chapters 4, 5 and 6. 
 
2.6.2 SIZE-EXCLUSION CHROMATOGRAPHY (SEC) 
Size-exclusion chromatography (SEC), or gel filtration, is a means of buffer exchange 
and allows the removal of density gradient media. Low molecular weight components are 
retarded in the Sephadex G-25 matrix, while proteins and VLPs are eluted from the 
column.  
Iodixanol gradient media has been found to be more efficiently removed by SEC than 
other methods such as dialysis (Thompson and Buck, 2007). In this study PD-10 desalting 
columns (Amersham) were used according to the manufacturer’s instructions.  
  
CHAPTER 2- MATERIALS AND METHODS 
 
57 
 
2.6.3 ULTRAFILTRATION 
Ultrafiltration was used as a method for buffer exchange and concentration of VLP 
samples. Dilute VLP preparations were applied to a 100 kDa molecular-weight cutoff 
column (Microcon or Amicon, Millipore) and centrifuged. This allowed buffer and small 
solutes to pass through the membrane while retaining and concentrating the VLP above.  
 
2.6.4 DIALYSIS 
Dialysis was used as a method of buffer exchange and to remove density gradient 
medium from samples. Buffer and small solutes pass through a semi-permeable 
membrane along a concentration gradient from the small sample reservoir into a large 
volume of buffer, and vice-versa. In this study, Slide-A-Lyzer dialysis cassettes (Pierce) and 
Float-A-Lyzer dialysis tubing (Spectrum Laboratories) were used. 
 
2.7 VLP ANALYSIS 
2.7.1 ABSORBANCE AT 280NM  
The absorbance of protein samples at 280 nm wavelength (A280) was used as a means 
of protein quantification. Readings from 1.5 μl of sample  were taken using a NanoDrop 
machine (Thermo Scientific). This technique was only used with purified protein and VLP 
samples. Due to the complex composition of some VLPs (inclusion of nucleic acid, 
heteromeric complexes), the A280 value was not heavily relied upon.  
 
2.7.2 DYNAMIC LIGHT SCATTERING (DLS) 
VLP and CLP samples were analyzed by Dynamic Light Scattering (DLS) to determine 
particle radii and the degree of aggregation. A Dynapro Titan DLS machine with dynamics 
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software version 6 was used in this study. Readings were taken at a count rate of 1-2 
million counts for 10 seconds and repeated 10 times.  
 
2.7.3 TRANSMISSION ELECTRON MICROSCOPY (TEM) 
Transmission electron microscopy (TEM) was used to image VLPs, measure their size, 
and as a qualitative means of determining particle integrity. Samples were adsorbed onto 
hexagonal, plastic- and carbon-coated copper grids, which were then washed by floating 
on water droplets. Finally, grids were negatively stained with 2% (w/v) uranyl acetate (UA) 
for 20 seconds, and stain removed using blotting paper.  
Particles were imaged using a FEI Tecnai G2 20 Twin TEM with a bottom-mounted 
digital camera. 
 
2.7.4 NATIVE AGAROSE GEL ELECTROPHORESIS 
Native agarose gel electrophoresis was used to determine qualitative differences in 
particle surface characteristics, and to show nucleic acid encapsidation. Agarose gels (1% 
w/v in TBE) were run in duplicate by loading 10 µg of purified protein sample per lane, 
then applying 60 V for 2 hours. One gel was stained in a dilute bath of ethidium bromide 
for 30 minutes to detect nucleic acid. To detect protein, the other gel was stained with 
Brilliant Blue R Concentrate (Sigma Aldrich) for 30 minutes and destained in 20% 
methanol, 7.5% acetic acid solution.  
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2.8 SOFTWARE 
• Vector NTI Advance 11 (Invitrogen) was used for vector design, in silico cloning strategies, 
sequence analyses and alignments, as well as predictions of protein sequences, sizes and 
attributes.  
• The BLAST function of the National Center for Biotechnology Information website 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) was used both for nucleotide and protein 
sequence alignments. 
• VIPERdb (http://viperdb.scripps.edu/), a database for published structures of icosahedral 
viruses, was used for visualization of whole capsid structures. 
• Crystallographic structures were viewed and imaged using the freeware PyMol 
programme (DeLano Scientific). 
• Microsoft Excel was used for calculations, plots and linear regressions associated with 
ELISA and fluorescence assays. 
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3 EXPRESSION VECTOR DEVELOPMENT 
3.1 INTRODUCTION 
The deleted CPMV expression system (Cañizares et al., 2006), particularly with the 
advent of HyperTrans (HT) technology (Sainsbury and Lomonossoff, 2008), has proved to 
be an extremely useful tool for the expression and production of heterologous proteins in 
plants. The CPMV-HT system is mainly used in transient expression rather than stable 
transformation, easily producing milligram quantities of recombinant protein within six 
days of infiltration, with detectable levels after as little as two days post infiltration. With 
the speed and simplicity of transient expression, the molecular cloning step presents the 
major bottleneck to the speed at which new constructs can be tested.  
 
3.1.1 THE EXISTING CPMV CLONING VECTORS 
In 2007, the standard cloning procedure into the existing CPMV vectors required a 
labour-intensive five days and often longer. The first step relied on the restriction enzyme-
based cloning of an amplified gene of interest (GOI) into a small, high-copy E. coli vector, 
pM81-FSC2 (Figure 3.1; Sainsbury and Lomonossoff, 2008). Constructs had to be carefully 
designed to ensure that the start codon of the GOI was at position 512 of the RNA-2 
sequence, and that it remained within the same frame as the start codon at position 161 
(see Figure 1.2 E). This was due to previous findings that disruption of this frame 
dependence and alterations to the 5’-UTRs had a detrimental effect on RNA-2 replication 
(Holness et al., 1989; van Bokhoven et al., 1993). These strict limitations meant that it was 
not possible to include a multiple cloning site (MCS) or site-specific recombination sites to 
facilitate cloning. After screening of pM81-FSC2 clones, an AscI-PacI fragment containing 
the GOI flanked by the delRNA-2 sequences was subcloned into the large binary vector 
pBINPLUS (Figure 3.1; Cañizares et al., 2006; van Engelen et al., 1995). This cloning strategy 
used existing vectors which were not created for transient expression but rather designed 
for stable integration.  
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Figure 3.1: Schematic representation of pM81-FSC2 and pBINPLUS, the key cloning vectors 
of the CPMV expression system in 2007. 
The unique restriction sites NruI and XhoI allow replacement of the GFP gene in pM81-FSC2 
with a gene of interest. Subcloning of the expression cassette into the binary vector pBINPLUS is 
achieved by restriction cloning into PacI - AscI. 
 
Two serendipitous discoveries allowed the existing two-step cloning system to be 
radically changed at the start of this project. First, it was noted that expression from 
delRNA-2 constructs upon co-infiltration with P19, was not severely impacted by the 
omission of RNA-1. Without the CPMV replication machinery, the expression system was 
now non-replicating. Secondly, the frame dependence within the 5’-UTR was investigated 
to see whether removal of the upstream AUGs had any deleterious effect on this non-
replicating vector. Incredibly, the removal of the in-frame start codon at position 161 
actually increased expression levels of the transgene over 10-fold (Sainsbury and 
Lomonossoff, 2008). Without the previous strict positioning limitations, it now appeared 
possible to improve the existing CPMV cloning system by implementing some of the 
recent advances in molecular cloning and plant binary vector development.  
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3.1.2 RECENT PLANT BINARY VECTOR DEVELOPMENTS 
For nearly three decades, Ti-based binary vectors have been used and optimized for 
the transfer of heterologous genes into plant cells (Lee and Gelvin, 2008). Recent 
optimizations of binary vectors have targeted five key areas: vector size, cloning 
efficiency, GOI targeting and tagging, expansion of host range, and use for multi-gene 
expression. Some examples of these advances are reviewed below. 
A smaller vector size greatly facilitates insertion of fragments of interest into the binary 
vector. The pCB vector series (Xiang et al., 1999) has a minimalized pBIN19-based 
backbone of less than half the original size, allowing the design of multiple-cloning sites 
with more unique restriction sites than in the parent plasmid. The pGreen series benefits 
from an even smaller backbone of less than 3 kb (www.pGreen.ac.uk). This is achieved by 
supplying essential replication genes in trans on a separate plasmid, pSoup (Hellens et al., 
2000).  
In the past decade, site-specific recombination has been increasingly used as an 
efficient alternative to restriction cloning. Gateway technology (see Section 2.2.7) based 
on bacteriophage lambda site-specific recombination (Hartley et al., 2000) has been most 
widely adopted. The earliest Gateway-compatible binary vector for Agrobacterium-
mediated overexpression in plants was p*2GW7, which contains a Gateway cassette 
flanked by 35S promoter and terminator sequences (Karimi et al., 2002). This and a wide 
array of other Gateway binary vectors have been made available through the University of 
Gent website (http://gateway.psb.ugent.be/). More recently, a cloning system based on 
Type IIs secretion restriction enzymes has been developed which allows efficient 
subcloning of a transgene into a pX vector in a 5 minute reaction (Engler et al., 2008). This 
‘Golden Gate’ cloning system promises to be as simple as Gateway cloning, but leaves 
genes of interest without flanking recombination sites.  
Precise subcellular targeting or tagging of a recombinant protein can be important for 
folding and assembly, accumulation, and purification. A number of vector series have 
been developed for these purposes. pSAT vectors allow N- and C-terminal tagging with 
fluorescent markers and have been shown to allow targeting to specific cellular 
compartments (Tzfira et al., 2005). The pEarleyGate series of Gateway-compatible vectors 
can be used for subcellular targeting, affinity tagging as well as fluorescent tagging 
(Earley et al., 2006).  
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Some of the aforementioned developments have enabled the construction of binary 
vectors for the simultaneous expression of multiple genes from a single plasmid. pSAT 
vectors have been used to co-express three cassettes from the same vector through 
sequential restriction cloning (Tzfira et al., 2005). A MultiRound Gateway vector system 
has been used for the co-delivery of seven transgenes from a single vector (Chen et al., 
2006). Remarkably, Golden Gate shuffling has been shown to enable the simultaneous 
subcloning of nine fragments in defined order and orientation within a single reaction 
(Engler et al., 2009).  
Binary vectors can generally be used for transient expression through agro-infiltration 
(see Section 1.2.2), but they are often designed to allow the recovery of stable 
transformants. For that reason, binary vectors generally contain a selectable marker gene, 
which is superfluous for transient expression purposes. Conversely, these vectors do not 
contain an expression cassette for a suppressor of gene silencing, as these are often not 
compatible with the recovery of stable transgenics. Gene silencing plays an important 
role in plant development, and impairment of the pathway by constitutive expression of a 
suppressor of gene silencing causes developmental defects in the regenerated tissue. 
When used transiently, a suppressor of gene silencing is generally supplied by co-
infiltration with another Agrobacterium strain containing a plasmid encoding the 
suppressor sequence (Cañizares et al., 2006; Voinnet et al., 2003). 
 
3.1.3 AIMS OF THIS CHAPTER 
The overall aim of the work described in this chapter was to make the CPMV-HT 
expression system (Sainsbury and Lomonossoff, 2008) more user-friendly. In order to 
facilitate the cloning steps required for the expression of numerous Hepatitis B and 
Bluetongue Virus proteins (see Chapters 4 – 7, Appendix A), the existing vector system 
was improved in several respects. Here, I firstly demonstrate the use of Gateway cloning 
technology as an alternative to restriction cloning. I subsequently show that the existing 
binary vector, pBINPLUS, can be reduced to half of its original size without impact on 
transient expression yields. Based on this minimalized backbone, the pEAQ vector series 
has been created and tailored to different expression requirements, such as transient 
expression through the inclusion of a suppressor of gene silencing. In particular, the 
benefits of co-expressing two genes from the same T-DNA construct have been shown.  
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3.2 SPECIFIC MATERIALS AND METHODS 
Materials and methods specifically pertaining to this chapter are described in detail 
below. Unless otherwise specified, the general molecular biological techniques were used 
as detailed in Chapter 2.  
3.2.1 CONSTRUCTION OF PENTR-ET2 AND PDEST-BINPLUS 
pBINPLUS (van Engelen et al., 1995) was converted into a Gateway destination vector 
using the Gateway Destination Vector Conversion Kit (Invitrogen) according to the 
manufacturer’s instructions. The vector was digested with AscI and PacI, followed by 
blunting with Polymerase I large (Klenow) fragment and dephosphorylation with Calf 
Intestinal Phosphatase (NEB).  
For the construction of pENTR-ET2, pM81-FSC2 was amplified with end-tailoring 
primers attB1-35S-pro-F and attB2-NosT-R (Table 3.1) to engineer portions of Gateway 
attachment B (attB) sites around the CPMV-HT expression cassette. A second round of 
amplification with attB1 adapter and attB2 adapter completed the flanking attB sites. BP 
clonase II enzyme (Invitrogen) was used for site-specific recombination with pDONR207 
(Invitrogen) to yield pENTR-ET2beta. Transformants were sequenced with pDONR207 F 
and pDONR207 R oligonucleotides. 
The NruI site of the pDONR207-derived backbone was removed by site-directed 
mutagenesis (see Section 2.2.6) using primers pENTR-FSC2-NruI-F and pENTR-FSC2-NruI-
R. This resulted in the entry vector pENTR-ET2 with unique NruI and XhoI sites to allow 
pM81-FSC2-based cloning strategies to be used.  
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Table 3.1: Oligonucleotides used in cloning of pENTR-ET2. 
Name Sequencea Function 
   
attB1-35S-pro F AAAAAGCAGGCTTAttaattaa Amplification of 35S-promoter upstream of 
PacI site of pM81-FSC1; end-tailoring of 
partial attB1; sense 
gaattcgagctccaccgc 
attB2-NosT R agaaagctgggtaggcgcgcc Amplification of nos terminator 
downstream of AscI site of pM81-FSC1; end-
tailoring of partial attB2; antisense 
aAG
CTTGAGACTC 
attB1 adapter GGGGACAAGTTTGTACAaaaa
agcaggct 
Universal adapter to end-tailor complete 
attB1 site; sense 
attB2 adapter GGGGACCACTTTGTACAagaa
agctgggt 
Universal adapter to end-tailor complete 
attB2 site; antisense 
DONR207 F gttaacgctagcatggatctcg Sequencing of pENTR207 Entry clones; 
sense 
DONR207 R tcagagattttgagacacggg Sequencing of pENTR207 Entry clones; 
antisense 
ENTR-FSC2-Nru-F gggtataaatgggctcgagataatgt
cgggcaatc 
Site-directed mutagenesis removal of NruI 
site in pENTR-FSC2 backbone; sense 
ENTR-FSC2-Nru-R gattgcccgacattatctcgagcccat
ttataccc 
Site-directed mutagenesis removal of NruI 
site in pENTR-FSC2 backbone; antisense 
a END-TAILORING is shown in uppercase, restriction enzyme recognition sites are underlined, 
mutations
 
 are underlined and bold. 
 
3.2.2 CONSTRUCTION OF THE PEAQ SERIES 
pBD-FSC2-GFP-HT (Appendix C, Figure 1; Sainsbury et al., 2009), a derivative of 
pBINPLUS (van Engelen et al., 1995) containing a CPMV-HT cassette for GFP expression 
within the AscI-PacI sites, was used as a parent plasmid for minimalization of the vector 
backbone. This GFP expression cassette contains the U162C HyperTrans mutation for 
increased translation efficiency (Sainsbury and Lomonossoff, 2008). 
The parent plasmid was amplified with three pairs of primers (Table 3.2) to produce 
three fragments: (1) pBD-LB-F (binding upstream of a natural AhdI site) and pBD-RB-ApaI-
R amplified the T-DNA region; (2) pBD-ColEI-ApaI-F and pBD-TrfA-SpeI-R resulted in a 
fragment comprising the TrfA and NPTII cassettes and ColE1 E. coli origin of replication; (3) 
pBD-oriV-SpeI-F and pBD-oriV-AhdI-R amplified oriV, the RK2 origin of replication. Purified 
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PCR products were restriction enzyme -digested as needed and subjected to a three-part 
ligation to yield pEAQbeta. Sequencing of junctions revealed that 1.2 kb near the nos 
terminator in the T-DNA fragment had been deleted unintentionally. In a second step, 
pBD-FSC2-GFP-HT was amplified with pMini>pMicroBIN-F2 and pBD-RB-ApaI-R, and 
pEAQ-beta was amplified with pBD-ColEI-ApaI-F and pMini>pMicroBIN-R. Following 
digestion with ApaI and FseI and purification, these fragments were ligated to yield pEAQ-
GFP-HT.  
pEAQexpress-GFP-HT was obtained by amplifying the 35S:P19 cassette of pBIN61-P19 
(Voinnet et al., 2003) with 35SP19-Fse-F and -R (Table 3.2), then cloning into the unique 
FseI site of pEAQ-GFP-HT. Similarly, pEAQspecialK-GFP-HT was obtained by amplifying the 
nos promoter and terminator NPTII cassette of pBD-FSC2-GFP-HT with pBD-NPTII-FseI-F 
and –R, then cloning into the FseI site of pEAQ-GFP-HT. Insertions resulting in 
transcription away from the left border gave consistently lower plasmid yields (3 clones of 
each orientation were tested, data not shown) and were termed pEAQselectK(rev). 
pEAQspecialK was obtained by amplifying the 35S:P19 cassette with 35SP19-PacI-F 
and 35SP19-AscI-R (Table 3.2) and cloning the fragment into the MluI – AsiSI sites of 
pEAQselectK. pEAQspecialK was used by Dr. Frank Sainsbury to make pEAQ-HT by 
replacing the GFP gene with a multiple cloning site (Sainsbury et al., 2009). 
To obtain the pEAQ-HT-DEST vectors, a Gateway vector conversion kit (Invitrogen) was 
used to insert the appropriate reading frame (Rf) cassettes containing a chloramphenicol 
resistance gene and ccdB gene for selection, flanked by attR recombination sites, into 
pEAQ-HT. In this way, ligation of RfC.1 into the StuI ⁄ NruI digested vector yielded pEAQ-
HT-DEST1; ligation of RfA into the SmaI ⁄ StuI digested vector yielded pEAQ-HT-DEST2; and 
ligation of RfB into the SmaI ⁄ NruI digested vector yielded pEAQ-HT-DEST3. 
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Table 3.2: Oligonucleotides used in cloning of pEAQ vectors. 
Name Sequencea Function 
   
35SP19-PacI-F TTAATTAA Amplification of 35S-P19 cassette; end-
tailoring of PacI; sense 
gaattcgagctcggtacc
cccctactcc 
35SP19-AscI-R GGCGCGCC Amplification of 35S-P19 cassette; end-
tailoring of AscI; antisense 
atcttttatctttagagtta
agaactctttcg 
35SP19-FseI-F GGCCGGCC Amplification of 35S-P19 cassette; end-
tailoring of FseI; sense 
gaattcgagctcggtac
cccc 
35SP19-FseI-R GGCCGGCC Amplification of 35S-P19 cassette; end-
tailoring of FseI; antisense 
atcttttatctttagagtta
ag 
C1 aacgttgtcagatcgtgcttcggcacc Sequencing of CPMV cassettes; sense 
C3 ctgaagggacgacctgctaaacagga
g 
Sequencing of CPMV cassettes; 
antisense 
pBD-ColEI-ApaI-F GACTTAGGGCCc Amplification of region 1704 – 5155 of 
pBD-FSC2-GFP-HT; end-tailoring of 
ApaI; sense 
gtccatttccgcg
cagacgatgacgtcact 
pBD-TrfA-SpeI-R GCATTAACTAGT Amplification of region 1704 – 5155 of 
pBD-FSC2-GFP-HT; end-tailoring of SpeI; 
antisense 
cgctggctgctga
acccccagccggaactgacc 
pBD-LB-F gccactcagcttcctcagcggcttt Amplification of region 6338-12085 of 
pBD-FSC2-GFP-HT; sense 
pBD-RB-ApaI-R TATTAGGGCCC Amplification of region 6338-12085 of 
pBD-FSC2-GFP-HT; end-tailoring of 
ApaI; antisense 
ccggcgccagatct
ggggaaccctgtgg 
pBD-oriV-SpeI-F GTAGCACTAGT Amplification of region 14373-670 of 
pBD-FSC2-GFP-HT; end-tailoring of SpeI, 
sense 
gtacatcaccgacg
agcaaggc 
pBD-oriV-AhdI-R CAGTAGACAGGCTGTC Amplification of region 14373-670 of 
pBD-FSC2-GFP-HT; end-tailoring of 
AhdI, antisense 
tcgcggc
cgaggggcgcagccc 
pMini-->pMicroBIN-F2 GGCCGGCCACGCGTTATCTGC
AGAGCGATCGC
Amplification of region 2969-85 of 
pEAQbeta; end-tailoring of FseI-MluI-
AsiSI; sense 
aacagctatgacc
atgattacgccaagctg 
pMini-->pMicroBIN-R GCGATCGCTCTGCAGATAACG
CGTGGCCGGCC
Amplification of region 2969-85 of 
pEAQbeta; end-tailoring of AsiSi-MluI-
FseI; antisense 
ctcactggtgaaa
agaaaaaccaccccagtacattaaaaac
gtcc 
pBD-NPTII-FseI-F GGCCGGCC Amplification of the NPTII cassette from 
pBD-FSC2-GFP-HT; end-tailoring of FseI; 
sense 
TACAGTatgagcgga
gaattaagggagtcacg 
pBD-NPTII-FseI-R GGCCGGCC Amplification of the NPTII cassette from 
pBD-FSC2-GFP-HT; end-tailoring of FseI; 
antisense 
TACAGTcccgatctag
taacatagatgacaccgcgc 
a END-TAILORING is shown in uppercase, restriction enzyme recognition sites are underlined, 
mutations
  
 are underlined and bold. 
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3.2.3 GFP EXTRACTION 
Samples for the analysis of GFP expression consisted of three discs from different 
leaves of the same plant, obtained using the end of a 15 ml Corning tube. These 
corresponded to approximately 90 mg healthy fresh weight tissue (hFWT). Samples were 
extracted in 270 μl Extraction buffer (ExB; Table 2.4).  
 
3.2.4 GFP ASSAY 
Fluorescence was used to quantify yields of active GFP in the samples using a modified 
version of a published protocol, as described previously (Section 2.5.6.4; Richards et al., 
2003). Information about sample size and dilution was used to back-calculate the yield of 
fluorescently active GFP expressed in g per kg hFWT. 
 
3.2.5 YFP + CFP EXPRESSION AND CONFOCAL MICROSCOPY 
The genes for YFP and CFP were obtained from vectors pEYFP and pECFP (BD Living 
Colors), respectively. EYFP has an excitation maximum at 513 nm and an emission 
maximum at 527 nm with a brightness [(quantum yield)*(extinction coefficient)] of 151% 
of EGFP (http://www.clontech.com/products/detail.asp?product_id=10419& 
product_group_id=1437&product_family_id=1417&tabno=2). ECFP has an excitation 
maximum at 433 nm and an emission maximum at 475 nm with a brightness of 17% of 
EGFP. The stark difference in relative brightness required the signal of ECFP to be boosted 
relative to EYFP in order to obtain images with a detectable colour shift in the merged 
image, indicating co-localization.  
Fluorescence was imaged using a Leica SP2 inverted confocal microscope. ECFP was 
excited with 85% laser intensity at 458 nm (836 V gain, 1.4 % offset). EYFP was excited 
with 21% laser intensity at 514 nm (488 V gain, 1.9% offset).  
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3.3 RESULTS 
The development of a more efficient vector system was seen as a necessity to make 
the CPMV-HT system more user-friendly. Following on from efforts to make the existing 
cloning vectors Gateway compatible (see Section 3.3.1), a whole new vector series (pEAQ) 
was created. The work described in sections 3.3.2 to 3.3.5 was shared equally with Dr. 
Frank Sainsbury (Laval University, Quebec City, Canada; formerly JIC). 
In order to monitor any possible effects of alterations to the expression vectors, a 
CPMV expression cassette encoding the enhanced green fluorescent protein (EGFP) was 
maintained in the vectors. Expression levels could thus be compared easily by UV 
irradiation of leaves (qualitative) or by a multi-well plate fluorescence assay (quantitative).  
 
3.3.1 GATEWAY ® COMPATIBLE VECTORS FOR SUBCLONING 
Transient expression using the CPMV-HT system is a quick method to determine 
whether a protein of interest is amenable to expression in plants. Once a gene is cloned 
into a binary vector and transformed into Agrobacterium, expression can be detected as 
soon as two days post infiltration. Thus, at the start of this thesis, the most time-
consuming steps in the screening of new constructs were the cloning and subcloning of 
the gene, which took at least five days, but often longer. Particularly the restriction 
enzyme-based subcloning of the expression cassette into the large pBINPLUS vector was 
inefficient and often required repeated attempts.  
Gateway cloning is an alternative to traditional restriction cloning, relying on site-
specific recombination to move DNA fragments from one vector to another (see Section 
2.2.7). This process is faster and often more reliable than restriction enzyme-based 
subcloning.  
In order to make the existing cloning system Gateway-compatible, both pM81-FSC2 
and pBINPLUS (Figure 3.1) had to be modified to accommodate site-specific 
recombination (attachment) sites. To achieve this, the expression cassette (PacI – AscI 
fragment) of pM81-FSC2 was amplified with end-tailoring primers to insert attB1 and 
attB2 sites up- and downstream of the cassette, respectively. A subsequent BP reaction 
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with pDONR207 yielded the entry clone pENTR-ET2 (Figure 3.2). This high-copy plasmid 
retained all of the unique restriction cloning sites utilized in customary cloning strategies 
for insertion of a gene of interest into pM81-FSC2. The resulting attL sites just outside of 
the PacI-AscI fragment made this vector amenable to Gateway LR reactions, while 
maintaining its ability to serve as a source for AscI-PacI cassettes, which will become 
relevant for pEAQexpress cloning (Section 3.3.3)  
 
Figure 3.2: Schematic representation of pENTR-ET2 and pDEST-BINPLUS, Gateway 
compatible versions of the key cloning vectors of the CPMV expression system. 
The unique restriction sites NruI and XhoI allow replacement of the gfp gene in pENTR-ET2 with 
a gene of interest. Subcloning of the expression cassette into the binary vector pDEST-BINPLUS is 
achieved by site-specific recombination between the attL sites of pENTR-ET2 and the attR sites of 
pDEST-BINPLUS.   
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Figure 3.3: Workflow comparison of restriction cloning and Gateway cloning. 
When obtaining a new clone for expression with the CPMV system, Gateway cloning is faster 
and more efficient. Key steps in each procedure are listed with their approximate duration in hours. 
Differences between the two strategies are highlighted in red and green. 
 
Using the Gateway Destination Vector Conversion Kit (Invitrogen), the widely used 
binary vector pBINPLUS was converted to the destination vector pDEST-BINPLUS. In this 
vector, the MCS inclusive of AscI and PacI was replaced by a cassette containing the 
cytotoxic ccdB gene and the chloramphenicol resistance gene, flanked by attR sites.  
Using these new Gateway vectors, subcloning could now be achieved in a one hour 
site-specific recombination reaction between the attL sites of a pENTR-ET2 clone and the 
attR sites of pDEST-BINPLUS, in the presence of the LR clonase enzyme. Potential 
background colonies are suppressed by the presence of the cytotoxic ccdB gene in 
unrecombined pDEST-BINPLUS, and the lack of kanamycin resistance in the pENTR-ET2 
clone.  
The Gateway LR reaction has never failed during my 3-year PhD project, showing that 
it is far more reliable than traditional restriction enzyme-based subcloning. Being able to 
forego the traditional AscI-PacI digest, gel purification, vector preparation and ligation 
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steps, Gateway subcloning is also less labour-intensive and saves approximately half of a 
day’s work (Figure 3.3). 
In order to determine whether the presence of Gateway attachment sites on the 
outside of the expression cassette has any effect on expression levels, GFP expression 
from pDEST-BINPLUS constructs were compared to those of pBINPLUS constructs. The 
observed GFP fluorescence intensity from constructs with the HT mutation was not 
affected by the presence of attB sites (Figure 3.4 A). By using equivalent constructs with 
wild type leader sequences (i.e. delRNA-2, not -HT) which give far lower expression levels, 
it was easier to see minute differences in fluorescence intensity between the two 
constructs. Comparison of pBINPLUS-GFP and pDEST-BINPLUS-GFP showed that 
expression from the Gateway construct may be slightly better than from the traditional 
pBINPLUS construct (Figure 3.4 A). Direct comparison of crude extracts derived from the 
infiltrated leaf tissue by SDS-PAGE (Figure 3.4 B) showed that there was minimal variation 
between the GFP expression achieved from the Gateway vectors, compared with 
restriction-cloned vectors. 
These results indicate that Gateway-compatible versions of the standard CPMV cloning 
vectors allow for easier and more reliable subcloning, without affecting expression levels.  
 
 
Figure 3.4: The presence of Gateway attB sites flanking the CPMV expression cassette does 
not negatively affect expression levels of GFP. 
Leaves were agro-infiltrated with P19 and the GFP constructs in pBINPLUS or pDEST-BINPLUS 
vector backbones as indicated. (A) UV photograph of leaves harvested 6 dpi. (B) Coomassie-stained 
SDS-PAGE of crude extracts from constructs indicated.  HT = HyperTrans; B = pBINPLUS backbone; 
D = pDEST-BINPLUS backbone.  
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3.3.2 STREAMLINING OF THE PBINPLUS BINARY VECTOR BACKBONE 
First generation binary vectors such as pBIN19 (Bevan, 1984) were created to allow 
efficient transformation of plant tissue by stable integration of a transgene. These vectors 
were constructed by using pre-existing restriction sites of other plasmids to assemble 
fragments with desired functional elements: T-DNA region, resistance cassette, origin of 
replication, etc. The complete sequence of pBIN19 was published 10 years after its first 
use, revealing large stretches of sequence which could not be annotated and assigned a 
function (Frisch et al., 1995). Improvements to this early binary vector resulted in 
construction of pBINPLUS (van Engelen et al., 1995). However, the changes undertaken 
did not include the rationalization of the vector backbone. To achieve the goal of creating 
a vector series for easy and efficient cloning, and ultimately one-step cloning, it was 
essential to reduce the backbone size of the binary vector. Smaller vectors often have 
more unique restriction sites and are more compatible with commercial DNA purification 
kits which often have a cut-off of 10 kb.  
In order to monitor any possible effects of alterations to the expression vector 
backbone, pBD-FSC2-GFP-HT was chosen as the parent plasmid. This is a pBINPLUS-
derived plasmid containing a HyperTrans cassette for the expression of the marker protein 
GFP.  
Figure 3.5 shows how selective amplification and ligation of certain regions of the 14.4 
kb pBD-FSC2-GFP-HT resulted in the intermediate vector pEAQbeta and ultimately 
yielded a minimalized vector of 7.2 kb, pEAQ-GFP-HT. Computational analysis of the 
pBINPLUS vector backbone revealed the regions deemed essential for the functionality of 
the binary vector for transient expression purposes. The fragment between the left and 
right borders, shown in red, is the T-DNA which is transferred to the plant cell via type IV 
secretion. The fragment shown in orange contains the ColEI origin of replication, the 
neomycin phosphotransferase (NPTIII) gene for kanamycin resistance, and the TrfA gene 
encoding a replication initiation protein. Finally, the original origin of replication of 
pBIN19, oriV, is shown in yellow. End-tailoring PCR allowed these fragments to be fused in 
a 3-part ligation to yield the intermediate vector pEAQbeta (Figure 3.5 B). Since the CPMV-
HT system is used for the transient expression of proteins, the neomycin 
phosphotransferase gene in the T-DNA region is superfluous, as there is no need to select 
for positive transformants. In a second cloning step, a portion of the T-DNA region 
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encompassing the NPTII cassette for kanamycin selection of transgenics was removed 
(dotted line). 
 
 
Figure 3.5: Schematic representation of the production of the first pEAQ vector. 
(A) pBINPLUS-based expression vector used as a template. Amplified regions highlighted (red, orange, 
yellow). (B) Resulting vector from three-part ligation of amplified regions. (C) Final pEAQ vector obtained 
by minimalization of the T-DNA region: removal of NPTII resistance cassette -dotted line in (B). 
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The resulting vector pEAQ-GFP-HT (Figure 3.5 C) was half of the size of its parent 
vector. However, the removal of 7.2 kb of sequence did not affect its ability to replicate in 
E. coli and A. tumefaciens, giving a plasmid yield comparable to other pBINPLUS-based 
plasmids (data not shown). The minimalization also did not appear to affect the transient 
GFP expression levels achieved from this vector, qualitatively determined by examination 
of infiltrated leaves under UV light (see Section 3.3.4).  The pEAQ backbone alone, without 
the CPMV expression cassette between the AscI and PacI sites, is 5137 bp in size, making it 
one of the smallest binary vectors in use.  
 
3.3.3 THE PEAQ VECTOR SERIES  
The optimal route for expression of a foreign protein using the CPMV system can be 
dependent on the protein product itself, as well as its intended use. For mass production 
of a protein, easy scale-up is essential and the development of stable transgenics may be 
ideal. However, for applications in research and product development, it may be more 
important to have an easy-to-use and fast expression system such as transient expression 
via agro-infiltration. For complex products such as Bluetongue Virus-like particles, it is 
essential to ensure efficient co-expression of two or more genes in the same cell. Since 
every one of these expression strategies has different vector requirements, such as the 
presence of a selectable marker, suppressor of gene silencing, or multiple expression 
cassettes on a single T-DNA, we decided to create a vector series tailored to different 
applications – the pEAQ vectors. 
When constructing pEAQ-GFP-HT, an MCS was introduced between the left border and 
the AscI site of the T-DNA region (Figure 3.6). The overhangs produced by digestion with 
MluI and AsiSI are compatible with the overhangs of AscI and PacI. This compatibility 
allows for the insertion of a second AscI – PacI CPMV expression cassette, resulting in the 
loss of the MluI and AsiSI restriction sites. The other expression cassette (containing gfp in 
the case of pEAQ-GFP-HT) can be easily replaced by any other AscI – PacI cassette from 
pM81-FSC2-, pBINPLUS- or pEAQ-based plasmids, thereby allowing co-expression of two 
genes of interest from one T-DNA. The benefits of this will be discussed in section 3.3.6.  
Subcloning of expression cassettes into the pEAQ vectors is facilitated by the small size of 
the vector.  
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The unique and rare 8-bp recognition sequence of FseI provides a site for the insertion 
of another expression cassette. This site was used to introduce a cassette for the co-
expression of P19, a suppressor of gene silencing. The resulting vector, pEAQexpress, is 
tailored for the high-level transient co-expression of two genes of interest. By having the 
P19 cassette present on the same T-DNA, this effectively allows expression of three 
foreign genes from a single Agrobacterium construct. This simplifies the preparation of 
infiltration solution, makes syringe infiltration easier, and decreases the amount of 
bacteria infiltrated into each leaf, thereby reducing both the stress on the plant and the 
load of contaminating bacterial proteins in downstream processing.  
A second vector was made by the insertion of a NPTII cassette for kanamycin 
resistance into the FseI site. By allowing for the selection of positive integration events 
through growth on kanamycin-containing media, the resulting vector pEAQselectK is 
tailored for the co-expression of one or two genes of interest in transgenic plants. By co-
infiltration with another Agrobacterium for P19 expression, this vector can also be used to 
screen constructs transiently. Whilst screening clones for the direction of insertion of the 
NPTII cassette, it was noted that all pEAQselectK clones with the cassette in the 
unintended reverse orientation (i.e. stop codon closest to the left border) gave up to 2-
fold higher plasmid yields. Hence, this vector should be preferentially used.  
A P19 cassette was also inserted into the MluI-AsiSI sites of pEAQselectK to yield 
pEAQspecialK. This vector can be used for high-level transient expression and has the 
potential to be used for stable integration.  
As stated previously, the discovery of enhanced translational efficiency through 
removal of the in-frame AUG at postion 161 obviated the need to maintain frame integrity 
between the open reading frames at positions 161 and 512 (see Figure 1.2 E). This made it 
possible to insert additional sequences, such as a MCS or Gateway recombination sites, 
between the 5’-UTR and the start codon of the GOI. In order to allow for direct cloning of a 
gene of interest into pEAQspecialK, and to enable easy N- and/or C-terminal His tagging, 
Dr. Frank Sainsbury created pEAQ-HT by replacing the GFP gene of pEAQspecialK with a 
MCS (see Figure 3.6, bottom; Sainsbury et al., 2009) 
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Figure 3.6: Schematic representation of T-DNA regions of the core pEAQ-series vectors. 
Genes and resistance cassettes are identified within the schematic. Unique restriction sites available 
for cloning and sub-cloning are indicated in green. For pEAQ-HT, a close-up of the multiple cloning site 
(MCS) allowing His-tagging is provided below. Promoters and terminators associated with NPTII genes 
were omitted for clarity.  
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3.3.4 THE PEAQ VECTORS RETAIN THEIR HIGH EXPRESSION CAPABILITY 
The transient expression efficiency of the pEAQ series of vectors was investigated by 
agro-infiltration of N. benthamiana leaves. Constructs without a P19 cassette were 
supplied with this suppressor of gene silencing in trans, by co-infiltration with pBIN61-P19 
(Voinnet et al., 2003). Irradiation of infiltrated leaf tissue with UV light qualitatively 
showed that expression levels of GFP are comparable between all pEAQ vectors and their 
parent plasmid pBD-FSC2-GFP-HT (Figure 3.7 A).  
Further analysis of leaf extracts by SDS-PAGE revealed a distinct protein band at 27 
kDa, corresponding to the size of GFP (Figure 3.7 C) . This band is visible in all samples 
except the negative control extract of pBINPLUS-infiltrated tissue, as expected.  
A spectrofluorometric GFP assay allowed the amount of GFP in the samples to be 
quantified by comparison to a standard curve of known concentrations of recombinant 
EGFP (Figure 3.7 B). Expression levels from the parent plasmid pBD-FSC2-GFP-HT and the 
pEAQ and pEAQexpress constructs approached 1 g/ kg FWT. Interestingly, the two 
constructs harbouring the NPTII cassette in reverse orientation, namely pEAQselectK and 
pEAQspecialK, gave significantly higher expression levels, reaching 1.25 g / kg FWT in the 
case of pEAQspecialK. 
To show whether plasmids containing a P19 cassette could be infiltrated at higher 
dilutions of inoculum, pEAQexpress and pEAQspecialK were infiltrated at 2-fold dilutions 
(indicated by 1:2 in Figure 3.7). Indeed, this dilution factor did not have a significant 
impact on expression levels. The ability to use less Agrobacteria further simplifies the 
preparation of infiltration solutions.  
These results show that the pEAQ-based constructs are equal or better in their 
transient expression capability when compared with pBINPLUS-derived constructs, and 
can be used interchangeably.  
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Figure 3.7: GFP expression levels of pEAQ vectors are comparable to those of the parent 
plasmid. 
Leaves were infiltrated with Agrobacterium suspensions of equal density as indicated.  * marks 
co-infiltrations with P19. Inoculums marked with ‘1:2’ were infiltrated with a 2-fold dilution. (A) UV 
illumination of leaves at 7 dpi. (B) Quantitative GFP fluorescence assay. Data represent six 
independent repetitions with standard error indicated. (C) Coomassie-stained SDS-PAGE of 
extracts derived from the leaves shown in (A). 
 
 
3.3.5 GATEWAY COMPATIBLE PEAQ VECTORS FOR HIGH-THROUGHPUT SCREENING 
Gateway technology, as introduced previously, provides an easy, quick and reliable 
alternative to restriction-based cloning, thereby making it a system of choice for high-
throughput screening applications. Gateway compatible vectors exist for all commonly 
used expression systems (bacterial, yeast, mammalian, insect and plant). In order to make 
it easier for researchers to test the benefits of the CPMV-HT system for their own 
purposes, we constructed three Gateway-compatible versions of the pEAQ-HT vector (see 
Section 3.3.3).  
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The pEAQ-HT MCS (Figure 3.6, bottom) was digested with three combinations of blunt-
cutting enzymes, followed by ligation of an appropriate Gateway ccdB cassette to 
maintain the desired reading frame. Digestion with StuI and NruI resulted in pEAQ-HT-
DEST-1 which is used to express untagged proteins (Figure 3.6). Digestion with SmaI and 
NruI gave rise to pEAQ-HT-DEST-2 which can be used to create a N-terminal His tag fusion. 
Digestion with StuI and SmaI resulted in pEAQ-HT-DEST-3 which is useful to create a C-
terminal His tag fusion when used in an LR reaction with an entry clone in which the GOI 
lacks a stop codon.  
To test the expression efficiency of these three vectors, they were used in 
recombination reactions with entry clones harbouring the gfp gene with or without a stop 
codon, as required (Figure 3.8 A). The resulting constructs, pEAQ-GW-GFP, pEAQ-GW-His-
GFP and pEAQ-GW-GFP-His, were used in a transient expression assay. Expression levels 
were quantified by GFP fluorescence assay (Figure 3.8 B). Active GFP was detected at 
levels of 0.7 – 1.1 g per kg FWT, with untagged GFP expressed at the lower and GFP-His 
expressed at the higher end. This large range could be due to plant-to-plant variability. It 
could also be caused by differences in protein stability or fluorescence intensity caused by 
the N- and C-terminal extensions of attachment B sites and His tags.  
Protein extracts were separated on SDS-PAGE gels (Figure 3.8 C). Coomassie blue staining 
revealed a size shift in the His-tagged GFP variants when compared to the untagged GFP, 
as expected. To prove protein identity and show the presence of affinity tags, Western 
blots and immunodetection were carried out. An anti-GFP antibody detected antigen in 
all GFP-containing samples but not the control, as expected. As in the Coomassie blue-
stained gel, the bands detected for the His tagged variants were slower migrating. In the 
case of GFP-His, the affinity tag appeared to be lost in some cases, resulting in a second, 
fast migrating GFP band which was also visible in the Coomassie blue-stained gel.  The 
anti-His antibody detected its antigen in the His-tagged GFP samples only, as expected.  
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Though equal amounts of sample were loaded when preparing the SDS-PAGE and 
Western blots, the signal intensities observed varied considerably. Most notably, N-
terminally His-tagged GFP gave the most intense staining in the Coomassie blue gel, 
indicating a higher amount of recombinant protein in this sample compared with GFP-
His. This is not, however, reflected in the GFP fluorescence assay or the anti-GFP Western 
blot, indicating that some of the expressed protein may be misfolded.  
When mistakenly using the GFP entry clone with a stop codon to make C-terminally 
His-tagged GFP with pEAQ-HT-DEST-3, the resulting construct pEAQ-GW-GFP-Stop 
produced an untagged version of GFP. This was analyzed alongside the other constructs. 
Surprisingly, the fluorescence level achieved from this clone was higher (1.25 g / kg FWT) 
than that of the other constructs (Figure 3.8 B). As expected, the protein did not contain a 
His-tag, as shown by the lack of signal in the anti-His Western blot (Figure 3.8 C). This 
result showed that all three GFP variants can be produced by different LR combinations of 
pEAQ-HT-DEST-2 or pEAQ-HT-DEST-3 with entry clones with or without stop codon.  
The results show that the pEAQ-HT-DEST vectors can be used for transient expression 
of untagged and His tagged proteins of interest, to levels comparable to the other pEAQ 
vectors (see Section 3.3.4). 
 
3.3.6 CONSISTENT CO-EXPRESSION WITH PEAQEXPRESS 
The vector pEAQexpress was constructed to allow efficient expression of two genes of 
interest with P19. Previously, co-expression of two proteins was achieved by co-
infiltration of three Agrobacterium clones, each harbouring either of the two genes of 
interest or P19, as was exemplified by the expression of IgG heavy and light chains 
(Sainsbury and Lomonossoff, 2008). This approach relies on the efficiency of the 
Agrobacterium-mediated T-DNA transfer to ensure that every cell expresses all three 
genes. By including all genes of interest on the same T-DNA, pEAQexpress constructs 
should offer more reliable co-expression.  
In order to demonstrate the benefits of pEAQexpress constructs for co-expression, 
confocal microscopy was utilized to show the co-localized expression of cyan fluorescent 
protein (CFP) and yellow fluorescent protein (YFP). For this purpose, three new constructs 
were made (Figure 3.9). pEAQ-HT-CFP and pEAQ-HT-YFP were based on pEAQ-HT and 
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allow expression of CFP or YFP, respectively. pEAQexpress-CFP-YFP contained both 
expression cassettes for YFP and CFP. These constructs, as well as pEAQ-HT as a negative 
control, were agroinfiltrated into separate leaves of N. benthamiana, each at an optical 
density of 0.2. Additionally, some leaves were infiltrated with a mixture of the pEAQ-HT-
YFP and pEAQ-HT-CFP inocula, with an overall total OD600 = 0.4. An optical density of 0.2 
was previously determined to be sufficient to give even coverage of expression in all cells 
(data not shown).  
On the sixth day post inoculation, leaves were observed using a Leica SP2 inverted 
confocal microscope (Figure 3.10 A). YFP was excited at 514 nm and the emission at 590 
nm was recorded in green. CFP was excited at 458 nm and the emission at 510 nm was 
recorded in red. Merged images of the two channels showed co-localization as a yellow or 
orange signal.  
 
 
 
Figure 3.9: Schematic representation of T-DNA regions of the ECFP and EYFP constructs. 
The arrangement of genes and resistance cassettes is identified within the schematic. ECFP and EYFP 
cassettes are presented with a red or green border, respectively, to indicate the colours chosen to 
represent fluorescent signals from these proteins in later experiments. Promoters and terminators 
associated with NPTII genes were omitted to preserve figure clarity.  
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Figure 3.10: Co-expression of two proteins from a single T-DNA is more homogeneous than co-
infiltration. 
Plants were agro-infiltrated with constructs as indicated. At 6 dpi, leaves were viewed using a Leica 
SP2 Confocal microscope to image YFP (green) and CFP (red) fluorescence.  (A) Expression of YFP and 
CFP from Agrobacterium solutions at OD₆₀₀ = 0.2. (B) Co -expression of YFP and CFP from 
Agrobacterium dilution series. YFP and CFP channels are merged. * For co-infiltrated tissue, original 
Agrobacterium solutions contain an OD₆₀₀ = 0.2 for each construct, overall OD₆₀₀ = 0.4. 
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As expected, pEAQ-HT-YFP gave a signal only in the YFP channel, resulting in only 
green cells in the merged image. Equally, pEAQ-HT-CFP gave a signal only in the CFP 
channel, resulting in red cells in the merged image. The cells of the leaf co-infiltrated with 
both the YFP and the CFP construct responded to excitation in both channels. Though the 
merged image showed an even coverage of expression throughout the tissue, i.e. most 
cells were fluorescent, only a few cells were noticeably yellow /orange. In most cells 
expression of either one or the other fluorescent protein appeared to dominate (Figure 
3.10 A, pEAQ-HT-CFP + pEAQ-HT-YFP).  
As expected, leaf tissue infiltrated with the pEAQexpress-CFP-YFP construct produced 
signals in both the CFP and the YFP channels (Figure 3.10 A). The merged image showed 
all cells in a shade of yellow or orange, indicating that these cells were efficiently co-
expressing both proteins. Though there were slight variations in the shading, with some 
cells redder or greener than others, this was far less pronounced than in the co-infiltrated 
leaf tissue.  
Interestingly, in the cases where both fluorescent proteins were co-expressed, the 
intensity of the fluorescent signal in each channel was lower than when the respective 
protein was produced on its own. This may indicate that cells have a specific capacity for 
the expression of a certain protein. In other words, when two versions of that protein (YFP 
and CFP differ only in nine amino acids) are co-expressed in the same cell, their respective 
expression levels do not appear to be additive.  
In order to determine whether efficient co-expression from pEAQexpress constructs 
persists even at high Agrobacterium dilutions, a two-fold dilution series of the previously 
used inocula was prepared. Confocal microscopy showed that at dilutions exceeding 1:4 
(i.e. total OD600 < 0.5), expression became far more patchy, with some cells not expressing 
any foreign protein. At a dilution factor of 1:32 (OD600 ≈ 0.006), only individual cells were 
expressing fluorescent protein, while most cells did not appear to be subjected to T-DNA 
transfer. At all dilutions, tissue infiltrated with pEAQexpress-CFP-YFP gave efficient co-
expression of both genes of interest in every expressing cell. Instances of co-expression in 
the case of tissue co-infiltrated with two Agrobacterium strains became rarer with 
increasing dilution factors, as expected. 
Upon protein extraction of these tissues, overall CFP and YFP yields would probably be 
similar irrespective of whether or not both genes were transferred on the same T-DNA, 
thereby giving the impression of efficient co-expression. However, this experiment shows 
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that the efficient cellular co-expression required by pairs of interacting proteins would be 
best achieved by cloning of two genes onto a single T-DNA in a vector such as 
pEAQexpress.  
 
3.4 DISCUSSION 
A series of cloning vectors has been constructed to facilitate the use of the CPMV-HT 
expression system for the easy and quick production of heterologous proteins in plants. 
The new vectors address the main drawbacks of the pBINPLUS-based (van Engelen et al., 
1995) cloning system previously used in the group. These drawbacks included the large 
size of the binary vector backbone, inefficiency of subcloning, the need for in trans 
delivery of a suppressor of gene silencing, and the heavy reliance on the efficiency of 
Agrobacterium-mediated T-DNA transfer for co-expression of multiple proteins. The pEAQ 
vector series has been published in Plant Biotechnology Journal (Sainsbury et al., 2009) 
and, together with the HyperTrans technology, is already a widely used tool in the 
research community and industry.  
A crucial step in the design of the new vector series was the minimalization of the 
pBINPLUS binary vector backbone. In 1999, Xiang et al. had shown that it is possible to 
remove half of the backbone of pBIN19, an early binary vector (Bevan, 1984), without 
impacting its functionality. We decided to use an existing pBINPLUS-based GFP 
expression vector as the parent plasmid, with the advantage of having a ColE1 origin of 
replication which produces higher plasmid yields when compared with the pBIN19 
vector. The CPMV-HT expression cassette for GFP allowed the easy monitoring of any 
impact of the vector manipulations on recombinant protein yield. A two-step cloning 
procedure yielded pEAQ-GFP-HT, an expression vector half the size of its parent plasmid, 
with no impact on functionality in transient expression. At a size of 5.1 kb, the vector 
(without the GFP cassette) is one of the smallest binary vectors currently available.  
A multiple cloning site was designed to allow for the insertion of three expression 
cassettes: two sites are compatible with AscI-PacI digested CPMV-HT expression cassettes, 
and another site can be used to insert an expression cassette for a suppressor of gene 
silencing or a selectable marker. Of the five restriction sites chosen for this MCS, four have 
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8 bp recognition sequences making them rare cutters. This design reduces the likelihood 
of these recognition sequences being present in the gene of interest. The adjacent MluI 
and AsiSI sites produce sticky ends which are compatible with the ends of any standard 
AscI – PacI digested CPMV expression cassette. This allows previously prepared fragments 
to be easily inserted into this second location, without the need for PCR to end-tailor new 
restriction sites. Upstream of these two expression cassette insertion sites, the FseI site 
allows for cloning of another fragment of interest, and was used to insert P19 in the case 
of pEAQexpress, or NPTII in the case of pEAQselectK.  
The pEAQexpress vector is particularly tailored for the transient expression of two 
genes of interest. This vector contains an expression cassette for the suppressor of 
silencing P19 (Silhavy et al., 2002; Voinnet et al., 2003), which is commonly used to boost 
expression levels of recombinant protein in plants. Gene silencing suppressors are 
commonly supplied in trans by co-infiltration with another Agrobacterium clone. 
Supplying P19 on the same T-DNA as the gene(s) of interest has four key advantages: 
Firstly, the preparation of inoculum is dependent on the growth of only one 
Agrobacterium culture, making the preparation of infiltration solutions easier. Secondly, 
using one Agrobacterium culture instead of two allows the use of an infiltration solution of 
lower optical density, making the infiltration process easier. Thirdly, the lower overall 
optical density means that the negative impact of Agrobacterium on the plant is reduced, 
which may, in turn, have a positive effect on expression levels. Finally, infiltrating less 
Agrobacteria yields less contaminating bacterial proteins upon extraction.  
This thesis reports the first successful attempt to include P19 on the same T-DNA as the 
gene of interest. Previously, P19 had been included on a separate T-DNA of the helper 
plasmid pSoup associated with pGreenII (Hellens et al., 2005). The effect of the suppressor 
of gene silencing from this second T-DNA was only evident six days post infiltration, 
indicating that the transfer of two T-DNAs from a single Agrobacterium is inefficient. The 
modular nature of the pEAQ vectors also enables the replacement of the P19 cassette 
with that encoding another gene silencing suppressor, if this is required. 
The pEAQselectK vector contains a kanamycin resistance cassette in the FseI cloning 
site and is especially suited for the production of transgenic plants expressing up to two 
genes of interest. Interestingly, the presence of the NPTII cassette in the opposite 
orientation, compared with pBINPLUS, yielded approximately twice as much plasmid in a 
standard miniprep, indicating an effect on copy number. A higher level of GFP 
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fluorescence was detected in both vectors containing this NPTII cassette (pEAQspecialK, 
see Figure 3.7), compared to the other pEAQ vectors and the parent plasmid. If the higher 
copy number observed in E. coli also occurs in Agrobacterium, this may result in the 
delivery of more transcriptionally active T-DNA in each host cell, thereby explaining the 
higher expression levels achieved with these vectors.  
By examining co-expression of ECFP and EYFP on a cellular level, I have shown that 
traditional co-infiltration is not able to produce consistent co-expression in every cell 
(Figure 3.10). In fact, most cells appear to express one fluorescent protein more than the 
other. This effect is not likely due to inherent properties of the proteins themselves, as 
ECFP and EYFP differ only in nine amino acids. Two theories could explain the effect: (1) 
The presence of T-DNA in a plant cell may have an inhibitory effect on future transfer 
events. This would allow the first T-DNA to dominate and cause the observed higher 
expression of one fluorescent protein. (2) The number of Agrobacteria infecting the same 
cell may be low. On average, the ratio of ECFP transfer events and EYFP transfer events 
should approach 1:1. Hypothetically, if a cell receives T-DNA at the same rate from each of 
only four bacteria, the chance of equal ECFP and EYFP transfer events is only 37.5%. At 
such a low inoculum concentration, it is more likely that a cell will receive more of one 
type of T-DNA than the other, thereby producing different relative amounts of the two 
proteins.  
As previously explained, pEAQexpress has the capacity to harbour two AscI – PacI 
CPMV expression cassettes for the consistent co-expression of two genes of interest, in 
addition to P19, from the same T-DNA. By examining the expression of ECFP and EYFP 
from this vector, I was able to show that co-expression from pEAQexpress is achieved in 
every infected cell (Figure 3.10). In fact, the relative expression levels of the two proteins 
appear to be consistent throughout the tissue, as indicated by the consistently yellow-
orange merge image. This consistency is likely due to the equal rate of transfer of the two 
encoding genes, by inclusion on the same T-DNA. The ability to achieve co-expression of 
two (or more) proteins in every single cell is especially important for proteins which need 
to interact, such as the different structural proteins comprising bluetongue virus-like 
particles. The expression of multiple components of an enzymatic pathway also requires 
all components to be present for efficient turnover of the substrate. For the expression 
and assembly of heteromeric complexes such as Bluetongue virus-like particles (see 
Chapters 5 - 7), it is not only important to ensure co-expression in every cell but to ensure 
a certain stoichiometric ratio. Other benefits of co-expression from a single T-DNA and 
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thus a single Agrobacterium strain mirror the four benefits of including P19 on the same 
construct, as discussed above.  
pEAQselectK can couple a kanamycin resistance cassette with two CPMV expression 
cassettes for co-expression in stable transformants. Though this has not been tested so 
far, the use of this vector to produce transgenic lines should also allow for consistent co-
expression of the two genes. Additionally, integration of the two genes of interest into 
the plant genome should be coupled to the same location. This strategy should reduce 
the influence of genetic locus and copy number on relative expression levels of the two 
proteins, though it does not ensure equimolar expression of the two proteins as in the 
case of self-cleaving 2A-polyproteins (Halpin et al., 1999). Most strategies for co-
expression of multiple transgenes involve the sequential transformation and recovery of 
homozygous lines until all wanted transgenes are inserted. By including two transgenes 
on the same T-DNA, a single transformation event should be sufficient to recover co-
expressing lines. For the obtaining of homozygous lines through selfing, the close 
proximity of the two genes should allow them to be selected as one.  
In pEAQspecialK, both the NPTII and P19 cassettes are present on the T-DNA. The NPTII 
cassette was found to enhance plasmid yield and expression levels compared with 
vectors lacking this cassette, or having it in the opposite orientation (Figure 3.7), 
pEAQspecialK thus combines the benefits of this cassette with the presence of a 
suppressor of gene silencing. It was also thought that this vector may be useful for 
checking constructs through transient expression followed by stable integration without 
the need for additional subcloning. However, the wild-type P19 included in this and the 
pEAQ-HT vector makes the recovery of transgenic plants impossible (Dr. Frank Sainsbury, 
personal communication). Recent work has shown that the replacement of wild-type P19 
with a mutant P19 to produce pEAQspecialKm allows recovery of apparently healthy 
transgenic plants while maintaining a boost of expression levels associated with co-
expression of a gene silencing inhibitor (Saxena et al., 2010).  
Gateway-compatible versions of pEAQ-HT provide a fast and efficient alternative to 
this standard restriction cloning vector. The pEAQ-HT-DEST vectors enable existing entry 
clones to be used to transfer a gene of interest into the CPMV-HT expression cassette 
whilst fusing a N- or C-terminal His affinity tag if needed. This is a convenient way to allow 
groups that have never worked with the system before to determine its usefulness for 
their purposes. Many researchers world-wide use Gateway compatible cloning vectors for 
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other expression systems (bacterial, fungal, mammalian, etc.) and may be more willing to 
try the CPMV-HT system in a compatible form. The production of new constructs is also 
greatly simplified by use of Gateway cloning. The few steps involved in this cloning 
method make it ideally suited to high-throughput applications. Recombination reactions 
can be performed in 96-well PCR plates incubated in a PCR machine without the need for 
labour intensive gel extractions. Subsequent screening of colonies can be restricted to 
one or two colonies per clone, due to the effective negative selection of bacteria 
transformed with the unrecombined, cytotoxic ccdB gene-containing destination vector.  
In conclusion, this chapter describes the construction of a series of pEAQ binary 
cloning vectors tailored for the use of the CPMV-HT system for different applications. All 
of the vectors, including Gateway-compatible versions, have been used to obtain 
expression levels equal to or exceeding those obtained with the pBINPLUS derived parent 
vector. This allows these vectors to be used interchangeably for the expression of 
heterologous proteins in plants. For the purposes of this project, the efficiency of cloning 
with these vectors is a particular asset, allowing many constructs to be developed and 
tested. The pEAQ’s small binary vector size, the ability to accommodate multiple 
expression cassettes, and the non-replicative nature of the CPMV-HT expression system 
make this combination uniquely suitable for the expression of heteromeric complexes 
such as Bluetongue VLPs, as well as the more simple Hepatitis B particles discussed next.  
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4 EXPRESSION OF HEPATITIS B TANDEM CORE-LIKE PARTICLES 
4.1 INTRODUCTION 
This chapter describes the use of the CPMV-HT transient expression system to produce 
Hepatitis B (HB) core particles at high levels in plants. These particles are homomultimeric, 
icosahedral structures assembled from the small Hepatitis B core antigen (HBcAg). As 
such, these particles were chosen as an example of a relatively simple VLP, to be 
contrasted with the highly complex, heteromeric Bluetongue particles discussed in the 
next chapters. HB particles have been used by many researchers for the display of foreign 
epitopes for vaccine development purposes. Steric hindrance associated with large 
epitope and protein insertions was the driving force in the development of Hepatitis B 
tandem cores by the groups of David Rowlands (University of Leeds) and David Stuart 
(University of Oxford), as well as the company Iqur Ltd. The tandem core construct allows 
the main immunogenic loop of every second HBcAg monomer to be modified, thus 
reducing steric hindrance associated with the folding insert. Hepatitis B tandem cores 
displaying a number of epitopes have been successfully expressed and shown to 
assemble in plants. 
Following a brief introduction of Hepatitis B virus, this chapter will focus on the 
structure of the HBcAg and the tandem Hepatitis B core antigen (tHBcAg), before moving 
onto the results obtained. 
 
4.1.1 HEPATITIS B VIRUS 
Hepatitis B Virus (HBV) is the type member of the Hepadnaviridae family of liver-
infecting DNA viruses. HBV infections are endemic in all areas of the globe, with an 
estimated 2 billion people infected and accounting for 600 000 deaths annually (WHO, 
2008).  
HBV can cause acute and chronic liver infections, depending on its route of transfer. 
Horizontal transfer via body fluids causes acute viral hepatitis in 90% of cases (reviewed 
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by Rehermann and Nascimbeni, 2005). The virus is usually cleared within several weeks, 
providing life-long immunity to re-infection.  Vertical transmission to the neonate is the 
major cause of chronic liver infections leading to death by liver cirrhosis or cancer in 25% 
of infected individuals later in life.  
The infectious agent of viral hepatitis, a 42 nm particle comprising a nucleocapsid of 
28 nm diameter enveloped by a lipid bi-layer, was first identified by electron microscopy 
of serum from infected individuals (Dane et al in 1970). These “Dane particles” are a minor 
fraction of the total HB antiserum-recognized particles, most of which are 22 nm subviral 
Hepatitis B surface antigen (HBsAg) particles.  
 
 
 
Figure 4.1: Schematic representation of the genome structure of HBV. 
The open reading frames of the four subgenomic mRNAs are indicated by arrows. HBcAg is the 
product of translation of the C region (1901 - 2455). HBeAg is the product of translation of the Pre 
C and C regions (1814 - 2307). C = core; S = surface; P = polymerase; X = X antigen. (Figure 
copyright: Park et al., 2006) 
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Within the first decade after identification of the Dane particle, DNA polymerase 
activity was shown to be associated with the DNA-containing core particle. The HBV 
genome was first cloned and heterologously expressed in E. coli in 1979 (Burrell et al., 
1979). In the same year, sequencing of the HBV genome (Figure 4.1) enabled the 
identification of the viral genes and allowed first analyses of the gene structure and 
amino acid composition (Pasek et al., 1979).  
The Hepatitis B virus structure is that of an enveloped icosahedral capsid containing a 
3.2 kb, partially double-stranded DNA genome. Upon receptor-mediated interaction with 
a hepatocyte membrane, the virus is internalized via endocytosis, thereby shedding its 
envelope through membrane fusion. The released nucleocapsid is transported to the 
nucleus where it disassembles, releasing the viral genome. The nicked circular genome 
acts as a template for transcription of four co-terminal messenger RNAs, which, upon 
export into the cytoplasm, allow production of viral proteins by the host translational 
machinery (reviewed by McLachlan, 1991). 
Assembly of the virus begins in the cytoplasm, where HBcAg assembles around the 
longest mRNA and the viral DNA polymerase to form the nucleocapsid. Six different 
lengths and glycoforms of surface antigen are co-translationally translocated to the 
endoplamic reticulum (ER) membrane and allow budding of the formed capsid into the 
ER lumen. Fully formed particles are then exported via the Golgi apparatus.  
In addition to the mature HBV particle, infection results in an accumulation of other 
viral products in the blood stream. Subviral particles of 22 nm diameter are the result of 
spontaneous budding of HBsAg particles without nucleocapsid (Dane et al., 1970). Some 
stages of infection also give rise to a large amount of freely circulating E antigen (HBeAg), 
a nonstructural protein encoded by the same gene as HBcAg. The E antigen is thought to 
cause T-helper cell tolerance in infants of HBeAg-positive mothers, resulting in the high 
90% rate of chronic infections through vertical transmission (Milich et al., 1997). 
 
4.1.2 HEPATITIS B ANTIGEN AND PARTICLE STRUCTURE 
The first insight into the structure of HBcAg came with the sequencing of the HBV 
genome and identification of the HBcAg gene in 1979 (Pasek et al., 1979). The core 
antigen used in this study is based on a 21 kDa protein consisting of 183 aa (Figure 4.2 A).   
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The 36 amino acid carboxy terminus features four arginine-rich repeats, giving it an 
overall positive charge. This protamine-like domain is required for nucleic acid binding 
and encapsidation, but is not essential for particle assembly (Gallina et al., 1989). 
HBcAg is expressed in the cytosol and adopts a largely alpha-helical structure (Figure 
4.2 B). A homodimer is formed by the interaction of a hairpin consisting of the two 
longest amphipathic helices of one monomer with that of another (Böttcher et al., 1997). 
As determined by cryo-electron microscopy (CEM), this gives the dimer a hammer-like 
appearance, with the four-helix bundle forming the ‘handle’ (Crowther et al., 1994).  
The stability of the HBcAg particle is, in part, due to the presence intra- and 
interprotein disulfide bridges. The full-length protein contains four cysteine residues: 
Cys48, Cys61, Cys107, Cys183. The dimer binding surface at the two hairpins is always 
stabilized by a Cys61-Cys61 disulfide bridge (Figure 4.2 B; Wynne et al., 1999; Zheng et al., 
1992). Zheng et al found that a Cys48-Cys48 bridge could also form in some cases to 
further stabilize the dimer. However, the crystallographic data of a truncated HBcΔ149 
particle showed no evidence of this covalent bond (Wynne et al., 1999). The cysteine 
residue at position 107 is buried within the monomer and is not involved in S-S bond 
formation. Although the amino-terminal 144 amino acids of HBcAg are sufficient for 
particle assembly (Birnbaum and Nassal, 1990), the truncation of the carboxy terminus 
has implications for the stability of the particles. In fact, Cys183 can form disulfide bridges 
with the same residue of an adjacent dimer, thereby stabilizing the core particle (Wynne 
et al., 1999).  
Despite the importance of the C-terminal domain of HBcAg for particle stability, a 
truncated version consisting of the first 149 amino acids (HBcΔ149, Figure 4.2 A) is often 
used, especially for biotechnological applications. This has the advantage of allowing 
high-level expression and efficient capsid assembly, while disabling the encapsidation of 
host mRNA (Zheng et al., 1992).  
The first electron micrographs of recombinant E. coli-derived HBcAg particles 
published in 1982 show two distinct size classes (Cohen and Richmond, 1982). These were 
later identified by CEM to be two icosahedral structures with different triangulation 
numbers. A minority of the particles measures 32 nm in diameter and consists of 180 
subunits, with a triangulation number of T=3. The majority of particles (~85%) are larger, 
measuring 36nm in diameter and consisting of 240 subunits arranged as 120 dimers 
(Böttcher et al., 1997; Crowther et al., 1994). Both particle structures have a ‘spiky’ 
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appearance, owing to the two alpha-helical hairpins protruding from each dimer (Figure 
4.2 C).   
 
4.1.3 HBCAG IMMUNOGENICITY AND DISPLAY OF FOREIGN ANTIGENS 
During natural HBV infection and clearance, antibodies are raised against surface 
antigen, E antigen as well as core antigen. The shared main antigenicity determinant of 
HBcAg and HBeAg, which are derived from the same open reading frame, was found to 
be located between amino acids 74-89 (Salfeld et al., 1989) of HBcAg. This corresponds to 
the hairpin loop exposed on the tip of the spike in the assembled HBcAg particle and is 
called the c/e1 loop (Figure 4.2 B).  
Hepatitis B core particles were first used as carriers for epitopes by N- terminal fusion 
of 20 amino acids of FMDV (Clarke et al., 1987), and C-terminal fusion of epitopes of 
HBsAg and HIV (Stahl and Murray, 1989). Although such particles elicit an immune 
response against the inserted epitope, a stronger immune response, especially a T-cell 
response, is still raised against HBcAg itself by way of the immunodominant c/e1 loop. 
Schödel et al have shown that the strongest response against a foreign epitope is 
achieved when this is diplayed internally at the c/e1 loop (Schödel et al., 1992).  
In 1991, researchers inserted foreign epitopes of up to 40 amino acids into the c/e1 
loop and found a 10-fold higher immune response against the foreign epitope from these 
particles when compared with an N-terminal fusion (Brown et al., 1991). The c/e1 loop has 
since been used by many groups for the display of foreign antigens (Schödel et al., 1996; 
Walker et al., 2008; Whitacre et al., 2009) 
 
4.1.4 HBCAG EXPRESSION IN PLANTS 
Having been successfully expressed in many heterologous systems, such as bacteria, 
yeast, and insect and mammalian cell culture, it is no surprise that HBcAg was one of the 
first VLPs to be expressed in plants. In 1998, the purification of HBcAg VLPs from 
transgenic tobacco plants was reported (Tsuda et al., 1998). Yields were estimated at 12-
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24 mg HBcAg per kg fresh weight tissue and plant-derived HBcAg was shown to be 
equivalent to bacterial HBcAg in terms of its use in haemagglutination inhibition assays. 
Transient expression of HBcAg was first achieved in the Lomonossoff group using PVX 
and CPMV full-length viral vectors (Mechtcheriakova et al., 2006). Using the CPMV viral 
vector, yields after purification were low (ca. 10 mg / kg FWT) and comparable to those 
achieved in transgenic tobacco, while yields from the PVX-based vector were at least five-
fold higher. Soon after, Huang et al (2006) expressed HBcAg using the ICON Magnifection 
system (Marillonnet et al., 2004) to high estimated levels of 2.4 g / kg FWT within seven 
days of infiltration. These particles were shown to be immunogenically equivalent to E. 
coli-derived HBcAg upon intraperitoneal injection. Interestingly, the plant-derived 
particles also induced an immune response upon mucosal delivery (intranasal and oral), 
indicating their potential as oral vaccines.  
More recently, HBcAg has been transiently expressed using the CPMV-HT system, to 
levels exceeding 1 g / kg FWT (Sainsbury and Lomonossoff, 2008). High yields (0.8 g / kg) 
were also achieved transiently using a DNA replicon vector based on Bean Yellow Dwarf 
Virus (Huang et al., 2009). 
To date, plants have been used to express two epitope-displaying HBcAg variants: A 21 
amino acid immunogenic epitope of FMDV and a 16 kDa anthrax protective antigen (PA-
D4) were both inserted into the c/e1 loop of HBcAg and expressed in transgenic tobacco 
plants (Bandurska et al., 2008; Huang et al., 2005). 
 
4.1.5 TANDEM CORE TECHNOLOGY 
Despite these successes in heterologous expression and epitope display, HBcAg is still 
not used as a universal peptide vaccine display platform. This has two main reasons: 
Firstly, the insertion of a foreign sequence into an internal protein loop places structural 
constraints on the insert. In order to allow proper folding, large inserts must either have 
their natural N- and C-terminus in close proximity, or they must be attached via long 
flexible peptide linkers. Secondly, the close proximity of the two c/e1 loops in the dimer 
structure limits the size of insert that can be successfully displayed. Large insertions 
prevent particle assembly through steric hindrance (Nassal et al., 2008). The tandem 
Hepatitis B core (tHBcAg) was developed to alleviate these steric constraints on the insert.   
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Through computational analyses of the HBcAg particle structure, the tandem core 
gene constructs were designed to allow fusion of two HBcAg monomers through a 
flexible peptide linker (Figure 4.3 A; Gehin et al., 2004) This genetic fusion increases the 
versatility of the HB core antigen as an epitope carrier in two ways. Firstly, expression of 
the complete dimer structure as a single peptide allows the display of a foreign epitope 
from one of the two c/e1 loops, while leaving the other loop unchanged. Thus, the 
resulting particles can be decorated with half of the number of foreign epitopes, 
providing more space for proper folding of large inserts, such as whole proteins (Figure 
4.3 B-C). Secondly, the two c/e1 loops of the dimer can now be addressed separately. This 
gives the tandem core potential to be used as a multivalent vaccine platform through the 
insertion of two different foreign epitopes in the two c/e1 loops of the tHBcAg  
When work on this project commenced in 2007, the developers of the tandem core 
technology had already demonstrated the ability of tHBcAg to form particles in E. coli. 
Insertion of a small HBsAg epitope as well as insertion of the gfp gene into the c/e1 loop 
of core B had also been successful. However, epitope-displaying particles prepared from 
E. coli were heterogeneous in their appearance under the TEM. In addition to the 
expected T=3 and T=4 particles, other particulate forms exceeding 100 nm in diameter 
were also abundant. This heterogeneity makes the characterization of these tandem core 
particles difficult, and it would also prove problematic in the bid for regulatory approval 
as a drug. 
In a bid to determine whether a plant-based expression system could alleviate these 
problems, I used the CPMV-HT system to express tandem core particles. Two versions of 
the tandem core were used in this work. Homotandem core (CoHo7e) constructs consist 
of two truncated HBcΔ149 genes fused by a glycine -serine-rich linker. Heterotandem 
cores (CoHe7e) consist of a truncated HBcΔ149 (core A) fused to a full length HBcAg (core 
B) through a glycine-serine-rich linker (Figure 4.3 D).  
 
4.1.6 AIMS OF THIS CHAPTER 
The work presented in this chapter demonstrates the use of the CPMV-HT expression 
system in the production of monomeric and tandem Hepatitis B particles in leaf tissue. 
Tandem core constructs with and without inserts can be expressed transiently and are 
CHAPTER 4- TANDEM HB CORE 
 
100 
 
shown to assemble into virus-like particles of regular shape and size. Development of the 
pEAQ vector series (Chapter 3) allowed many different constructs to be cloned and tested 
with relative ease. The expression levels of HBcAg achieved using the HyperTrans 
technology (Sainsbury and Lomonossoff, 2008) are 100-fold higher than those previously 
reported from the full-length CPMV viral vector (Mechtcheriakova et al., 2006), bringing 
them in line with the yields achieved using the MagnICON system (Huang et al., 2006), but 
without the need for viral replication. The use of the CPMV-HT system also avoids the 
problem of contaminating CPMV virions. These characteristics make the CPMV-HT system, 
in conjunction with the pEAQ vector series, an ideal system for the transient expression of 
tandem HB particles for medical applications.  
 
4.2 SPECIFIC MATERIALS AND METHODS 
4.2.1 CLONING 
Tandem HB constructs CoHe7e-empty, CoHe7e-eGFPs, CoHo7e-sAg, CoHo7e-
sAg,eGFP contained within the pET28b backbone were obtained from Dr. Lucy Beales 
(Iqur Ltd). From these, new pET28b clones for CoHo7e-empty, CoHe7e-sAg, CoHe7e-
sAg,eGFP were prepared by restriction cloning using unique restriction sites contained 
within the hetero- and homotandem core constructs (see Figure 4.3). Constructs were 
transferred to the CPMV-HT expression system in one of two ways: (1) Constructs were 
amplified with T7_20mer_for and HBcAg_dual_StuI_rev (see Table 4.1), digested with 
NcoI - StuI and ligated into pM81-FSC1 (as pM81-FSC2, but with other unique restriction 
sites), followed by AscI – PacI subcloning into pBINPLUS or pEAQ-HT, as previously 
described. (2) Constructs were amplified with attB1-CoHx7e-fwd and attB2-CoHe7e-rev or 
attB2-CoHo7e-rev, followed by amplification with attB1 adapter and attB2 adapter to end-
tailor Gateway attachment B sites. These PCR products were then transferred to pEAQ-
DEST-1 (Chapter 3) by sequential Gateway BP and LR recombination reactions.  
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Table 4.1: Oligonucleotides used in cloning of HB tandem core constructs. 
Name Sequencea Function 
   
T7_20mer_for taatacgactcactataggg Universal primer for amplification from the 
T7 promoter; sense 
HBcAg_dual_StuI_rev GGAGGCCT Primer for end-tailoring of StuI site to 
CoHe7e constructs; antisense 
ATCTCActcgagac
attggctttcacg 
attB1-CoHx73-fwd AAAAAGCAGGCTTAatggacat
cgatccgtac 
Primer for end-tailoring of partial attB1 site 
to 5’-end of tandem core constructs; sense 
attB2-CoHe7e-R AGAAAGCTGGTATCActcgag
acattggctttc 
Primer for end-tailoring of partial attB2 site 
to 3’-end of CoHe7e constructs; antisense 
attB2-CoHo7e-R AGAAAGCTGGGTATCActcga
gaacaaccgtcgt 
Primer for end-tailoring of partial attB2 site 
to 3’-end of CoHo7e constructs; antisense 
attB1 adapter GGGGACAAGTTTGTACAaaaa
agcaggct 
Universal adapter to end-tailor complete 
attB1 site; sense 
attB2 adapter GGGGACCACTTTGTACAagaa
agctgggt 
Universal adapter to end-tailor complete 
attB2 site; antisense 
a END-TAILORING is shown in uppercase, restriction enzyme
 
 recognition sites are underlined. 
 
4.2.2 EXTRACTION OF HB TANDEM CORE PARTICLES  
Protein extractions of small and large-scale samples were performed as previously 
described (Section 2.5.1). The aggregation experienced with some epitope-containing 
constructs necessitated the use of two different extraction protocols. 
1. Monomeric HBcAg, CoHe7e-empty, CoHo7e-empty:  Tissue was homogenized in 3 
volumes of Extraction Buffer (ExB): 50 mM Tris-HCl pH 7.25, 150 mM NaCl, 2 mM 
EDTA, 0.1% (v/v) Triton X-100, supplemented with 1 mM DTT and Complete 
Protease Inhibitor Cocktail (Roche).  Whole extracts were clarified by centrifugation  
at 13 000 rpm (16 000 x g in microcentrifuge), 2 minutes, 4°C.  
2. Epitope-containing tandem core constructs: Tissue was homogenized in 3 
volumes of HB Extraction Buffer 1 (HBexB1): 10 mM Tris-HCl pH 8.4, 120 mM 
NaCl, 1 mM EDTA, 0.75% (w/v) Sodium deoxycholate, supplemented with 1 mM 
DTT and Complete Protease Inhibitor Cocktail (Roche). Whole extracts were 
clarified by initial centrifugation at 9 000 x g, 10 minutes, 4°C, followed by 
decanting and a second spin at 3 500 x g, 5 minutes, 4°C.  
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Due to the reduced contamination with chlorophyll upon extraction with HBexB1, this 
buffer was also sometimes used to purify monomeric and empty tandem core particles, 
albeit at lower yield.  
4.2.3 SUCROSE GRADIENTS 
Sucrose solutions of 50%, 40% and 30% (w/v) sucrose were prepared by dilution of a 
60% (w/v) solution of sucrose in 10 mM Tris-HCl pH 8.4, 120 mM NaCl stock solution with 
the appropriate amount of 10 mM Tris-HCl pH 8.4, 120 mM NaCl. Gradients were prepared 
by underlaying sucrose solutions of increasing density (500 µl each) in a suitable 
ultracentrifuge tube and carefully overlaying the clarified extract to fill the tube. Gradients 
were centrifuged in a swing-out rotor (SW41Ti) at 40 000 rpm, 2.5 hours, 4°C. Depending 
on the scale of the experiment, larger or smaller swing-out rotors were used and the 
volume of sucrose solutions and centrifugation speed were adjusted accordingly.  
 
4.2.4 CRYO-EM 
Cryo-electron microscopy (CEM) and reconstructions were performed in collaboration 
with Dr. Robert Gilbert and Dr. Alistair Siebert (Division of Structural Biology, University of 
Oxford).  
Sucrose fractions were buffer exchanged for 10 mM Tris-HCl pH 8.0, 50 mM NaCl. Holey 
carbon grids were glow discharged for 30 seconds, then loaded into a Cryoplunge 3 
machine (Gatan UK).  Samples (5 μl) were adsorbed onto grids at ~60% humidity, blotted 
for 2 seconds, then plunged into liquid ethane to flash-freeze. CEM was perfomed on a 
Tecnai F30 microscope at 300 kV accelerating voltage under low-dose conditions. Images 
on Kodak S0-163 film were scanned at 7 µm step size. Selected particles were corrected 
for contrast transfer function and processed using EMAN and Spider software. 
3D reconstructions were prepared using computational tools for icosahedral particle 
reconstructions based on the method described by Fuller (1987; 
http://www.embl.de/ExternalInfo/fuller/EMBL_Virus_Structure.html).  
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4.3 RESULTS 
4.3.1 HBCAG AND TANDEM CORE GENE EXPRESSION 
The expression of HBcAg particles using CPMV-based expression systems had 
previously been demonstrated (Mechtcheriakova et al., 2006; Sainsbury and Lomonossoff, 
2008). To examine whether high-level expression of tHBcAg could also be achieved, 
constructs obtained from Dr. Lucy Beales (iQur Ltd.) were cloned into pEAQ vectors 
containing the HT mutations. The constructs tested included homo- and heterotandem 
cores with insertions two different foreign polypeptides within the c/e1 loop of core B 
(Figure 4.4): (1) A 40 aa immunogenic epitope of HBsAg epitope (sAg) as an example of a 
medically relevant antigen insertion; (2) The 27 kDa EGFP protein as a model large protein 
insert whose expression and proper folding could be tracked easily. Tandem HBcAg 
containing both of these inserts, one in each c/e1 loop of cores A and B, were also 
expressed to demonstrate the versatility of the tHBcAg technology for the display of two 
different antigens on the same particle.  
The constructs were agroinfiltrated into N. benthamiana leaf tissue and samples were 
harvested after seven days. All HB constructs induced chlorosis in the infiltrated leaf 
tissue, when compared to an empty vector control (Figure 4.5 A). Necrotic spots were 
visible in some leaves infiltrated with monomeric HBcAg, CoHe7e-empty and CoHo7e-
empty. Generally, this effect was more visible in older leaves (not shown). Tandem core 
constructs containing an insert did not appear to induce necrosis at 7 dpi. 
For reducing, denaturing SDS-PAGE analysis, whole crude extract (without 
clarification) was used for each sample to avoid any loss of tHBcAg within the clarification 
pellet (Figure 4.5 B-C). An anti-HBcAg Western blot detected distinct bands of different 
mobility in all samples infiltrated with HB constructs, corresponding to the expected 
molecular weights (MW) of the constructs (compare Figure 4.4 and Figure 4.5 C). This was 
very good news, because it showed that good expression could be achieved from a wide 
range of different tHBcAg constructs using the CPMV-HT system. Tandem cores, 
consisting of two HBcAg monomers linked by a peptide linker, were of approximately 
twice the molecular weight of monomeric HBcAg (21 kDa). Where both hetero- and 
homotandem versions were examined, the heterotandem band was of higher MW than 
the homotandem band, as expected. With the exception of CoHo7e-empty, all tandem   
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core samples gave some additional bands of higher MW than the monomer detected in 
the blot. These likely corresponded to dimers and multimers which were insufficiently 
disrupted during boiling, indicating that the expressed proteins assemble into higher 
order structures or aggregates. Homotandem core antigens containing inserts (CoHo7e-
sAg and –sAg,eGFP) also produced some fast migrating bands recognized by the primary 
antibody. These were most likely breakdown products, indicating that the homotandem 
core construct is inherently less stable than the corresponding heterotandem core 
construct. Our collaborators were impressed by the generally low level of tHBcAg 
breakdown products in the plant samples, because protein stability had been a problem 
in the E. coli and yeast expression systems.  
Coomassie blue staining of a duplicate SDS-PAGE gel run in parallel with that used for 
Western blotting showed that the tHBcAg versions differed markedly in their expression 
levels (Figure 4.5 B). The most intense band by far was obtained from the homotandem 
CoHo7e-sAg,eGFP, while the protein band corresponding to the heterotandem version, 
CoHe7e-sAg,eGFP, was barely detectable. These differences in band intensity were not 
due to variations in loading: Since the band obtained from the Rubisco large subunit at 51 
kDa was similar in intensity in all samples loaded, it can be inferred that any differences in 
other band intensities were due to variability in expression levels of those proteins. 
Generally, the homotandem core constructs appeared to be expressed to higher levels 
than their heterotandem equivalents. This is consistent with the observation that 
homotandem constructs are also expressed to higher levels in E. coli (iQur, personal 
communication). The clear visibility of tHBcAg bands in crude extract samples provides a 
clear indication that these proteins were expressed at high levels in plants, which was a 
very important prerequisite for the success of future work on their characterization. 
These results show that tHBcAg displaying different polypeptides, ranging from small 
epitopes to whole proteins, can be expressed in plants, both as homotandem cores as 
well as heterotandem cores. One construct, however, failed to express. This was a 
homotandem core with a very large, 789 aa insertion of Hepatitis A VP1 in the c/e1 loop of 
core B (CoHo7e-HAVP1; Figure 4.4). On numerous attempts, I failed to detect any HBcAg 
in these samples, indicating that there may be a limit to the size and/or complexity of the 
inserts tolerated in the tandem core (data not shown).  
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Figure 4.5: Hepatitis B tandem cores can be transiently expressed in Nicotiana benthamiana. 
(A) Day light photograph of leaves harvested 7 dpi, after infiltration with indicated pEAQ-based 
Hepatitis B constructs. (B) Coomassie-stained SDS-PAGE of crude extracts from constructs indicated. (C) 
Duplicate SDS-PAGE, subjected to Western blotting and monoclonal anti-HBcAg Ab immunodetection of 
HBcAg and tHBcAg. Red arrows indicate the location of bands corresponding to HBcAg or tandem core 
monomers. M = SeeBlue Plus 2 marker; C = empty vector control. 
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4.3.2 HBCAG AND TANDEM CORE ACCUMULATION OVER TIME 
To determine the optimal time point for harvesting of monomeric and tandem core-
expressing leaf tissue, a time course experiment was performed. Twelve plants were 
infiltrated in such a way that each of three leaves had three infiltrated patches expressing 
different constructs: pEAQ-HT as a negative control, pEAQ-HT-HBcAg (monomeric) or 
pEAQ-HT-CoHe7e-empty (tandem). The leaves of one plant were harvested every 24 
hours (later time points at 48 hour intervals), and samples consisting of three leaf discs 
from three separate leaves were frozen for later analysis. 
Clarified extracts were used in an enzyme-linked immunosorbent assay (ELISA) to 
quantify the extractable immunogenic material (Figure 4.6 A). A commercially available 
recombinant E. coli-produced HBcAg (AbD Serotec) standard was used to prepare a 
standard curve. Monomeric HBcAg was expressed to high levels of 300 mg /kg FWT 
within the first 48 hours post infiltration. The yield continued to rise until the fifth day, 
when a plateau was reached. After seven days, necrosis was evident in some of the 
infiltrated tissue, and more pronounced in the older leaves. The extent of the necrosis was 
highly variable between plants and after 10 days some leaf tissue was dry and brittle 
while other leaves still contained moisture. Yields measured from dry samples were lower 
than those achieved from tissue with some remaining moisture. 
Due to the variability in sample weight depending on the extent of necrosis, yields 
were calculated per kilogramme of healthy
In this particular experiment, the highest yield of soluble HBcAg was 0.5 g / kg hFWT. 
In other experiments, yields were up to 2-fold higher than this, which could be due to 
variability in plant age and health, or seasonal variabilty.  
 fresh weight tissue (hFWT). The samples 
contained the same area of leaf tissue (2.85 cm2), which weighs approximately 100 mg if 
obtained from a healthy plant. 
As seen for monomeric HBcAg, the CoHe7e-empty construct also showed a maximum 
expression at 5 dpi, followed by a plateau and a decline in extractable immunogenic 
material around day 10. However, appreciable levels of tandem core were only detected 
after 3-4 dpi, which was later than in the case of monomeric HBcAg. The maximum yield 
of soluble CoHe7e-empty appeared to be five-fold lower than that obtained for 
monomeric HBcAg. This is inconsistent with the results of other experiments, where 
Coomassie blue staining and anti-HBcAg Western blot analysis indicated similar   
CHAPTER 4- TANDEM HB CORE 
 
108 
 
 
 
 
Figure 4.6: Quantification of extractable Hepatitis B core antigen over time. 
Plants were agro-infiltrated with constructs as indicated. Leaf samples (3 discs from separate 
leaves of the same plant) were harvested and stored at -20˚C every 24 hrs. Samples were 
homogenized in HBexB1 and clarified at 3000 x g, 5 min. (A)  Direct ELISA quantification of HB core 
antigen expression from monomeric HBcAg (black) and heterotandem core (grey) constructs. 
Measurements represent single extracts. * sample consisting of entirely necrotic tissue - not 
representative. (B) Coomassie-stained 12% SDS-PAGE of monomeric HBcAg extracts. M = SeeBlue 
Plus 2 marker; + = E. coli recombinant HBcAg control  
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expression levels of monomeric and empty tandem HB core (see Figure 4.5 B-C). This low 
signal may, in part, be due to altered accessibility of the epitopes recognized by the anti-
HBcAg polyclonal antibody used in ELISA, which could have a negative impact on signal 
intensity. The ELISA result would be more reliable if a tHBcAg control of known 
concentration was used to generate the standard curve for the tandem core samples.  
The results of the time course experiment indicate that the ideal time point to harvest 
tandem and monomeric HB core antigen expressing tissue is at least 5 dpi.  
 
4.3.3 INFLUENCE OF DISPLAYED EPITOPES ON PROTEIN SOLUBILITY 
The display of foreign epitopes on the surface of a virus particle can significantly alter 
the surface characteristics (charge, hydrophobicity, structure) of the particle. These 
changes also have a profound effect on physical properties such as molecular weight and 
isoelectric point (pI), making the chimaeric particle behave differently during extraction 
and purification.  
At the start of this project, a standard procedure used successfully for HBcAg was used 
in particle preparation, involving extraction in Extraction Buffer (ExB), followed by a 
clarification spin at 13 000 rpm (16 000 x g avg) to remove cell debris. Subsequent 
Western blotting and immunodetection revealed the presence of HB antigen in the 
clarified extracts of empty tandem core samples, but not in the clarified extracts of cores 
displaying GFP (data not shown). Illumination of the clarified extract and cell debris pellet 
using UV light revealed the presence of fluorescence in the pellet, but not the soluble 
fraction of this sample, indicating that the GFP-tagged tHBcAg is expressed, but forms 
insoluble aggregates.  
To verify the location of HB antigen after the low-speed clarification spin, both the 
soluble fraction (clarified extract) and the insoluble fraction (pellet) were boiled in 
reducing LDS-SB and separated by SDS-PAGE (Figure 4.7 A). In the case of monomeric 
HBcΔ176 and empty heterotandem core, the HB antigen was found almost entirely in the 
clarified extract (E) with main bands of 20 kDa and 41 kDa, respectively. These particles 
were expected to have similar surface properties as they both do not contain a foreign 
epitope.  
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Figure 4.7: Epitope presentation at the c/e1-loop significantly increases aggregation of tandem core proteins. 
Plants were agroinfiltrated with constructs as indicated. Leaf samples (3 discs) were homogenized in 3 
volumes of extraction buffer and clarified. Pellets were extracted by boiling in LDS-SB (same volume as 
extraction buffer), followed by clarification. (A)  Standard extraction buffer (ExB) was used, resulting in 
aggregation of cores carrying epitopes. (B) Hepatitis B extraction buffer 1 (HBexB1) was used, resulting in 
reduced aggregation of epitope carrying cores, and increased aggregation of ‘empty’ cores. M1 = NEB 
Broad Range marker; M2 = SeeBlue +2 Marker; + = recombinant HBcAg; E = extract; P = pellet; -ve control 
= empty vector.  
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Insertion of a 50 amino acid epitope of HBsAg into the e1-loop of homotandem core B 
(CoHo7e-sAg) reduced the solubility of this protein in comparison with the empty 
tHBcAg. While there was still a good signal in the clarified extract, a more intense signal 
was obtained from the insoluble pellet. This indicates that much of the expressed HB 
protein had aggregated, thereby causing it to be removed during the clarification spin. 
Insertion of the whole gfp gene (encoding 245 amino acids) into the heterotandem 
core B (CoHe7e-eGFPs) caused all of the expressed tHBcAg to pellet as a result of the 
initial clarification step. While there was a strong HB antigen signal in the pellet fraction of 
this sample, no HB antigen was detected in the clarified extract. This validated the 
previous observation that the GFP fluorescence is detected exclusively in the pellet.  
Though the display of a foreign sequence was shown to cause aggregation of the 
tHBcAg, the presence of dimers in the pellet fractions indicated that some ordered 
interactions between the proteins was still taking place. The strong signal near the wells 
of all tandem core samples was a further indication that the protein may be assembling 
into stable structures which are not easily dissociated by boiling in reducing LDS-SB. If the 
epitope-displaying tHBcAg are able to assemble into ordered particles, the apparent 
aggregation may be caused by the extraction conditions used in the experiment.  
In an effort to recover soluble GFP tandem cores, the extraction buffer composition 
was altered several times to change buffer and salt concentrations, or to change the pH. 
The recovery of a protein in soluble form depends on interactions of the surface residues 
with the surrounding solution, the composition of which can have profound effects on 
protein solubility. Ultimately, changes to the standard protein extraction buffer (ExB), 
mainly by raising the pH and lowering the salt content, resulted in HB extraction buffer 
(HBexB1) which is better suited to the extraction of soluble epitope-displaying tHBcAg 
particles. The Western blot in Figure 4.7 B was prepared following the same procedure as 
used previously (Figure 4.7 A), but using HBexB1 instead of ExB as the extraction buffer. In 
the case of GFP-displaying tandem core (CoHe7e-eGFPs), this extraction buffer allowed a 
small portion of the expressed antigen to be recovered in the soluble fraction. However, 
HBexB1 was less well suited to the extraction of empty monomeric and tandem HB core 
antigen, as shown by the presence of strong signals in the pellets of these samples which 
had previously been soluble.  
The results show that the display of foreign epitopes in the c/e1-loop of tandem HB 
core antigen alters its solubility. Furthermore, aggregation may be avoided by changing 
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the buffer composition. A new buffer, HBexB1, which allows for better extraction of GFP-
displaying cores and also produces extracts with lower chlorophyll contamination levels, 
was used subsequently for work on tHBcAg chimaeras.  
 
4.3.4 PLANT-PRODUCED HB TANDEM CORE ANTIGENS ASSEMBLE INTO CORE-LIKE PARTICLES 
The superior immunogenicity of VLPs, compared with subunit vaccines, is widely 
accepted (see section 1.1; Tissot et al., 2010). To realize their true potential, tandem 
Hepatitis B core constructs must be shown to assemble into particles resembling 
monomeric HBcAg particles.  
Homo- and heterotandem core constructs (empty, -sAg and –sAg,eGFP) were 
transiently expressed as previously described. Leaf tissue was harvested 6 dpi, extracted 
using HBexB1, clarified and loaded onto discontinuous sucrose gradients (Figure 4.8 A). 
After centrifugation, fractions were collected, separated on denaturing SDS-PAGE gels 
and tested for anti-HBcAg reactivity on a Western blot (Figure 4.8 B-C). CoHe7e-empty 
was detected in fractions 3 and 4, corresponding to the 30-40% sucrose fractions where 
monomeric HBcAg particles are generally found. The sedimentation of the material to the 
middle of the gradient and the lack of signal from lower density fractions indicated 
efficient assembly into large structures such as VLPs. In contrast, CoHo7e-empty gave 
strong signals in all fractions of the gradient, with a peak in fraction 3. The presence of 
tandem core protein in fractions 1 and 2 indicates that a proportion of homotandem core 
did not assemble into particles and therefore did not band with the particulate material at 
30-40% sucrose.  
Tandem core constructs with an HBsAg epitope, with and without eGFP, have been 
shown to express well in plants (Figure 4.5). However, extracts derived from 
heterotandem core constructs did not give the expected signal in sucrose gradient 
fractions (Figure 4.8 B). CoHe7e-sAg was not detected in the gradient, indicating that it 
was not present in the clarified extract but pelleted during the clarification spin, a sign of 
aggregation. A weak signal was detected for CoHe7e-sAg,eGFP in fractions 1 and 2, 
indicating that the small amount of antigen present in the clarified extract did not form 
particles resembling empty heterotandem cores, which banded in fraction 3. The low 
signal intensity may be due to aggregation and removal of a majority of CoHe7e-
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sAg,eGFP during clarification. In contrast to these heterotandem versions, CoHo7e-sAg 
and CoHo7e-sAg,eGFP did produce a good anti-HBcAg signal (Figure 4.8 C). However, 
most of the immuno-reactive material was found in fractions 1 and 2 of the gradient, 
indicating that it had not formed particles.  
 
 
 
Figure 4.8: Density gradient analysis of HB tandem cores. 
Leaf tissue was extracted with HBexB1, clarified at 9000 x g prior to loading on sucrose step 
gradients as shown in (A). After ultracentrifugation (217 000 x g avg, 4°C, 2.5 hrs), gradients were 
fractionated from top as shown in red. (B-C) Anti-HBcAg Western blot analysis of gradient fractions 
(numbered in red) separated on 12% SDS-PAGE gels.  M = SeeBlue Plus2.  
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In order to conclusively show that plant-produced empty hetero- and homotandem 
cores assembled into VLPs, transmission electron microscopy (TEM) was used to observe 
the major immuno-reactive fractions of discontinuous sucrose gradients (Figure 4.9). For 
comparison, purified E. coli-derived tandem and monomeric HB cores (a kind gift from Mr. 
Kris Holmes, University of Leeds), as well as purified plant-derived monomeric HBcΔ176 
expressed with the CPMV-HT system, were also imaged at the same magnification. 
TEM showed that empty tHBcAg produced using the CPMV-HT system did assemble 
into VLPs of regular shape and size (Figure 4.9 A, C). Furthermore, the particles resembled 
monomeric HBcΔ176 (Figure 4.9 E). In all three cases, a majority of the particles appeared 
to be of the larger T=4 type. However, smaller T=3 particles were also visible (arrows). 
Closer scrutiny revealed that the surface of the particles was not smooth but covered in 
small spikes, as is expected of Hepatitis B core particles.  
E. coli-derived empty hetero- and homotandem cores (Figure 4.9 B and D, respectively) 
also assemble into VLP. Homotandem cores, however, appear less stable and more 
heterogeneous than the heterotandem core version. This may, however, be an artefact of 
sample preparation, storage and age: The supplied E. coli monomeric HBcΔ149 sample 
was at least 5x more concentrated than the tHBcAg samples, as revealed by Coomassie 
blue-stained SDS-PAGE (data not shown). However, I was only able to find one cluster of 
particles (Figure 4.9 F) in grids prepared from this sample. These particles resemble plant-
derived HBcΔ176 particles, but are not abundant enough to allow analysis of their size.  
The mean particle size of homo- and heterotandem cores, regardless of their origin, 
was approximately 34 nm diameter, as determined by TEM (Figure 4.10). Plant-produced 
monomeric HBcΔ176 have a mean diameter of 37 nm and appear to be more regular in 
size.  
These results show that empty tandem core proteins can assemble into structures 
resembling monomeric HBcAg particles in plants as well as in E. coli. However, inclusion of 
an epitope in the c/e1 loop significantly impacts solubility and assembly of these 
constructs.  
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Figure 4.9: Plant-produced Hepatitis B tandem cores assemble into particles. 
Samples are negatively stained with 2% UA and imaged at 50 000 x magnification. Scale bar = 100 
nm. Arrows indicate smaller, T=3 particles. (A-B) CoHe7e-empty; (C-D) CoHo7e-empty; (E-F) 
monomeric HBcAg as indicated. (A-C-E) plant-produced particles. (B-D-F) E. coli - produced particles, a 
kind gift of Mr. Kris Holmes, University of Leeds.  
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Figure 4.10: Size distribution of plant- and E. coli-produced monomeric and tandem HB 
particles. 
Box plot analysis of the size distribution of particles in TEM images of different constructs. 100 
or 50 particles were measured for N. benthamiana or E. coli samples, respectively, using Adobe 
Photoshop. Data was analyzed with Microsoft Excel. 
 
4.3.5 WHOLE PROTEIN INSERTIONS ALLOW TANDEM CORE ASSEMBLY 
Previous experiments have shown that it is possible to express tHBcAg with an insert 
of a whole protein, namely GFP, in one of the c/e1 loops (Sections 4.3.1 and 4.3.3). It was 
found, however, that these fusion proteins tended to aggregate leading to their loss 
during the initial clarification step. This problem was partially overcome by adapting the 
extraction buffer to allow some of the CoHe7e-eGFPs to be recovered in the soluble 
fraction (Section 4.3.3). In this section, I report the results of an investigation into whether 
the recovered soluble CoHe7e-eGFP protein assembles into VLP displaying functional 
GFP. 
Hepatitis B tandem core constructs containing GFP (i.e. –eGFPs and –sAg,eGFP) were 
transiently expressed in N. benthamiana leaves as previously described. Upon irradiation 
with a hand-held UV lamp, GFP fluorescence was detected in all leaves infiltrated with the 
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GFP-containing constructs, but not in control tissue (Figure 4.11 A). Visually, the 
fluorescence intensity obtained from CoHo7e-sAg,eGFP was as high as that of the control 
construct expressing soluble GFP (pEAQ-GFP-HT). The heterotandem core constructs 
showed slightly lower fluorescence intensity, indicating lower GFP yields or reduced 
fluorescence intensity due to misfolding. 
To further investigate the ability of GFP tandem cores to form particles, leaf tissue 
expressing CoHe7e-eGFPs was harvested 7 dpi and extracted with HBexB1 as described 
previously. This particular construct was chosen because it enabled recovery of some 
soluble antigen, while the –sAg,eGFP constructs were entirely insoluble.  Clarified extract 
was loaded onto a short discontinuous sucrose gradient. Following ultracentrifugation, 
the ultracentrifugation tube was illuminated with a hand-held UV lamp, revealing an 
intensely fluorescent band in the 40% sucrose step (Figure 4.11 B). No visible fluorescence 
was detected in the top part of the gradient, indicating that the majority of the 
fluorescent material had assembled into large structures that sediment to the 40% 
sucrose layer. Similar results were obtained with CoHe7e-eGFPL, a construct in which the 
GFP insert is flanked by longer (10 aa) glycine-serine-rich linkers (data not shown).   
To conclusively show the presence of VLP, and to determine their morphology and 
purity, the GFP-containing fraction was observed using TEM (Figure 4.11 C). Particles in 
this fraction had a regular shape and size, proving that a 27 kDa protein insertion in the 
c/e1 loop of the heterotandem core does not abolish its ability to fold and assemble into 
CLPs. The mean particle size was 41 nm in diameter (n = 10), which constituted a 3.5 nm 
increase in radius when compared with CoHe7e-empty particles (Section 4.3.4). This 
increase in size correlates well with the dimensions of GFP, a beta barrel of 4.2 nm length 
and 2.4 nm diameter (Pawley, 2006). Morphologically, the GFP tandem core particles were 
distinctly different from their empty counterparts, with a less rigid appearance (compare 
Figure 4.11 C and Figure 4.9 A).  
The yield of purified GFP tandem cores was estimated at 10 ug / g FWT, or 
approximately 5-10% of the yield of purified CoHe7e-empty particles.  
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4.3.6 CRYO-ELECTRON MICROSCOPY OF GFP-TANDEM CORES 
The ability to prepare soluble GFP tandem core particles to high purity and at yields of 
10 ug/ g FWT made it possible to use these particles for structural analysis by cryo-
electron microscopy (CEM). This technique enables the determination of a particle’s 3D 
structure through computational averaging of multiple particle images. Three types of 
tandem core particles were transiently expressed and purified as described in Section 4.2: 
CoHe7e-empty, CoHe7e-eGFPs and CoHe7e-eGFPL. Grids were prepared for these 
samples by flash freezing in liquid ethane to embed the particles in vitreous ice. CEM and 
subsequent reconstructions were performed in collaboration with Dr. Robert Gilbert and 
Dr. Alistair Siebert, University of Oxford. 
 
 
 
Figure 4.12: CryoEM reconstructions of HB tandem cores displaying GFP. 
Purified CoHe7e-eGFPL particles were flash-frozen in vitrious ice, then subjected to cryo 
electron microscopy. (A) Class averages obtained from 339 individual particles using EMAN 
software. (B) Cross-section of a  surface rendered reconstruction of particles. HB tandem core-
associated density shown as a grid. Density associated with GFP (outside) and internal density 
(nucleic acid) is shown in silver. Cryo-EM and computational analyses were performed in 
collaboration with Dr. Alistair Siebert and Dr. Robert Gilbert (Univ. of Oxford).  
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Images obtained from the CoHe7e-eGFPL (approx. 40 µg/ ml) were used for 
subsequent computational analysis. 339 independent particles were picked from the CEM 
image and class averages produced with EMAN software (Figure 4.12 A). These were used 
to obtain a digital reconstruction image using computational tools for icosahedral particle 
reconstructions based on the method described by Fuller (1987).  
The cross-section of the digital reconstruction shows the location of areas of density 
associated with protein or nucleic acid in the particle (Figure 4.12 B). The density 
associated with the Hepatitis B core is shown as a grid. The outside surface of this density 
layer is covered with protrusions corresponding to the two amphipathic α-helical hairpins 
which form the handle of the wild-type HBcAg dimer’s hammer shape (see Section 4.1.2) 
This hammer-like appearance of the tandem core is best visible in the frontal sections of 
the three spikes at the 3 o’clock position. These data indicate that the GFP tandem core is 
able to assemble into particles with a core structure resembling that of wild-type HBcAg.  
Surrounding the tandem core particle is a layer of density shown in grey. This 
represents the protruding GFP barrels attached to one c/e1 loop of every tandem core 
spike. The lack of visible barrel structures is most likely due to the flexibility of the linker 
between GFP and the rigid core structure. Nevertheless, the presence of this density layer 
proves that the insertion in the c/e1 loop is presented on the outside of the particle. Some 
density is also visible at the core of the particle (grey). This may be due to encapsidation 
of nucleic acid through the interaction of the arginine-rich C-terminus of the 
heterotandem core.  
Further refinement of the obtained CEM reconstruction of CoHe7e-eGFPL is currently 
underway. The other two particle types, CoHe7e-empty and CoHe7e-eGFPs, have not 
been reconstructed to date.  
 
4.3.7 PRESENCE OF THE ARGININE-RICH C-TERMINUS IMPACTS NUCLEIC ACID ENCAPSIDATION 
The C-terminal Arginine-rich 34 amino acids of HBcAg play a role in stabilizing the 
assembled core particle, but they are not essential for particle assembly (Birnbaum and 
Nassal, 1990; Wynne et al., 1999). The truncated HBcΔ149 retains its  abilty to assemble 
while losing its ability to non-specifically bind host RNA (Gallina et al., 1989). For medical   
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applications such as the use as vaccines, it may be easier to gain regulatory approval for 
such nucleic-acid free particles.  
The ability of plant-produced homo- and heterotandem cores to bind plant nucleic 
acid was investigated by native agarose gel electrophoresis. 10 μg  of partially purified 
tandem cores and two monomeric HB cores were separated at 60 V for 2 hours. One gel 
was stained with Coomassie blue protein stain (Figure 4.13 A), while a duplicate gel was 
stained with ethidium bromide to visualize nucleic acid (Figure 4.13 B).  
 
 
Figure 4.13: Heterotandem cores encapsidate plant nucleic acid, while homotandem cores 
are empty. 
Partially purified particles from sucrose gradients were subjected to duplicate native agarose 
gel electrophoresis. Approximately 10 μg of particles were loaded per lane. HBc∆149 was 
produced in E. coli (a gift from Mr. Kris Holmes, University of Leeds), all other samples were 
produced in N. benthamiana. (A) Coomassie blue staining to detect total protein. (B) Ethidium 
bromide staining to detect nucleic acid. M = DNA marker Hyperladder I.  
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Distinct bands were visible in the Coomassie blue-stained gel only for particles which 
retained the protamine-like domain at their C-terminus (HBcΔ176 and CoHe7e -empty). 
The electrophoretic mobility of the truncated versions (HBcΔ149 and CoHo7e -empty) is 
not distinct, resulting in a broad smear. This may be due to the lower stability of particles 
lacking the C-terminal domain.  
The duplicate ethidium bromide-stained gel revealed the presence of nucleic acid in 
monomeric HBcΔ176 particles, indicated by a stro ng signal at equal electrophoretic 
mobility as the Coomassie-visualized band. By comparison, the truncated HBcΔ149 (E.coli-
produced; a kind gift from Mr. Kris Holmes, University of Leeds) did not appear to bind 
nucleic acid, which would otherwise have resulted in a broad smear in the EtBr-stained 
gel.  
Equally, the heterotandem cores were able to bind some nucleic acid, indicated by a 
faint signal in the EtBr-stained gel. However, binding was much reduced when compared 
with the monomeric HBcΔ176. This finding can be explained by the presence of only one 
arginine-rich domain per tandem core, resulting in half as many of these nucleic acid 
binding domains per particle when compared with monomeric HBcAg. In the case of 
homotandem cores, the lack of any arginine-rich domain resulted in empty particles, 
shown by the lack of EtBr staining in this lane.  
Overall, the results indicate that plant-produced heterotandem cores, but not 
homotandem cores, are able to bind some host nucleic acid. However, this binding is 
much reduced compared with monomeric HBcΔ176.  
 
4.3.8 SUMMARY 
The results obtained using the different HBcAg and tHBcAg constructs expressed in 
this project are summarized in Table 4.2. 
 
  
 
 
Table 4.2: Summary of results obtained from expression of HBcAg and tHBcAg constructs in plants. 
Construct Name Insert A Insert B Expression Solubility Gradienta Assemblyb 
monomeric HBcΔ176 n/a n/a yes yesc,d middle TEM 
ta
nd
em
 
He empty none none yes yesc,d middle TEM 
Ho  none none yes yesc,d top - middle TEM 
He sAg none sAg (40 aa) yes nod n/a n/i 
Ho  none sAg (40 aa) yes partiald top no (TEM) 
He eGFPs none EGFP (245 aa) yes partiald middle TEM 
He eGFPL none EGFP (245 aa) yes partiald middle CEM 
He sAg,eGFP sAg (40 aa) EGFP (245 aa) yes marginald top TEM 
Ho  sAg (40 aa) EGFP (245 aa) yes partiald top n/i 
Ho HAVP1 none HA VP1(789 aa) no n/a n/a n/a 
 
He = heterotandem; Ho = homotandem; n/a = not applicable; n/i = not investigated 
a) position within sucrose gradient after ultracentrifugation. “Top” indicates unassembled particles, “Middle” indicates assembled particles. 
b) particles visualized by TEM or CEM 
c) solubility in ExB 
d) solubility in HBexB1 
 
123 
CHAPTER 4 – TANDEM HB CORE 
 
124 
 
4.4 DISCUSSION 
In this project, several tHBcAg fusions have been successfully expressed in plants using 
the CPMV-HT system. Furthermore, the ability of some of these constructs to form stable 
core-like particles has been demonstrated. Particularly in the case of GFP tandem cores, 
plant-produced particles appear to be far more regular in size and shape than particles 
expressed in E. coli and yeast (personal communication, Prof. David Rowlands, University 
of Leeds) 
As previously introduced, HBcAg lends itself to the display of foreign epitopes for 
vaccine development. HBcAg can be expressed to high levels in E. coli and other 
expression systems and is able to self-assemble. HB core particles are heat- and pH-stable 
structures which are highly immunogenic. When epitopes are displayed in the 
immunodominant c/e1 loop on the tip of the dimer, the resulting particles induce a 
stronger immune response than the epitope would on its own (Brown et al., 1991). 
Insertions into the c/e1 loop are limited in size and shape, due to the close proximity of 
the two loops in the dimer structure. In E. coli, it is possible to produce particles displaying 
GFP in every c/e1 loop (Kratz et al., 1999). However, only 40% of the GFP is functional, 
indicating that folding of the fluorophore may be sterically hindered. Other proteins may 
be less suitable for internal fusions due to instability or the distance between their N- and 
C-terminus. One recent strategy to tackle these problems has been the insertion of a 
protease cleavage site immediately upstream of the foreign protein sequence, allowing 
the insert more freedom to move and fold while also having a positive impact on 
assembly (Walker et al., 2008). The tandem HB core (Gehin et al., 2004) presented in this 
work represents another strategy to improve assembly and folding of HBc displaying 
large protein inserts. 
As previously introduced, the tHBcAg is a genetic fusion of a truncated HBcAg 
(HBcΔ149) with another full-length or truncated core antigen, thereby yielding 
heterotandem and homotandem cores, respectively. The two halves of the tandem core 
are connected by a flexible glycine and serine-rich peptide linker, enabling them to fold 
into an HBcAg dimer-like structure and assemble into VLP in E. coli and yeast. This genetic 
fusion has two main advantages: Firstly, the two c/e1 loops of each particle spike can be 
addressed separately, allowing the display of only one large insert per spike and 120 per 
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particle, thereby providing more space for correct folding (e.g. CoHe7e-eGFPs). Secondly, 
the two c/e1 loops of the tandem core can contain two different smaller inserts, thus 
ensuring co-localisation on each spike (e.g. CoHe7e-sAg,eGFP). This may be particularly 
useful if the pair of inserts interact. 
Plant expression of tandem HB core constructs with and without inserts has been 
possible using the CPMV-HT system (Figure 4.5). The mobility of tandem core proteins in 
SDS-PAGE varies with the length of insert and the presence of the arginine-rich C-
terminus of the heterotandem core, as expected. Some bands of lower mobility, likely 
corresponding to dimers and multimers, are visible particularly in the constructs 
containing an insert. Notably, breakdown products are only visible in homotandem core 
constructs containing an insert, providing a first indication that these are less stable than 
their heterotandem core counterparts. The apparent stability of plant-produced tandem 
core proteins was particularly notable, as the E. coli-produced material suffers from 
proteolysis and breakdown. 
Transient expression of HBcAg is very fast, being detectable within two days and 
reaching yields of over 0.5 g / kg within five dpi (Figure 4.6). Empty heterotandem core 
accumulation is detectable from 3 dpi, but apparently only reaches 1/5 of the level of 
monomeric HBcAg, as detected by ELISA. However, the quantification of tHBcAg using 
ELISA optimized for HBcAg may be unreliable: During the ELISA test, extracted core 
antigen is not denatured and remains in its particulate state. The polyclonal antibody 
used in the test may have a lower affinity for tHBcAg, which may be in a different 
conformational state than HBcAg. ELISA quantification relies on the comparison to a 
standard of known concentration, in this case commercially available monomeric HBcAg, 
thereby possibly underestimating the concentration of tandem HB present in each 
sample. The qualitative results of other experiments (Figures 4.5, 4.7) did not reflect the 
stark difference in yields between monomeric and tandem HB core antigen observed 
using ELISA. 
Insertions into the c/e1 loops of the tandem core play a large role in determining the 
particle’s characteristics due to their exposure on the outside of the particle. Surface 
morphology is visibly different when GFP is inserted in this position (Figure 4.11). More 
importantly, the charge, isoelectric point and hydrophobicity of an insert can alter the 
particles’ solubility in certain buffers, causing them to aggregate (Figure 4.7). Whether the 
observed aggregation occurs upon synthesis in the plant cytosol, or happens after 
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extraction is not clear. However, I would expect aggregated protein within the cell to be 
targeted and degraded by the cellular machinery. The high yield of epitope-displaying 
tHBcAg suggests that this does not occur and may be an indication that aggregation 
takes place upon extraction, or that tandem HBcAg evades the plant’s proteolytic 
machinery.  
Recovery of even small amounts of CoHe7e-eGFPs was only possible when extraction 
conditions and the extraction buffer were changed drastically. The resulting HB extraction 
buffer 1 (HBexB1) contains lower concentrations of buffer, salt and EDTA, a different 
detergent, and has a higher pH than the extraction buffer used as standard (ExB). Though 
HBexB1 has a negative effect on solubility of empty tHBcAg, it was used preferentially for 
all HB samples due to the dramatically reduced levels of contaminating chlorophyll found 
in the soluble fraction (data not shown).  
Neither HBexB1, nor standard extraction buffer were amenable to the extraction and 
detection of soluble particles containing a portion of the HB surface antigen (-sAg). 
Computational analysis found that this epitope has an isoelectric point of 7.7, very close 
to the pH of plant extracts and possibly playing a role in the aggregation of these 
proteins. However, substitution of the Tris buffer component of HBexB1 with two other 
Good buffers to raise and lower the pH, respectively, did not solve this problem (data not 
shown).  
Due to the stringency of the regulatory approval process, only constructs which 
assemble into particles of regular shape and size will have potential merit as a vaccine. 
Hence, it was important to show that tandem HB core antigens can assemble into HB 
core-like particles when expressed in plants.  
Sucrose density gradients were used to determine whether HB tandem core material 
sediments in the expected density fractions of 30-40% sucrose, as is the case for 
particulate monomeric HBcAg (Birnbaum and Nassal, 1990; Figure 4.8). As expected, 
empty homo- and heterotandem core proteins sediment to this area of the gradient, 
indicating that they are able to form VLP. This was confirmed by TEM analysis of the 
relevant fractions (Figure 4.9). In contrast to the heterotandem version, CoHo7e-empty is 
found in all fractions of the gradient, indicating that the sample consists of a 
heterogeneous population of assembled, disassembled and possibly aggregated 
particles. This reflects the finding of Birnbaum and Nassal (1990) that the truncated 
HBcΔ149 does not sediment in a clear band but rather produces a smear throughout the 
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gradient. This result provides further evidence of the inherently lower stability and 
integrity of HBc Δ149-based homotandem core particles.  
At first glance, sucrose gradient analyses of sAg and sAg,eGFP homo- and 
heterotandem cores seemed to show that these did not assemble into VLP, because they 
did not sediment to the same area of the gradient as assembled empty tandem core 
particles. However, I hypothesize that a proportion of these constructs do form particles 
and that the presence of the sAg epitope on their surface causes them to aggregate. This 
would explain why the total amount of HBcAg detected by Western blotting of these 
sucrose fractions seemed far lower than the amount detected in crude extract, indicating 
that a large proportion of the tHBcAg was removed during the initial clarification step 
prior to gradient loading. If assembled sAg-displaying particles aggregate, then the only 
soluble form of these antigens will be unassembled, explaining their position in the low 
density layers of the gradients. Furthermore, the finding that homotandem core 
constructs are generally less stable than their heterotandem counterparts explains why 
the homotandem versions of sAg-containing constructs gave more intense anti-HBcAg 
signals in the gradient analysis.  
A further indication of the particulate nature of aggregated tandem core material is 
the finding that CoHe7e-eGFPs particles can be recovered after optimization of extraction 
conditions. Only upon changing of the extraction buffer and clarification spin was it 
possible to recover soluble GFP tandem core antigen, which was pelleted during 
clarification on previous attempts (Figure 4.7). The recovered GFP tandem core is in the 
form of regular core-like particles of 41 nm diameter (Figure 4.11). These particles, though 
regular in shape and size, are morphologically distinct from empty tandem core particles, 
as expected (compare Figure 4.9 A). I expect that similar results can be achieved by 
stringent optimization of extraction conditions for sAg and sAg,eGFP tHBcAg particles, 
however time did not permit this to be undertaken. 
The production of homogeneous GFP tHBcAg particles constituted a breakthrough in 
the establishment of tandem core technology. To date, it has not been possible to 
produce particles of comparable quality using E. coli and yeast expression systems. A key 
aim of this project, namely obtaining cryo-EM data for GFP tandem core particles, was 
now possible. The resulting cross-section image (Figure 4.12) provides new insight into 
the structure of epitope-presenting tHBcAg particles. The structure of the HB core is easily 
distinguishable by the presence of spikes on its outer surface. Where the cross-section 
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dissects a spike, the hammer-like appearance of the folded tandem core is visible and 
resembles the shape of natural HBcAg dimers (Crowther et al., 1994).  
In the GFP tandem core particle, each spike should be decorated with one GFP barrel 
structure as shown in Figure 4.3 C. Though the GFP barrels are not uniquely 
distinguishable in the cryo-EM reconstruction, the presence of a density layer surrounding 
the tHBcAg particle, and the fluorescence of the particle are indicative of the presence of 
GFP. In the CoHe7e-eGFPL fusion protein, the GFP barrel is separated from the HB core 
protein by a flexible 10 aa glycine-serine-rich linker to allow it more space and flexibility 
to fold properly. It is not surprising, therefore, that cryo-EM reconstructions, through 
averaging of many separate particles, would show a diffuse density layer, because the 
fluorophores are not rigidly attached to the structural core. Further refinement may allow 
more detailed structures to be identified. It would also be interesting to see whether CEM 
reconstructions derived from the CoHe7e-eGFPs construct, which has shorter 3 aa G/S-
linkers would allow individual GFP molecules to be resolved.  
Cryo-EM detects all protein and nucleic acid density associated with a particle. The 
density on the inside of the GFP heterotandem core is likely due to nucleic acid 
encapsidation. This is not surprising, as the heterotandem core protein has an arginine-
rich C-terminus which has been shown to bind host RNA non-specifically (Birnbaum and 
Nassal, 1990; Cohen and Richmond, 1982; Gallina et al., 1989). To further investigate 
nucleic acid binding of hetero- and homotandem cores, purified empty tandem core 
particles were subjected to native agarose gel electrophoresis, followed by ethidium 
bromide staining (Figure 4.13). This revealed that heterotandem cores do encapsidate 
nucleic acid, though at a much lower level than monomeric HBc Δ176. 
Native agarose gel electrophoresis is a useful tool to detect slight changes is surface 
charge and composition of particle variants. It is thus not surprising that heterotandem 
cores have a shifted mobility compared with monomeric HBcΔ176, as the latter contains 
more nucleic acid, has more arginine-rich regions and lacks the glycine-serine-rich linker 
of tHBcAg. It was surprising to find, however, that empty homotandem core particles did 
not produce a distinct band in the Coomassie blue-stained gel (Figure 4.13 A), but rather a 
diffuse smear. As these particles are not expected to contain any nucleic acid, this is an 
indication that even purified homotandem core particles consist of a heterogeneous, less 
stable population than heterotandem cores. 
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TEM analysis of plant- and E. coli-produced monomeric and tandem core particles 
shows that all particles are similar in size and morphology. A spiky surface is visible even 
at 50 000 x magnification. Measurement of particle diameter reveals that tandem core 
particles are on average 2 nm smaller than monomeric HBcΔ176 particles (Figure 4.11. 
This may be due to differences in amino acid composition and folding, making the 
tandem core particles more compact. It is also evident that plant-produced empty 
homotandem core particles are more variable in size than heterotandem cores.  
Overall, the data suggest that plant-produced homotandem core constructs are less 
stable than their heterotandem core counterparts. From a regulatory perspective, 
homotandem cores may be preferred due to their lack of nucleic acid. However, the high 
proportion of unassembled antigen, low stability, and structural heterogeneity of 
homotandem core particles are drawbacks.  
The work reported in this chapter has shown that tHBcAg can be produced efficiently 
in plants using the CPMV-HT system, that it assembles into regular CLP structures, and 
that it is possible to display whole protein chains on their surface. Through optimization 
of extraction conditions and density gradients, it was possible to produce particle 
preparations of superior purity and homogeneity to those prepared from E. coli. The 
plant-produced GFP tandem core particles were of regular size and shape, and did not 
exhibit the size variation (up to 100 nm diameter) seen with E. coli-produced GFP tandem 
cores (Aadil El-Turabi, personal communication). This enabled us to obtain cyro-EM 
reconstructions of the GFP-displaying tandem core, a major breakthrough for the tandem 
core technology. The GFP tandem core presented here is the largest “epitope” to have 
been displayed on plant-produced HBcAg. Plant-based expression may be the most 
efficient and economical method of producing HB tandem core particles for commercial 
applications. 
The success achieved in expressing many versions of the relatively simple tHBcAg was 
very encouraging and led us to attempt the expression of more complex VLPs, namely 
Bluetongue virus-like particles (Chapter 5).  
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5 EXPRESSION AND ASSEMBLY OF BTV-10 STRUCTURAL PROTEINS 
5.1 INTRODUCTION 
Given the success achieved with the production of hepatitis B particles using the 
CPMV-HT system (Chapter 4), I decided to investigate whether the expression system 
could be used to produce more complex VLPs. To this end, I focussed on the expression of 
Bluetongue virus-like particles, whose size, composition and stoichiometry would make 
them the most complex VLPs to have been expressed in plants. Expression of a 
heteromultimeric VLP takes full advantage of the pEAQ vectors (Chapter 3), which 
allowed me to easily clone and test many constructs, and provided the ideal tool for the 
simultaneous co-expression of multiple proteins within the same cells.  
Bluetongue Virus (BTV) is the type member of the Orbivirus genus within the 
Reoviridae family of double-stranded RNA (dsRNA) viruses. BTV causes the most severe 
symptoms in sheep and cattle, but is able to infect other domesticated and wild 
ruminants. First identified in South Africa, the virus has rapidly spread throughout the 
world and is now found wherever its vector, the biting midge, thrives (Carpenter et al., 
2009). There are currently 24 known serotypes of BTV and recovery does not result in 
significant cross-protective immunity. 
Bluetongue disease is characterised by an inflammation of the face, mouth and tongue 
of the animal, sometimes resulting in a cyanotic (blue) tongue. Other symptoms of acute 
infection include lameness, fever and abortion of the foetus. Recovery is generally slow 
and mortality rates vary widely depending on serotype. The economic impact of BTV 
arises not only from the loss of livestock, but also the emaciation of recovering animals 
and the movement and trade restrictions imposed by governments in a bid to stop the 
spread of the disease.  
The spread of BTV is influenced by several factors. Gradual climate change is 
contributing to the widening of potential habitats for the vector Culicoides species 
(Wittmann and Baylis, 2000). The small size of the insect vector enables it to be 
transported over great distances by strong winds, thereby enabling it to spread BTV 
across large bodies of water. Additionally, the use of airplanes in cargo transport provides 
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an additional accelerant of spread. Finally, the use of multivalent inactivated and live-
attenuated vaccines has been shown to be the cause of emergence of previously 
unreported serotypes in areas of vaccine use.  
In contrast to FMDV, BTV cannot be eradicated by the culling of an infected animal 
population. Once an area has been exposed, reservoirs of virus will be found in the host 
animal, the vector, as well as wild ruminants in the area. The only feasible means of 
combating BTV is a comprehensive vaccination programme.  
 
5.1.1 CURRENT BTV VACCINES 
Two types of vaccine are currently used. Live-attenuated vaccines have been used 
successfully for many years, are inexpensive and require only a single dose. However, the 
risks of reversion, recombination in the host or vector, and spread to newly impregnated 
ewes must be carefully considered. Since the 1980s, chemically inactivated vaccines have 
been available and are currently used to control the European outbreak. These are more 
expensive to produce than live-attenuated vaccines, require the administration of two 
doses and each batch must be thoroughly tested. However, these inactivated vaccines are 
safer, due to the inability of the virus to replicate.  
Multivalent vaccines are available to afford simultaneous protection against several 
BTV serotypes. However, cross-protection is limited due to the high variability in the outer 
shell of the different serotypes (Section 5.1.3) Multivalent vaccines thus consist of a 
cocktail of different serotypes. The danger of using such a multivalent vaccine has 
recently been highlighted by the finding that a genome segment of a BTV-16 isolate from 
Italy shared 100 % sequence identity with the same segment of a BTV-2 live-attenuated 
vaccine strain used in Italy in 2002 (Batten et al., 2008). This indicates that gene segment 
reassortment had occurred, resulting in a novel field strain. Such reassortants of 
orbiviruses can often have novel characteristics and heightened virulence compared to 
their parent strains (Nuttall et al., 1992).  
Virus-like particle and subunit vaccines could provide an inherently safe alternative to 
traditional vaccines. At doses exceeding 50 μ , recombi nant VP2, the main 
immunogenicity determinant of BTV, induces neutralizing antibody production when 
tested in sheep (Roy et al., 1990). Efficacy is increased up to 100-fold when VP2 is 
CHAPTER 5 – BTV-10 
 
132 
 
assembled within a VLP, and doses of 10 μg VLP are sufficient to confer protective 
immunity when administered with an adjuvant  (Roy et al., 1992). Despite its potential, 
after nearly 20 years, no commercial VLP vaccine has been produced for BTV. This is likely 
due to the high cost associated with the only proven BTV VLP production system, insect 
cells. Though commercial production of VLP vaccines is possible for human application, 
the low cost needed for a viable veterinary vaccine cannot be achieved in this way. A 
more cost-effective production platform for BTV VLP is therefore needed to enable this 
superior vaccine technology to be deployed in practice.  
 
5.1.2 LIFE CYCLE 
Bluetongue virus is able to replicate in its ruminant host as well as the insect vector. 
Cell entry and replication are schematically illustrated in Figure 5.1. Upon feeding, the 
midge transfers the virus into the host, where the outer shell protein VP2 mediates cell 
attachment. The virus enters the cell by way of endocytosis, with conflicting reports 
suggesting clathrin-dependent and clathrin-independent pathways (Forzan et al., 2007; 
Gold et al., 2010). The acidification of the early endosome is necessary for infection and 
allows the outer shell of the virus to dissociate from the core particle. The other outer 
shell protein, VP5, plays a role in membrane permeabilisation, allowing the core particle 
to enter the cytoplasm (Hassan et al., 2001).  
The BTV core particle contains the 10 dsRNA genome segments as well as three minor 
structural proteins: VP6 has helicase activity allowing it to unwind dsRNA (Stäuber et al., 
1997), VP1 is an RNA-dependent RNA polymerase (Boyce et al., 2004), and VP4 synthesizes 
‘cap’ structures at the 5’-end of viral messenger RNA (vmRNA; Martinez-Costas et al., 
1998).  The minor structural proteins and the viral genome are enclosed within a stable 
core of VP3 and VP7, which remains intact throughout viral replication. Within the 
cytoplasm, the core becomes transcriptionally active and extrudes capped viral mRNA 
(vmRNA) which is translated by the host machinery to synthesize the seven structural (VP) 
and three non-structural (NS) proteins. The positive-strand vmRNA also serves as a 
template for minus-strand synthesis to form dsRNA.  
The assembly mechanism of BTV particles is not well understood. BTV structural 
proteins have been shown to co-localize to virus inclusion bodies with non-structural   
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Figure 5.1: Bluetongue virus replication cycle. 
Schematic illustration of the stages of cell entry, replication and cell egress of Bluetongue virus in 
infected cells. Non-structural proteins were omitted from the illustration.  
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protein NS2, indicating that this is the site of viral assembly. Here, the dsRNA genome is 
associated with BTV structural proteins (Grimes et al., 1998; Loudon and Roy, 1992; Nason 
et al., 2004), however it is not known how the selective encapsidation of ten different 
dsRNA segments occurs. Non-structural protein NS3 is located in the cellular membrane 
of infected invertebrate cells and has been shown to allow fully assembled virus particles 
to egress from insect cells without lysis (Celma and Roy, 2009).  
In insects, viral uptake occurs during feeding. While virus particles can infect both 
mammalian and insect cells, it has been shown that only insect cells can also be infected 
by core particles. These attach to the cells via an RGD motif of VP7 (Basak et al., 1997; Tan 
et al., 2001), providing another mode of virus entry into cells.  
 
5.1.3 BTV CAPSID STRUCTURE AND ASSEMBLY 
Bluetongue virus is a non-enveloped, icosahedral virus of approximately 80 nm 
diameter. Here, I will focus on the four major structural proteins VP2, VP3, VP5 and VP7, 
which are sufficient for the assembly of virus-like particles (French et al., 1990). These 
proteins assemble to form a capsid consisting of three concentric protein shells (Figure 
5.2). The outer two shells of the virus can be removed to produce core and subcore 
particles.  
5.1.3.1 Subcore-like particles (SCLP) 
The innermost subcore layer of BTV is formed of 120 subunits of VP3. This 103 kDa 
protein has the shape of a thin (up to 35 Å) triangular wedge, and interacts with dsRNA 
and the minor structural proteins on the inside of the particle, and VP7 on the outside. 
VP3 is highly conserved between the 24 serotypes of BTV, indicating its crucial role in 
particle formation. 
The protein forms decamers as the first detectable structure in BTV assembly (Kar et al., 
2004). These decamers consist of five dimer structures in which each of the two VP3 
molecules takes on a slightly different conformation. The decamers assemble into a thin 
subcore structure of pseudo T=2 symmetry, with a diameter of approximately 55 nm 
(Grimes et al., 1998). VP3 is amenable to N- and C-terminal extensions without abolishing   
CHAPTER 5 – BTV-10 
 
135 
 
 
 
 
Figure 5.2: Bluetongue virus particle structures. 
Schematic illustration of the subunits and forms of BTV-like particles and subparticles. (A) The four 
main structural proteins and information about their molecular weight (MW), multimer assembly, copies 
per particle and triangulation number. (B) Schematic representation of subcore-like particle (SCLP), core-
like particle (CLP) and virus-like particle (VLP) and their components. (C) Surface-rendered representations 
of subcore, core and virus particles. Modified from published structural images 
(http://viperdb.scripps.edu; www.iah.bbsrc.ac.uk).  
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its ability to assemble, allowing peptides, epitopes and even GFP to be fused to the 
particles (Kar et al., 2005; Tanaka et al., 1995). 
BTV subcore-like particles can be obtained from full VLP by removal of the outer shell 
and stripping of the VP7 layer by low pH and low salt treatments, respectively (Loudon 
and Roy, 1991). It is possible to produce SCLPs directly by co-expression of VP3 with a 
mutant VP7 incapable of assembly; however, it is reportedly not possible to produce 
subcore-like particles by expression of VP3 alone using the baculovirus system (Hewat et 
al., 1992; Loudon and Roy, 1992). BTV subcore particles have a strikingly angular 
appearance when visualized using negative staining and TEM, and a spherical appearance 
when observed by cryo-EM (Hewat et al., 1992).  
5.1.3.2 Core-like particles (CLP) 
Core-like particles are formed by the assembly of a VP7 layer onto SCLPs. VP7 is the 
smallest (39 kDa) and most abundant of the structural proteins of BTV, with 780 copies 
making up a full complement in each particle. VP7 molecules have two domains: an upper 
β-sandwich domain comprising the internal section of the polypeptide, and a lower α-
helix bundle composed of the N- and C-terminal sections (Grimes et al., 1995). Large 
hydrophobic surfaces allow the protein to form stable trimers which interact tightly with 
the VP3 surface below. Like VP3, the sequence of VP7 is highly conserved between 
serotypes, and N- and C-terminal extensions to VP7 weaken its interaction with VP3.  
In authentic core particles, VP7 trimers assemble on to the VP3 scaffold to form 260 
protrusions, with a triangulation of T=13. This gives the particles a distinct “spiky” 
appearance when viewed using TEM. BTV core particles were first termed “BTV D” (D for 
dense), referring to the higher buoyant density of the core in relation to the full virus 
particle, termed “BTV L” (L for light; Martin and Zweerink, 1972). It is interesting to note 
that both virus and core particles were obtained in these early purification attempts, due 
to the higher relative stability of the core. It was later found that pure core particle 
preparations can be easily obtained from virus preparations by low pH treatment 
(Mertens et al., 1987).  
BTV CLPs have been produced in insect cells using a dual recombinant baculovirus for 
the co-expression of VP3 and VP7 (French and Roy, 1990). These particles are devoid of 
nucleic acid and have a sedimentation coefficient of 225 S, much lower than the 470 S of 
the authentic core particle, which can be produced by removal of the outer shell of the 
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authentic virus (French and Roy, 1990; Martin and Zweerink, 1972). Though they resemble 
authentic core particles when imaged using TEM, structural analyses by CEM revealed 
that baculovirus-produced CLPs lack 60 trimers of VP7 around the five-fold axes. When 
produced from full VLP, these 60 trimers are present as expected, indicating that an 
interaction with the outer shell proteins VP5 and/or VP2 may be necessary for full CLP 
assembly (Hewat et al., 1994). It is also interesting to note that baculovirus-produced CLPs 
have a larger diameter than authentic core particles (Hewat et al., 1992).  
Co-expression of VP7 causes a stark change in intracellular localization of VP3: When 
expressed on its own VP3 is co-localized with proteasomes, but in the presence of VP7 its 
cellular localization is close to the nucleus (Kar et al., 2005). This is evidence of the 
importance of the close interaction of VP3 and VP7 in the assembly of BTV particles.  
5.1.3.3 Virus-like particles (VLP) 
Bluetongue virus-like particles consist of all four major structural proteins, with an 
outer layer of VP5 and VP2 surrounding the CLPs. In the full virion, this outer shell consists 
of 360 copies of the 59 kDa VP5, and 180 copies of the 111 kDa VP2.  
VP2 is the major immunogenicity determinant of BTV and its sequence varies greatly 
among the different serotypes. The protein has haemagglutination activity and is 
involved in cell attachment and entry of BTV into vertebrate host cells (Hassan and Roy, 
1999). VP2 (T=3) forms triskelion-shaped trimers with two distinct domains: A central hub 
domain has sialic acid-binding activity while the tip domains protrude from the virion 
surface and are likely receptor-binding domains (Zhang et al., 2010). No receptor has 
been found to date, however. 
The spaces between the three “legs” of the VP2 trimers are filled with 120 globular VP5 
trimers which form weak interactions with the underlying VP7 layer (Zhang et al., 2010). 
VP5 (T=6) lies slightly recessed from the outer edge of the particles. Structural studies 
have shown VP5 to have features resembling membrane fusion proteins of enveloped 
viruses and it has been confirmed that VP5 acts to permeabilize the membrane of the 
host cell (Forzan et al., 2004). It is thought that VP5 undergoes a conformational change 
upon receptor binding and endocytosis, which activates it to allow permeabilization of 
the endosome and movement of the core particle into the cytoplasm. VP5 also contains a 
SNARE-like domain which is essential in its interaction with lipid rafts and cellular 
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membranes. It may also play a role in virus assembly and egress, through interaction with 
the membrane and viral NS3 (Bhattacharya and Roy, 2008).  
Full VLPs of BTV were first expressed in the baculovirus system in 1990 (French et al.). 
Assembly of VP5 and VP2 was found to be co-dependent, with neither protein assembling 
into stable particles in the absence of the other. It has been possible to produce chimeric 
VLP by expressing the core proteins VP3 and VP7 of one serotype with the outer shell 
proteins VP5 and VP2 of another serotype (Loudon et al., 1991). This is likely due to the 
homology of core proteins between serotypes.  
 With a diameter of up to 85 nm, VLPs are significantly larger than CLPs. However, most 
TEM images of virus-like and authentic virus particles published in the available literature 
contain some core-like or core particles as well, indicating that purified virus and VLP 
preparations are always a mixture of different viral particles (French et al., 1990; Hewat et 
al., 1994; Martin and Zweerink, 1972; Roy et al., 1992).  
 
5.1.4 AIMS OF THIS CHAPTER 
Bluetongue VLPs have been shown to be a safe and effective alternative to traditional 
BTV vaccines, but have not been exploited as such. To date, VLPs have only been 
successfully produced in insect cell systems, which are too expensive to yield affordable 
veterinary vaccines. Transient expression in plants is a potentially cheaper alternative 
eukaryotic expression platform.  
In this chapter I will show that it is possible to express the major structural proteins of 
Bluetongue virus serotype 10 in plants by using the CPMV-HT expression system. BTV-10 
is an isolate from the USA, which had previously been shown to assemble into VLPs in the 
insect cell system (French et al., 1990). Furthermore, plant-produced BTV-10 VP3 and VP7 
can to assemble into core-like particles upon co-expression. An association with VP5 is 
also indicated.  
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5.2 SPECIFIC MATERIALS AND METHODS 
5.2.1 CLONING 
The genes for BTV-10 VP2, VP3, VP5, VP7 and NS1 contained within pUC19 vectors 
were kindly provided by Prof. Polly Roy (London School of Hygiene and Tropical 
Medicine). Genes for VP3 and VP7 were amplified from their source using the primers 
listed in Table 5.1 and inserted between the RNA-2 5’- and 3’-UTR sequences of pENTR-
ET2 using NcoI and StuI. C-terminally His-tagged versions were made by end-tailoring. 
Expression cassettes were then transferred to pDEST-BINPLUS by recombination. Cloning 
into pEAQ-HT using AgeI and XhoI was used for the production of C-terminally His-tagged 
constructs of VP5, VP2 and NS1. A table of constructs is provided in Appendix A. 
Table 5.1: Oligonucleotides used in cloning of BTV-10 constructs. 
Name Sequencea Function 
   
BTV-10 VP3 NcoI F GACATGCCatgg Primer for end-tailoring of NcoI site to BTV-10 VP3; sense 
ctgctcagaatg
agcaac 
BTV-10 VP3 StuI R GAAGGCct Primer for end-tailoring of StuI site to BTV-10 VP3; antisense 
acacagttggcgcagcc
ag 
BTV-10 VP7 NcoI F GACATGCCatgg Primer for end-tailoring of NcoI site to BTV-10 VP7; sense 
acactatcgccgc
aagag 
BTV-10 VP7 StuI R GAAGGCct Primer for end-tailoring of StuI site to BTV-10 VP3; antisense acacataggcggcgcg 
BTV10.2-AgeI-F TTACCGGT Primer for end-tailoring of AgeI site to BTV-10 VP2; sense 
atggaggaattcgtcat
accagtg 
BTV10.2-XhoI-R TTCTCGAG Primer for end-tailoring of XhoI site to BTV-10 VP2; antisense 
ctaaacatttagtagctt
cg 
BTV10.3-HIS-StuI-R GAAGGCCT Primer for end-tailoring of 6 x His tag and StuI site to BTV-10 VP3; antisense 
AGTGGTGGTGGTG
GTGGTGcacagttggcgcagccag 
BTV10.5-AgeI-F TTACCGGT Primer for end-tailoring of AgeI site to BTV-10 VP5; sense 
atggggaagataatca
aatcg 
BTV10.5-XhoI-R TTCTCGAG Primer for end-tailoring of XhoI site to BTV-10 VP5; antisense 
tcaagcatttcgtaaga
agagg 
BTV10.7-HIS-StuI-R GAAGGCCT Primer for end-tailoring of 6 x His tag and StuI site to BTV-10 VP7; antisense 
AGTGGTGGTGGTG
GTGGTGcacataggcggcgcg 
BTV10.NS1-AgeI-F TTACCGGT Primer for end-tailoring of AgeI site to BTV-10 NS1; sense 
atggagcgctttttgag
aaaatacaatatcagtgg 
BTV10.NS1-XhoI-R TTCTCGAG Primer for end-tailoring of XhoI site to BTV-10 NS1; antisense 
ctaatactccatccacat
ctgag 
a END-TAILORING is shown in uppercase, restriction enzyme recognition sites are underlined, 
mutations are underlined and bold.  
CHAPTER 5 – BTV-10 
 
140 
 
5.2.2 EXTRACTION BUFFERS 
The extraction buffers used for the work presented in this chapter are detailed in Table 
5.2. 
Table 5.2: Buffers used for extraction of BTV-10 proteins and particles. 
Name Recipe 
  
Extraction buffer (ExB)  
50 mM Tris-HCl , pH 7.25; 150 mM NaCl; 2 mM EDTA; 0.1% (w/v) Triton X-100; 1 
mM DTT; Complete Protease Inhibitor Cocktail (Roche, add fresh) 
BTV extraction buffer 
(BTV ExB) 
20 mM Tris-HCl , pH 8.4; 140 mM NaCl; 1 mM EDTA; 0.1% (w/v) sodium 
deoxycholate;  Complete Protease Inhibitor Cocktail (Roche, add fresh) 
Smith Stabilization 
buffer (SSB) 
50 mM Bicine, pH 8.4; 140 mM NaCl, 0.5 % (v/v) NP-40; 10 % glycerol; 1 mM DTT 
(add fresh);  Complete Protease Inhibitor Cocktail (Roche, add fresh) 
 
5.3 RESULTS 
5.3.1 EXPRESSION AND INTERACTION OF VP3 AND VP7 
To date, Bluetongue virus proteins have not been expressed in plants. However, it has 
been shown that structural proteins VP2 and VP6 of the closely related rotavirus assemble 
into core-like particles when co-expressed in tomato (Saldaña et al., 2006).  In order to 
determine whether BTV structural proteins could be expressed in N. benthamiana using 
the CPMV-HT system, genes for the structural proteins of BTV serotype 10 were obtained 
from Prof. Polly Roy and cloned into pENTR-ET2 for easy subcloning by Gateway 
recombination into pDEST-BINPLUS (Chapter 3).  
Agrobacterium suspensions containing the constructs pDEST-BD-BTV10.3 and pDEST-
BD-BTV10.7, encoding VP3 and VP7 (Figure 5.3 A), were infiltrated (individually or in 
combination) into leaf tissue which was harvested 5 dpi (Figure 5.3 A). Samples were 
extracted using regular extraction buffer (ExB; as used previously for HBcAg) and clarified 
extracts separated by SDS-PAGE and subjected to Western blotting using a polyclonal 
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antibody raised against baculovirus-produced BTV 10 cores which should detect both VP3 
and VP7 (a kind gift from Prof. Polly Roy). A signal was observed on film only after 20 
minutes of exposure (Figure 5.3 B). Tissue expressing VP3, with and without VP7, 
produced a signal deemed to correspond to VP3 (103 kDa). Tissue expressing VP7 alone 
produced a signal at approximately 38 kDa, which is likely VP7. This VP7 band was not as 
pronounced in the co-infiltrated tissue. Negative control extract did not produce co-
migrating bands, giving further indication that the observed signal was specific.  
 
 
 
Figure 5.3: Expression and co-expression of core proteins VP3 and VP7. 
(A) Schematic representation of the T-DNA regions of plasmids for expression of BTV-10 VP3 and 
VP7. (B-C) Leaves were (co-)infiltrated with constructs as indicated, harvested 5 dpi and frozen for 
storage.  Samples were extracted using 3 volumes of ExB. (B) Western blot detection of VP3 and VP7 
in clarified extracts using anti-BTV-10 core polyclonal antibody (received from Prof. Polly Roy).(C) 
Anti-BTV-10 core Western blot analysis of sucrose cushion fractions. Clarified extract was spun 
through a two-step 70%-35% sucrose cushion and fractions collected from top (1) to bottom (9). M = 
SeeBlue protein marker; C = empty vector control; E = clarified extract; bars under constructs 
indicate 5’- and 3’-UTRs.  
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To determine whether VP3 and VP7 could assemble into larger structures, leaf tissue 
was co-infiltrated with VP3 and VP7 constructs. Co-infiltration is a method often used for 
the co-expression of multiple proteins in leaf tissue, and is reasonably effective at high 
Agrobacterium titres (Chapter 3). Leaf tissue was first extracted and clarified, then loaded 
onto a sucrose cushion. After ultracentrifugation, fractions were obtained from the top of 
the gradient and analysed by SDS-PAGE and Western blotting (Figure 5.3 C). A strong 
signal for VP3 was detected in the clarified extract as well as all sucrose fractions. The 
signal was most intense, however, in fractions 6-9, indicating that most of the VP3 had 
assembled into particles or aggregated and thus sedimented further down the gradient. 
A clear signal for VP7 was not present in any fractions. However, three faint bands at 30 – 
38 kDa were present in the extract and fractions 1-2, and may correspond to unassembled 
VP7 and breakdown products thereof. Another prominent band at 25 kDa was present in 
fractions 6-9 showing co-migration with VP3. This band is not seen in the negative control 
extract, indicating that it is BTV-specific. However, it cannot be said whether this is a 
breakdown product of VP7 or VP3. It is important to note that the antibody, which had 
been subjected to ambient temperature during shipping, was showing signs of fungal 
growth at the time that this blot was produced.  
 
5.3.2 CLP ASSEMBLY IS NOT INHIBITED BY AFFINITY TAGGING OF VP3 
To aid detection of VP3 and VP7 expression, and to determine the effect of C-terminal 
extensions on the assembly potential of the two proteins, a histidine affinity tag was 
genetically fused to the C-terminus of these proteins, by amplification of the genes with 
BTV10.3-HIS-StuI-R (for VP3) and BTV10.7-HIS-StuI-R (for VP7) end-tailoring primers (Table 
5.1). Combinations of untagged and His-tagged VP3 and VP7 were co-expressed and 
extracts separated on discontinuous 10 - 60 % sucrose gradients (Figure 5.4). Gradient 
fractions were run on duplicate SDS-PAGE and Western blots probed with anti-BTV-10 
core and anti-His antibody, respectively.  
After co-expression, untagged VP3 and VP7 were detected in fractions 6 and 7 at the 
bottom of the gradient, using anti-BTV-10 core antibody. The intensity of the VP3 signal 
was higher than the VP7 signal, indicating that either there was less VP7 than VP3 in these 
fractions, or that the polyclonal anti-BTV-10 core antibody had a higher affinity for VP3 
than for VP7. While VP3 was found exclusively in the high density fractions, VP7 was also  
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Figure 5.4: Assembly potential of C-terminally His-tagged core proteins. 
Leaves were infiltrated with combinations of untagged and His-tagged VP3 and VP7 
constructs as indicated. Clarified extracts were separated on 10% - 60% discontinuous 
sucrose gradients and fractioned from the top. Fractions were run on SDS-PAGE in duplicate 
and Western blots probed with anti-BTV-10 core polyclonal antibody (left) or anti-His 
monoclonal antibody (right). M = SeeBlue +2 protein marker with molecular weights 
indicated.  
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detected in fractions 1 – 3, indicated by a band which was not present in the negative 
control. This suggests that all of VP3 was bound in a larger structure, while some VP7 was 
unbound. The anti-His antibody did not pick up the untagged proteins, as expected. 
Co-expression of C-terminally His-tagged VP3 with untagged VP7 also resulted in VP3-
His sedimenting in fractions 6 and 7. This indicates that its ability to form 
particles/aggregates was not inhibited by the His tag. VP3-His was also detected by the 
anti-His antibody, as expected. A faint signal for free VP7 was detected in fractions 1 and 
2. However, the absence of a signal in fractions 6 and 7 may be due to the lower affinity of 
the antibody for VP7.  
Co-expression of C-terminally His-tagged VP7 with untagged VP3 appears to inhibit 
the formation of larger structures. VP7-His is detected by both antibodies in fractions 1 – 
3. The sensitivity of the anti-His antibody is far higher, producing a strong signal in 
fractions 1 – 3 and some signal in the rest of the gradient. This may be due to a small 
proportion of VP7-His aggregation/assembly, or it may be due to inaccuracies in 
fractionation. Interestingly, VP3 is not detected by anti-BTV-10 core antibody. Co-
expression of both His-tagged proteins produced only a small signal for VP7-His in 
fractions 1 and 2 in the anti-His Western blot (data not shown).  
 
5.3.3 THE TIMECOURSE OF ACCUMULATION OF VP5, VP2 AND NS1 VARIES 
Full BTV virus-like particles contain an outer layer consisting of VP5 (59 kDa) and VP2 
(111 kDa), which must be co-expressed with VP3 and VP7 to achieve assembly. In order to 
test whether VP5 and VP2 are expressed using the CPMV-HT system, it was necessary to 
produce His-tagged versions due to a lack of a specific antibody. This was done by 
amplification of constructs (obtained from Prof. Polly Roy) with end-tailoring primers 
(Table 5.1) to allow cloning into pEAQ-HT using AgeI-XhoI restriction fragements (Figure 
5.5 A). The initial expression test, in which leaves were infiltrated with individual 
constructs followed by harvesting 6 dpi, resulted in detectable levels of VP5-His, but not 
VP2-His (data not shown). To determine whether this finding was specific to harvesting 
after six days, a time course experiment was performed. Infiltrated leaves were harvested 
2, 4, 6 and 9 dpi, and frozen for later analysis. Crude extracts were separated on SDS-PAGE 
and an anti-His Western blot was performed (Figure 5.5 C). A strong signal was observed 
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for VP5-His at the expected size of 59 kDa. Surprisingly, VP5-His was already detectable 
two days post infiltration, and levels increased until at least 9 dpi. Multimers of >100 kDa 
were observed, resulting in a smear near the top of the blot. In contrast, VP2-His was only 
detectable at 9 dpi, confirming previous findings that it is not found in significant 
quantities in leaf tissue harvested 6 dpi. This could be due to slower transcription and/or 
translation, lower stability, faster degradation, or a combination of these factors. This 
result shows that optimal expression of BTV proteins and particles requires later 
harvesting than expression of HBcAg (Chapter 4).  
 
 
Figure 5.5: Accumulation of BTV-10 structural and non-structural porteins is time-dependent. 
(A) Schematic representation of the T-DNA regions of plasmids for expression of BTV-10 VP2-
His, VP5-His and NS1-His. (B) Expected sizes of His-tagged BTV-10 proteins. (C) Anti-His Western 
blot of crude extracts separated on SDS-PAGE. Leaves were infiltrated with the above constructs 
separately and harvested 2, 4, 6 and 9 days post infiltration. C = empty vector control; M = SeeBlue 
+2 protein marker; P = positive control BTV-10 VP3-His.  
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The BTV non-structural protein NS1 forms tubules in infected cells and has been 
shown to be amenable to epitope presentation and use in medical applications 
(Mikhailov et al., 1996). To test whether NS1 can be expressed in plants, a C-terminally His-
tagged version was expressed in the previously described time course experiment (Figure 
5.5). It is noteworthy that leaf tissue became necrotic after six days, and was dry and 
brittle by day nine. However, NS1-His was detectable as early as 2 dpi and throughout the 
time course (Figure 5.5 C). In earlier expression trials, immunodetection was performed on 
clarified extracts (in BTV extraction buffer) and yielded no detectable NS1-His (data not 
shown), suggesting that all of the antigen was lost during clarification. This may be due to 
assembly of NS1-His into long tubules which remain entangled in the cell debris, or it 
could be due to aggregation, or a combination of the two. Alteration of the extraction 
conditions and especially the extraction buffer may make it possible to extract soluble 
NS1, however this work was not undertaken due to time constraints. 
 
5.3.4 CO-EXPRESSION OF THE FOUR STRUCTURAL PROTEINS OF BTV-10 
Assembly of BTV structural proteins into regular core-like and virus-like particles is 
crucial for their potential use as a vaccine. Co-sedimentation of VP3 and VP7 in sucrose 
gradients, as shown previously (Figure 5.3), provided an indication that core-like particles 
can assemble in plants. However, to provide conclusive evidence of particle formation, 
visualisation using TEM was required. In order to produce enough material for TEM 
analysis, and to allow all four (untagged) BTV proteins to be expressed, plants were 
subsequently harvested at a later time point, 9 dpi. Production was also scaled up by 
loading more extract (in SSB buffer, an extraction buffer developed to stabilize BTV 
particles; see Table 5.2) onto larger gradients. This provided enough material for 
visualisation using Coomassie blue-staining (Figure 5.6 A-B).  
Co-expression of VP3 and VP7 resulted in bands of the expected mobility in fractions 
7-11 of the gradient, with most accumulating in fraction 9, corresponding to the 30 – 40% 
iodixanol interface (Figure 5.6 A). Iodixanol (OptiprepTM, Axis-Shield) is a density gradient 
medium which was recommended to me by collaborators, who had found it to be 
superior to sucrose for use in VLP preparation. In this experiment, most of the plant 
protein was restricted to the upper eight fractions of the gradient, away from the BTV 
proteins, showing that the BTV core proteins can be readily purified by density gradient 
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centrifugation. TEM analysis of such fractions revealed particles of regular shape and size 
(Figure 5.6 D). These plant-produced BTV-10 core-like particles had a diameter of 
approximately 70 nm and a spiky appearance, characteristic of authentic BTV core 
particles and baculovirus-produced CLPs (French and Roy, 1990).  
 
 
 
  
Figure 5.6: BTV-10 structural 
proteins assemble into particles. 
Constructs containing the 
genes of untagged BTV-10 
structural proteins were infiltrated 
as indicated. Extracts were 
separated on 10% - 50% iodixanol 
step gradients, fractionated from 
the top and run on SDS-PAGE. (A) 
Coomassie blue-stained fractions of 
CLP gradient. (B) Coomassie blue-
stained fractions of VLP gradient. 
(C) Anti-VP5 probed Western blot. 
(D) TEM of purified CLP. Scale bar = 
100 nm. M = SeeBlue +2 protein 
marker; E = clarified extract; C = 
empty vector control extract. 
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Co-expression of all four structural proteins and P19 by co-infiltration of five different 
Agrobacterium constructs did not give evidence of full VLP formation (Figure 5.6 B). 
Allthough VP3 and VP7 were detectable in fraction 9 as before, bands corresponding to 
the expected sizes of VP2 and VP5 were not visible. Without access to anti-VP2 antibody, 
it was impossible to determine whether VP2 was present in the sample. VP5 expression 
could be detected by Western blotting. As before, a strong signal for monomeric VP5 was 
detected at 59 kDa, and multimers were detected at higher molecular weight. The 
presence of multimers is a good indication that VP5 is able to form homotrimers, the 
functional units which assemble around the BTV core. Surprisingly, VP5 did not co-
sediment with the majority of VP3 and VP7, and was entirely absent in fractions 9-12.  
Most VP5 was detected in fractions 5 – 6, corresponding to 20 – 30 % iodixanol. This 
suggests that VP5 was associated with particles or aggregates, allowing it to sediment in 
the gradient. A slower sedimentation rate does not preclude its association with CLPs, as 
it has been shown that authentic BTV particles have a lower buoyant density (1.36 g/cm3) 
in caesium chloride than core particles (1.38 g/cm3; Martin and Zweerink, 1972).  
Interestingly, the expression levels of VP3 and VP7 were far lower when co-expressed 
with VP5 and VP2 than when expressed independently of the outer shell proteins. Since 
the optical density of each Agrobacterium was the same in both infiltrations, this should 
not be due to dilution factor, but could be an effect of multiple competing Agrobacteria. 
Another explanation for this may be that the SSB extraction buffer is unsuitable for the 
extraction of soluble VLPs, but amenable to CLP extraction. It is likely that an extract will 
contain VLPs, CLPs, SCLPs and intermediates. In that case, fully assembled VLPs would be 
lost during the clarification spin, along with most of the VP5 and VP2 protein, leaving only 
CLPs and some intermediate structures to be separated on the density gradient. However, 
all subsequent attempts with different extraction buffers failed to yield detectable levels 
of fully assembled BTV-10 VLPs (data not shown), indicating that the production of these 
particles may not be possible with the production system. In order to investigate these 
possibilities further, it would be crucial to obtain anti-BTV-10 VP2 antibody, and to 
increase expression levels by codon-optimisation, for example (Chapter 6). 
The results show that it is possible to express BTV-10 structural proteins VP2, VP3, VP5 
and VP7, as well as non-structural protein NS1 in plants. Furthermore, VP3 and VP7 co-
expressed in plants assemble into core-like particle structures resembling CLPs and core 
particles produced in other systems. However, the evidence of VP5 association with CLP 
structures is not conclusive.  
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5.4 DISCUSSION 
Virus-like particles of BTV-10 have been shown to assemble through co-expression of 
the four main BTV structural proteins in insect cells, and their efficacy as a vaccine has 
been validated by several groups (French and Roy, 1990; Roy et al., 1994; Roy et al., 1992; 
Stewart et al., 2010). Nevertheless, a VLP-based commercial vaccine has not been 
developed, owing to the high cost associated with the baculovirus expression system. In 
this chapter I have shown that it is possible to express BTV-10 structural proteins in plants, 
and that some of these assemble into particles. This opens the door to the exploitation of 
plants as a potentially cheaper production system for the production of an inherently safe 
Bluetongue vaccine.  
Expression was attempted using structural proteins of BTV serotype 10, isolated in the 
USA (Sugiyama et al., 1982). The core proteins VP3 and VP7 of BTV-10 were successfully 
expressed using the CPMV-HT system. They assembled into core-like particles resembling 
authentic, virus-derives cores  as well as CLPs produced in insect cells (French et al., 1990).  
For the production of an effective vaccine, it is essential to produce VLPs which 
present a full complement of VP5 and VP2 on the outside. Expression of these two 
proteins individually revealed that their expression and accumulation vary widely, with 
VP5 detectable after two days, and VP2 detectable after nine days. This presents a 
problem for the production of full VLP, and was the reason to delay harvesting until 9 dpi 
in all subsequent experiments.  
Though it was not possible to conclusively show the assembly of VP5 and VP2 on these 
CLPs, the use of an anti-VP5 antibody showed that VP5 forms multimers and sediments 
within a sucrose gradient, indicating that it may be associated with CLPs. Assuming that 
the recovery of particles decorated with VP5 is dependent on the simultaneous assembly 
of VP2, as previously reported (French et al., 1990), the presence of VP5 in high density 
gradient fractions implies that BTV-10 VP2 also assembles on CLPs when co-expressed in 
plants. Proof of this could be provided by immunogold labelling of expressed particles 
with antibodies raised against VP2, but these were not available.  
In addition to being efficient vaccines in their own right, some virus-like particles, such 
as Hepatitis B cores (Chapter 4), can also be used as carriers for the display of foreign 
epitopes. BTV proteins also have the potential to be used in this manner. Epitope fusions 
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to BTV VP3 are also possible and C-terminal extensions have been shown to allow core-
like particles to assemble when co-expressed with VP7 in insect cells (Tanaka et al., 1995). 
Efforts to express C-terminal His-tag fusions of VP3 in plants have also resulted in 
assembled particles which co-migrate with VP7 in density gradients. In contrast, His-
tagging of VP7 inhibited particle formation. Interestingly, it has been found that the 
insertion of a 13 amino acid epitope of Bovine Leukemia Virus (BLV) at the C-terminus of 
VP3 has resulted in insect cell-produced CLPs which were shown to raise antibodies 
against BLV (Tanaka et al., 1995). This shows that presentation of an epitope on the inside 
layer of BTV, likely within the empty cavity of the particle, provides a means of using BTV 
as an epitope carrier. In fact, the large lumen of the BTV-like particle is able to 
accommodate 120 copies of GFP, N-terminal VP3 fusions of which have allowed core-like 
particles to assemble within VP7-expressing insect cells (Kar et al., 2005). Attempts to 
produce such fluorescent particles in plants are discussed in Chapter 7.  
Another BTV protein which has been used for epitope display is non-structural protein 
NS1, which forms long tubules in infected cells and is thought to function in assembly of 
the virus (Owens et al., 2004). It has been possible to express NS1 fusion proteins 
displaying large foreign epitopes and even whole proteins, using the baculovirus system 
(Ghosh et al., 2002b; Mikhailov et al., 1996). Furthermore, it was shown that these fusion 
proteins form tubule structures and can be used as immunogens (Ghosh et al., 2002a). 
Preliminary expression trials with BTV-10 NS1 show that this protein can be efficiently 
expressed in N. benthamiana using CPMV-HT contstructs, with detectable levels 
accumulating within two days post infiltration (Figure 5.5). NS1 was found to be entirely 
insoluble; however this might be alleviated through optimisation of the extraction 
conditions and buffer. In the future, further experiments could be performed to test 
whether expression of NS1 fusion proteins is possible in plant tissue. 
The results presented in this chapter provide evidence that BTV-10 proteins can be 
expressed in plants using the CPMV-HT system, and that they can assemble into particle 
structures. However, proof of the assembly of full VLPs consisting of all four structural 
proteins eluded me. This motivated me to attempt the expression of another, more 
pertinent BTV serotype, BTV-8 (Chapter 6).  
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6 EXPRESSION OF BTV-8 VIRUS-LIKE PARTICLES 
6.1 INTRODUCTION 
The successful expression and assembly of the structural proteins of BTV serotype 10 
provided a good indication that the CPMV-HT transient plant-based expression system 
could be used to produce BTV particles. However, attempts to produce full BTV-10 VLPs 
failed to give conclusive evidence of the assembly of the outer shell proteins VP5 and VP2 
onto the core-like particle. This led me to investigate the expression and assembly of 
another serotype, BTV-8, to determine whether this inability to produce full BTV VLP was 
general. Being the first BTV serotype to break out in the United Kingdom in 2007, BTV-8 
was also highly pertinent at the time.  
BTV serotype 8 was first detected in the Netherlands in August 2006 and quickly 
spread to surrounding Central Europe with 2000 farms being affected by January of the 
following year. The vector Culicoides obsoletus was shown to survive the winter, and BTV-8 
spread widely within continental Europe in 2007, affecting tens of thousands of farms 
(Mehlhorn et al., 2007; Szmaragd et al., 2010). The first case of BTV in the UK was detected 
in Suffolk at the end of September, 2007. Due to the cold autumn temperatures, spread 
was minimal and restricted to 125 farms by early 2008. During the winter, a swift response 
by government and scientists, as well as the recent availability of a vaccine made it 
possible to commence a vaccination programme in May 2008 (Szmaragd et al., 2010). 
While BTV-8 continued to spread in continental Europe in 2008, no cases were reported in 
the United Kingdom. The 2006-2008 outbreak in Europe demonstrated the effectiveness 
and importance of fast and comprehensive vaccination against BTV.  
 
6.1.1 AIMS OF THIS CHAPTER 
The aim of this chapter is to demonstrate the expression of BTV-8 structural proteins in 
plants, and their assembly into subcore-like, core-like and virus-like particles. In an effort 
to maximize the yield of these proteins, codon-optimized versions of the wild-type genes 
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were also expressed. The pEAQ vectors (Chapter 3) were used as an essential tool in the 
expression of BTV-8 proteins, ensuring that multiple proteins could be consistently co-
expressed in the same plant cells. Furthermore, selective use of wild-type and HyperTrans 
CPMV RNA-2 leaders was used to modulate relative expression levels of the four BTV 
proteins to maximize recovery of fully assembled VLPs. A purification protocol for 
recovery of high quality VLP preparations was developed to enable sufficient material to 
be produced for immunological analysis. 
 
6.2 SPECIFIC MATERIALS AND METHODS 
6.2.1 CLONING 
Wild-type genes for BTV-8 VP2, VP3, VP5, VP7 and NS3 were amplified from BTV-8 
cDNA (BTV-8 strain NET2008, sequences published in GenBank) provided by Dr. Ann 
Meyers (University of Cape Town). Genes were amplified from their source using the 
primers listed in Table 6.1 and inserted between the RNA-2 5’- and 3’-UTR sequences of 
pEAQ-HT using restriction cloning. The gene for NS3 was amplified to end-tailor Gateway 
attB sites for cloning into pDONR207 and subcloning into pEAQ-HT-DEST-1 (Gateway 
cloning is described in Chapters 2 and 3). 
Codon-optimized versions of the BTV-8 genes for expression in N. benthamiana were 
synthesized by GeneArt AG (see Appendix B). These genes were excised and cloned into 
pEAQ-HT using restriction cloning. Expression cassettes were excised from the pEAQ-HT 
clones and subcloned into the vector pEAQexpress (Chapter 3) to yield pEAQex-BTV8.5co-
BTV8.2co, pEAQex-BTV8.7co-BTV8.3co and pEAQex-BTV8.7-BTV8.3. These were combined 
to form pEAQex-BTV8-52co73 for expression of four structural proteins and P19 from a 
single T-DNA, as described in section 6.3.5.2. 
A further clone was prepared by replacing the 5’UTR of the BTV8.3 cassette of pEAQex-
BTV8.7co-BTV8.3co with the wild-type CPMV RNA-2 5’UTR, thereby producing pEAQex-
BTV8co-7HT-3, as described in section 6.3.5.3. A table of constructs is provided in 
Appendix A.   
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Table 6.1: Oligonucleotides used in cloning of BTV-8 constructs. 
Name Sequencea Function 
   
BTV8-NS3-attB1 AAAAAGCAGGCTatgctatccgggctgatc 
Primer for end-tailoring of partial attB1site to 5’-end 
of BTV-8 NS3; sense 
BTV8-NS3-attB2 AGAAAGCTGGGTtcaggttaatggcatttcg 
Primer for end-tailoring of partial attB2 site to 3’-
end of BTV-8 NS3; antisense 
BTV8-VP7-F CGatggacactatcgctgcaagag Primer for amplification of BTV-8 VP7; sense 
BTV8-VP7-R Cctacacataggcggcgcg Primer for amplification of BTV-8 VP7; antisense 
BTV8.2-SalI-R TATCGTCGAc Primer for end-tailoring of SalI site to BTV-8 VP2; antisense 
tatacattgagcagc
ttagttaacatc 
BTV8.2-XmaI-F TATCCCGGG Primer for end-tailoring of XmaI site to BTV-8 VP2; sense 
atggaggagctagc
gattc 
BTV8.3-StuI-R TACAGGCct Primer for end-tailoring of StuI site to BTV-8 VP3; antisense acacagttggcgcagc 
BTV8.3-XmaI-F TATCCCGGG Primer for end-tailoring of XmaI site to BTV-8 VP3; sense 
atggctgctcagaat
gagc 
BTV8.5-SalI-R TATCGTCGAC Primer for end-tailoring of SalI site to BTV-8 VP5; antisense 
tcaggcatttcttaa
gaagagtgggatatc 
BTV8.5-XmaI-F TATCCCGGG Primer for end-tailoring of XmaI site to BTV-8 VP5; sense 
atggggaaaatcata
aagtccctaag 
a END-TAILORING is shown in uppercase, restriction enzyme recognition sites are underlined, 
mutations
  
 are underlined and bold. 
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6.2.2 BTV EXTRACTION AND PURIFICATION 
6.2.2.1 Extraction buffers 
The extraction buffers used for the work presented in this chapter are detailed in Table 
6.2. 
Table 6.2: Buffers used purification of BTV-8 particles. 
Name Recipe 
  
BTV extraction buffer 
(BTV ExB) 
20 mM Tris-HCl , pH 8.4; 140 mM NaCl; 1 mM EDTA; 0.1% (w/v) sodium 
deoxycholate;  Complete Protease Inhibitor Cocktail (Roche, add fresh) 
Smith Stabilization 
buffer (SSB) 
50 mM Bicine, pH 8.4; 140 mM NaCl, 0.5 % (v/v) NP-40; 10 % glycerol; 1 mM DTT 
(add fresh);  Complete Protease Inhibitor Cocktail (Roche, add fresh) 
Low-salt SSB 50 mM Bicine, pH 8.4; 20 mM NaCl, 0.5 % (v/v) NP-40; 10 % glycerol; 1 mM DTT 
(add fresh);  Complete Protease Inhibitor Cocktail (Roche, add fresh) 
BTV VLP extraction 
buffer 
50 mM Bicine, pH 8.4; 20 mM NaCl, 0.1 % (w/v) NLS sodium salt; 1 mM DTT (add 
fresh);  Complete Protease Inhibitor Cocktail (Roche, add fresh) 
BTV CLP extraction 
buffer 
50 mM Bicine, pH 8.4; 140 mM NaCl, 0.1 % (w/v) NLS sodium salt; 1 mM DTT (add 
fresh);  Complete Protease Inhibitor Cocktail (Roche, add fresh) 
 
6.2.2.2 Core-like particles 
The purification protocols for core-like particles were optimised throughout the 
project. Optimal results deemed to produce sufficient material for animal trials were 
obtained from leaves infiltrated with pEAQex-BTV8co-7HT-3 using the following protocol.  
Leaf tissue expressing BTV-8 VP3 and BTV-8 VP7 was harvested 9 dpi and fresh tissue 
homogenized in three volumes of BTV CLP extraction buffer using a Waring blender at 
4°C. Note that tissue was never frozen. Homogenate was filtered through two layers of 
Miracloth and clarified by centrifugation at 4 200 x g, 10 °C, for 5 minutes. Clarified extract 
was layered onto sucrose four-step gradients of 30 – 60 % sucrose in  20 mM Tris-HCl, 140 
mM NaCl, pH 8.4. Gradients consisted of 3 ml of each sucrose solution, overlayed with 24 
ml of clarified extract. Gradients were spun in an ultracentrifuge at 21.5 K rpm, 10 °C, for 3 
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hours using a Surespin 630 rotor. Nine fractions of 1 ml were collected by piercing the 
bottom of the tube. Fractions were analysed by separating 1/100th  of each sample on 4-
12 % NuPage SDS-PAGE gels followed by Coomassie blue staining. The best fractions (in 
terms of BTV protein content, stoichiometry and lack of contamination; usually fractions 
2-3) were incrementally diluted to a final factor of 1:2 with 140 mM Tris-HCl, 140 mM NaCl, 
pH 8.4 and separated on a second sucrose gradient as before, this time using 1 ml sucrose 
steps in an SW41-Ti rotor. Gradients were fractionated from the bottom and fractions 
analysed for purity by SDS-PAGE, as before. Particles were stored at 4 °C.  
6.2.2.3 Virus-like particles 
The procedure described for CLP preparation was also followed for the purification of 
virus-like particles, after co-infiltration with pEAQex-BTV8co-7HT-3 and pEAQex-BTV8.5co-
BTV8.2co. BTV VLP extraction buffer was used, and all sucrose solutions and dilution 
buffers contained a lower salt concentration of 20 mM NaCl.  
 
6.3 RESULTS 
6.3.1 STRUCTURAL PROTEIN EXPRESSION FROM WILD-TYPE AND CODON-OPTIMISED GENES 
Following the demonstration that it is possible to produce BTV-10 CLPs (though not 
VLPs) in plants using the CPMV-HT system, attention turned to the expression of a more 
relevant serotype, BTV-8, which was rapidly spreading throughout Europe from 2006.  
BTV serotypes share a high degree of sequence similarity in their core proteins, but 
differ markedly in the primary structure of their outer shell. Table 6.3 compares the four 
structural proteins and genes of BTV-8 and BTV-10 at the nucleotide and amino acid level. 
Sequence conservation is highest for the innermost protein VP3 (90.3 %) and lowest for 
the outer shell protein VP2 (53%). The differences in the genes of VP3 and VP7, however, 
are not reflected in the amino acid composition. The core proteins of BTV serotypes 8 and 
10 are (nearly) identical. In stark contrast, the outer shell protein VP2, the major 
immunogenicity determinant of BTV, shares only 40.7 % sequence identity between these 
two serotypes. This supports the finding that BTV VLP vaccines afford limited protection 
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across heterologous serotypes (Roy et al., 1994). VP5 is also not well conserved at an 
amino acid sequence identity of 78.8 % between these serotypes. However, the 
quaternary structures of these two proteins, globular trimers of VP5 and triskelial trimers 
of VP2, have not been reported to differ considerably between serotypes. However, only 
limited structural information is available for the outer shell of BTV.  
 
Table 6.3: Sequence similarity of expressed BTV genes and proteins. 
 BTV-10 BTV-8 codon optimized 
BTV-8 Nucleotide Amino acid Nucleotide Amino acid 
VP3 90.3 % 99.7 % 76.9 % 100 % 
VP7 87.8 % 100 % 77.1 % 100 % 
VP5 69.4 % 78.7 % 75.8 % 100 % 
VP2 53.0 % 40.7 % 75.6 % 100 % 
Sequence identity expressed in % of BTV8 wild-type genes / proteins. 
 
Codon-optimisation is widely used as a means of increasing heterologous protein 
yield, though it is not always successful (Laguía-Becher et al., 2010; Maclean et al., 2007). 
In order to test whether codon-optimisation for N. benthamiana would have a beneficial 
effect on expression levels of BTV-8 proteins, optimised version of all four genes were 
synthesized by GeneArt AG (Appendix B). Though identical to the wild-type proteins at 
the amino acid level, these genes were only approximately 75 % identical at the 
nucleotide level (Table 6.3). The wild-type genes were amplified from cDNA of BTV-8 (a 
kind gift from Dr. Ann Meyers University of Cape Town). Both versions of each gene were 
cloned into pEAQ-HT using restriction cloning (Section 6.2). Codon-optimised versions are 
labeled “co.”  
To test for efficiency of expression of the BTV-8 genes, all constructs were expressed 
individually in N. benthamiana. Agro-infiltrated tissue was harvested 8 dpi and clarified 
extract analysed by SDS-PAGE (Figure 6.1). The expression levels achieved for all four 
structural proteins, regardless of codon usage, were high enough to enable distinct bands 
to be identified by comparison to a negative control extract. In all cases, codon-
optimization for N. benthamiana had a positive effect on recombinant protein yield, 
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though the degree of improvement varied between the four genes. Remarkably high 
yields of VP2 were achieved using the codon-optimized construct. The difference in 
expression level between codon-optimized and wild-type versions of VP5 and VP7 was 
not as marked, but estimated at 3-fold. The codon-optimized VP5 construct also 
produced to bands of lower electrophoretic mobility, which were identified as BTV-8 VP5 
and likely correspond to VP5 multimers (Figure 6.1, asterisks). In the case of VP3, the 
codon-optimized construct caused necrosis in the leaf tissue which rendered it dry and 
brittle. Though the state of the tissue made a yield comparison between the two 
constructs impossible, it is worth noting that the most abundant extractable protein in 
the necrotic VP3co tissue was VP3, indicating that it is indeed expressed at very high 
levels. The presence of VP3 in the necrotic tissue also indicated that the protein is very 
stable.  
 
Figure 6.1: Codon optimization increases the expression level of BTV-8 structural proteins by 
varying amounts. 
Leaves were agro-infiltrated with codon-optimized (co) and wild-type (wt) BTV-8 constructs as 
indicated and harvested 8 dpi. Clarified extracts from three leaf discs were separated 4-12% SDS-
PAGE and stained with Coomassie blue. Note that the tissue infiltrated with the VP3co construct 
was necrotic and dry. Note also that the wild-type VP7 construct used contained wt VP3 on the 
same T-DNA. * = bands of this mobility later confirmed as VP5. M = SeeBlue +2 marker; C = empty 
vector control.  
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Figure 6.2: BTV-8 proteins are toxic to N. benthamiana in some combinations. 
Leaves were agro-infiltrated with codon-optimized BTV-8 constructs individually and in 
combinations as indicated. Leaves were harvested 9 dpi and imaged in bright light. Note: The black 
background was created digitally using Photoshop to enhance clarity - leaf images were not 
altered. 
 
 
Some of the expressed BTV-8 protein constructs, namely VP3, VP5 and NS3, appeared 
to induce chlorosis and/or necrosis in the expressing tissue. To test this further, codon-
optimised constructs were agro-infiltrated individually or co-infiltrated in the 
combinations needed to produce CLPs and VLPs and observed 9 dpi (Figure 6.2). 
Expression of VP2 and VP7 alone appeared to have little effect on leaf tissue, similar to the 
empty vector control. Young tissue expressing VP3 alone appeared to grow more slowly 
than surrounding healthy tissue, was chlorotic and had large necrotic patches. Necrosis 
appeared to be worse in older leaves, an effect also seen with other toxic constructs. 
Expression of VP5 alone made the leaf tissue chlorotic and induced small necrotic lesions.  
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Leaf tissue expressing VP3 and VP7 was chlorotic, but did not exhibit the necrosis and 
growth inhibition seen from VP3 alone. Similarly, tissue expressing all four structural 
proteins was chlorotic but not necrotic. These results suggest that structural proteins 
which are toxic to the plant on their own (VP3 and VP5) lose their toxicity when expressed 
in combination with the structural proteins with which they interact. For example, if most 
VP3 assembles into core-like particles when co-expressed with VP7, it would be 
surrounded by a VP7 layer and ‘hidden’ from host machinery which would otherwise 
mount a response. The effect of co-expression on leaf response suggested that the BTV 
structural proteins may be interacting in a favourable way. 
The non-structural protein NS3 has been shown to localize to the plasma membrane of 
infected cells and is key to virus-particle egress (Celma and Roy, 2009; Hyatt et al., 1991). 
Assuming that the interaction of NS3 and the outer shell of assembled particles is 
sufficient for egress, it is possible that co-expression of NS3 with the four BTV structural 
proteins may allow BTV VLPs to accumulate in the intercellular space. Heterologous 
proteins which are secreted can be harvested from the intercellular spaces by re-
infiltration with buffer and low-speed centrifugation, thereby circumventing the 
contamination of preparations with plant cell proteins (Dr. Ann Meyers, personal 
communication). Such a strategy would facilitate downstream processing. To test 
whether this is possible, leaves were co-infiltrated with five constructs for NS3 and the 
four structural proteins. Though NS3 was never detected after extraction, the co-
infiltration of this construct had a toxic effect on the leaf tissue, indicating that the gene 
was expressed (Figure 6.2). Necrosis was observed five days post infiltration, making re-
infiltration of the tissue with buffer impossible. Later attempts to infiltrate the NS3 
construct 5 days after the other constructs failed to provide proof of the presence of VLP 
in the intercellular space.  
These data show that it is possible to express BTV-8 structural proteins in N. 
benthamiana using the CPMV-HT system. Furthermore, the milder effects of co-expression 
on leaf health indicate that the expressed proteins interact in vivo, indicating that the 
production of BTV-8 CLP and even VLP would be possible.  
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6.3.2 SELF-ASSEMBLY OF SCLPS BY EXPRESSION OF VP3 
Hewat et al. (1992) reported that BTV subcore-like particles (Section 5.1.3.1) consisting 
of only VP3 cannot be obtained by sole expression of VP3 using the baculovirus system, 
but that they can be made from CLPs by stripping off the VP7 layer in low salt buffer. In 
the same year, it was reported that SCLPs can be purified from insect cells directly only by 
co-expression with an N-terminally tagged VP7 which is unable to form a stable shell 
around the VP3 (Loudon and Roy, 1992).  
To determine whether plant-produced VP3 is able to self-assemble without the 
presence of VP7, tissue was infiltrated with pEAQ-HT-BTV8.3co and harvested 9 dpi. As 
previously found, expressing tissue was largely necrotic, though a band of chlorosis 
appeared immediately adjacent to the infiltrated area (Figure 6.3 A), suggesting that a 
mobile plant response was raised. Upon extraction in BTV VLP extraction buffer, clarified 
extract was separated on sucrose step gradients. Fractions corresponding to 40 - 50% (i.e. 
where assembled BTV particles are usually found) were separated on SDS-PAGE and 
stained with Coomassie-blue (Figure 6.3 B). A clear band was visible near the 97 kDa 
marker at the expected mobility of VP3, suggesting that VP3 had self-assembled or 
aggregated.  
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Transmission electron microscopy of gradient fraction provided proof that BTV-8 VP3 
was able to self-assemble when expressed in plants (Figure 6.3 C). Subcore-like particles 
are clearly visible after negative staining. Depending on their orientation on the TEM grid 
and the viewing angle, particles have three different appearances: (1) angular particles 
with 6 very thin sides; (2) less angular particles, with less distinct sides; (3) rounded 
particles. These observations are in accordance with the published structure of 
baculovirus-produced SCLPs and correspond to views along the two-, three- and fivefold 
axis, respectively (Hewat et al., 1992).  
These results show that BTV-8 VP3 can self-assemble independent of other BTV 
proteins when expressed in N. benthamiana, in contrast to the situation in insect cells.  
  
Figure 6.3: BTV-8 VP3 is able to 
self-assemble when expressed 
alone. 
Leaves were agro-infiltrated with 
pEAQ-HT-BTV8-VP3co and harvested 
9 dpi. Clarified extract was run on a 
discontinuous sucrose gradient and 
fractionated. (A) Photograph of 
infiltrated leaf. (B) Coomassie blue-
stained SDS-PAGE gel with three 
sucrose gradient fractions 
containing VP3. (C) TEM image of 
purified BTV-8 subcore-like particles. 
Arrows indicate 3 different 
orientations of the same particle 
species. Scale bar = 100 nm. 
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6.3.3 ASSEMBLY OF CLPS BY CO-EXPRESSION OF VP3 AND VP7 
Previous work had shown that it is possible to express BTV-10 VP3 and VP7 in plants, 
and that they assemble into CLP structures resembling baculovirus-produced CLPs 
(Section 5.3.4). In order to determine whether BTV-8 CLPs can also be produced, codon-
optimised constructs for VP3 and VP7 were co-infiltrated and harvested 9 dpi. Tissue was 
extracted in SSB and clarified extracts loaded onto 10 – 45 % iodixanol gradients (Figure 
6.4 A). Fractions were collected from the bottom, then separated on SDS-PAGE gels which 
were stained with Coomassie blue (Figure 6.4 B). As found previously with BTV-10 (Figure 
5.6 A), VP3 and VP7 co-sedimented in the gradient. Bands corresponding to the two 
proteins were found in the range of 15 – 40 % iodixanol, with a peak at 35 %. The majority 
of contaminating plant protein did not sediment below 25 % iodixanol, thereby leaving 
the BTV-containing fractions relatively pure. From the staining observed on the gel, yield 
was estimated to be at least 200 µg / g FWT.  
Purified BTV-8 CLPs were visualised by TEM using negative staining (Figure 6.4 C) The 
particles had the spiky appearance characteristic of BTV cores and resembled the 
previously produced BTV-10 CLPs (Figure 5.6 D), with a mean diameter of 70 nm. Dynamic 
light scattering (DLS) analysis of BTV-8 CLPs shows that 95% of the sample has an average 
diameter of 73.2 nm (data not shown), a figure that is in good accordance with the size 
estimated by TEM. 
  
CHAPTER 6 – BTV-8 
 
163 
 
 
 
6.3.4 ASSEMBLY OF VLP BY CO-EXPRESSION OF VP3, VP7, VP5 AND VP2 
Previous work on BTV-10 had failed to conclusively show production of full virus-like 
particles (Section 5.1.3.3) by co-expression of the four main structural proteins (Section 
5.3.4). However, co-expression of the four main BTV-8 structural proteins showed a 
decrease in toxicity associated with VP5 expressed on its own, thereby indicating that VP5 
may be able to interact with the other BTV structural proteins in planta (Section 6.3.1). To 
determine whether this interaction occurs and whether full VLPs are produced, the four 
BTV-8 structural proteins were co-expressed by co-infiltration of four constructs, and 
subjected to analysis as described in the previous section.   
Figure 6.4: Co-expression of BTV-8 
VP3 and VP7 enables assembly of 
core-like particles. 
Constructs containing the genes of 
BTV-8 structural proteins VP3 and VP7 
were co-infiltrated and leaves 
harvested 9 dpi.  (A) Extracts were 
separated on 10% - 45% iodixanol step 
gradients and fractions collected from 
the bottom. (B) Coomassie blue-
stained 4-12% SDS-PAGE gel of 
gradient fractions. M = SeeBlue +2 
protein marker; U = upper phase (0% 
iodixanol). (C) TEM of purified BTV-8 
CLP. Scale bar = 100 nm. 
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Coomassie blue staining of density gradient fractions revealed a high yield and co-
sedimentation of the expressed BTV-8 structural proteins (Figure 6.5 B). Bands 
corresponding in mass to VP2, VP3, VP5 and VP7 were found in the range of 15 – 40 % 
iodixanol, with a majority found in the 35 % fraction. As with CLPs, this provided a good 
degree of purity due to lower sedimentation rate of contaminating plant proteins. The 
clean and well separated bands of the 30% fraction were excised and submitted for mass 
spectrometric analysis which confirmed the identity of the proteins (see asterisks in 
Figure 6.5 B). Total BTV protein yield in the gradient fractions was estimated to be 
approximately 300 ug / g FWT.  
Figure 6.5: Co-expression of four 
BTV-8 structural proteins enables 
assembly of virus-like particles. 
Constructs containing the genes 
of BTV-8 structural proteins VP2, VP3, 
VP5 and VP7 were co-infiltrated and 
leaves harvested 9 dpi.  (A) Extracts 
were separated on 10% - 45% 
iodixanol step gradients and fractions 
collected from the bottom. (B) 
Coomassie blue-stained 4-12% SDS-
PAGE gel of gradient fractions. 
Protein bands excized for mass 
spectrometric analysis indicated by 
asterisk.  M = SeeBlue +2 protein 
marker; U = upper phase (0% 
iodixanol). (C) TEM of purified BTV-8 
VLP. Contaminating CLP indicated by 
arrow. Scale bar = 100 nm. 
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Purified particles were observed using TEM. The micrograph in Figure 6.5 C illustrates 
well the morphology of BTV VLPs. With a mean diameter of 87 nm, virus-like particles 
have a less distinct surface than CLPs. They are characterised by a thicker shell, with the 
empty inside of the particle appearing smaller than in CLPs. For comparison, a CLP in the 
same micrograph is marked with an arrow. DLS analysis of purified BTV VLPs shows that 
67% of the mass of the sample forms a species of particle with an average diameter of 96 
nm, the rest of the sample forms aggregates (data not shown). Though this value is not a 
reliable measure of size due to the heterogeneity of the sample, it does illustrate a size 
shift and tendency to aggregate which is not seen for CLPs (Section 6.3.3).  
The recovery of high yields of all four structural proteins in gradient fractions was the 
most exciting day of my PhD. The confirmation of the presence of VLP by TEM 
represented a major leap forward in my project, opening up many possibilities for 
optimization of expression and purification. It was also key to the later production of 
particles for immunogenicity studies, as well as fluorescent BTV VLPs (Chapter 7).  
The appearance of VLP preparations under TEM was highly variable throughout this 
project, often showing an abundance of partially (dis-)assembled VLPs, CLPs or SCLPs, 
with only few VLP structures. Optimisation of extraction and purification conditions as 
well as practice in grid preparation and TEM technique improved the consistency in the 
quality of VLPs imaged. This indicates that much of the variability in particle preparation 
may be due to damage during down-stream processing and TEM grid preparation. 
However, the stoichiometric ratio of the expressed proteins also plays a crucial role and is 
discussed in more detail in the next section.  
 
6.3.5 STOICHIOMETRY: OPTIMIZATION OF RELATIVE VLP YIELD 
In contrast to other viruses, such as CPMV and FMDV, the structural proteins forming 
the capsid of BTV are not present in equimolar ratios. Full BTV-like particles contain 180 
copies of VP2, 120 copies of VP3, 360 copies of VP5 and 780 copies of VP7. This complex 
stoichiometry is further complicated by differing affinities of the structural proteins for 
one another, resulting in highly stable core-like particles and less stable VLP and SCLP 
structures.  
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Aiming to achieve the highest possible expression levels of each of the four proteins 
may lead to high yields of BTV proteins, but does not guarantee the recovery of particle 
preparations containing a high proportion of fully assembled VLPs. This section reports 
three attempts to modulate expression of the four structural proteins in order to optimise 
virus-like particle yield by (1) the targeted use of wild-type and codon-optimised genes, 
(2) the co-expression of all structural proteins from a single T-DNA, and (3) the use of 
CPMV RNA-2 5’-untranslated regions with and without the HT mutations.  
The stoichiometry of the proteins in a given VLP preparation can be easily judged by 
observation of the relative intensity of Coomassie blue-stained bands on an SDS-PAGE 
gel. In Bluetongue virus capsids, structural protein size is, to some extent, inversely 
proportional to the copy number per assembled particle: The lower the mass of a 
structural protein, the higher its copy number in each particle. Hence, separation of 
purified virus on reducing SDS-PAGE followed by Coomassie blue staining produces 
bands of similar intensity for the four main structural proteins (Martin and Zweerink, 
1972). Analyses in this section take advantage of this characteristic. In a density gradient 
fraction, a relative excess of VP3 and VP7 is indicative of a high proportion of CLP, while 
an excess of just VP3 indicates contaminating subcore-like particles. Inspection of the 
Coomassie gel of Figure 6.5 B shows that BTV-8 VLP preparations produced by co-
infiltration of four codon-optimized HyperTrans constructs contained an excess of VP3 and 
VP7, resulting in a high proportion of CLP. This made such preparations unsuitable for 
immunogenicity studies.  
6.3.5.1 Modulation of relative expression levels by targeted use of wild-type genes 
In order to achieve a lower amount of contaminating CLP structures in VLP 
preparations, an attempt was made to modulate expression levels of VP3 and VP7 
through the use of wild-type genes. Initial expression trials had made use of the high 
expression levels achieved from codon-optimised genes for all structural proteins. 
New pEAQexpress constructs were made by sequential subcloning of AscI-PacI 
digested expression cassettes from the BTV-8 pEAQ-HT plasmids. These new pEAQex 
constructs incorporate two BTV-8 genes as well as P19 on the same T-DNA, thereby 
ensuring consistent co-expression of these genes in every plant cell. Two constructs were 
made for expression of VP7 and VP3 from codon-optimised and wild-type genes: pEAQex-
BTV8.7co-BTV8.3co and pEAQex-BTV8.7-BTV8.3, respectively. It was previously found that 
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codon-optimized genes give at least 3-fold higher expression levels than the wild-type 
genes (Figure 6.1). One construct was made for co-expression of codon-optimised VP5 
and VP2 (pEAQex-BTV8.5co-BTV8.2co).  
 
 
Figure 6.6: Co-expression of codon-optimized VP5 and VP2 with wild-type VP7 and VP3 
reduces the over-representation of VP3 in particle preparations. 
Leaves were agro-infiltrated with constructs as indicated and harvested 8 dpi. Clarified extracts 
were separated on iodixanol step gradients. Fractions were collected from the bottom, separated 
on 4-12% SDS-PAGE gels and Coomassie blue stained. (A) Co-infiltration of pEAQexpress 
constructs carrying codon-optimized genes for all four structural proteins. (B) Co-infiltration of 
pEAQexpress constructs carrying codon-optimized genes for VP5 and VP2, and wild-type genes for 
VP3 and VP7. M = SeeBlue +2 marker; 2-5 = gradient fraction numbers. 
 
To analyse the effect of combining wild-type genes for core proteins with codon-
optimised genes for outer shell proteins, combinations of these constructs were 
agroinfiltrated and iodixanol gradients performed on harvested material 8 dpi, as 
previously described. Relevant gradient fractions were analysed by reducing SDS-PAGE 
and Coomassie staining (Figure 6.6). In both combinations, all four BTV structural proteins 
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were clearly visible in the stained gel. In this particular experiment, by far the most 
abundant structural protein isolated from tissue expressing entirely codon-optimized 
genes was VP3, indicating a high proportion of SCLP in the preparation. This may be due 
to the location of the VP3 gene near the right border of the T-DNA, thus favouring its 
expression relative to VP7. This does not explain the low abundance of VP5 and VP2, 
however. It is necessary to note that the plants were grown under aberrant growth 
conditions at the time, due to technical problems, and were stunted in growth and 
generally unhealthy. This may also have played a significant role in these experiments.  
However, the two combinations presented in this experiment were prepared in parallel 
and were subject to the same conditions, and can nevertheless be directly compared.  
The amount of VP3 in the preparation from the wild-type construct (Figure 6.6 B) is 
much lower than that obtained from the codon-optimised construct (Figure 6.6 A), as was 
hoped.  Allthough it can be assumed that overall levels of VP7 expression are lower from 
the wild-type construct, the amount of VP7 obtained from this combination was higher 
than that obtained from the codon-optimised construct. The relative intensities of the 
VP3 and VP7 bands in Figure 6.6 B more closely approach the expected ratio than those of 
the codon-optimised versions in Figure 6.6 A, indicating a higher proportion of CLPs than 
SCLPs. Expression levels of VP5 and VP2 were expected to be equal in the two 
experiments. However, the combination of codon-optimised VP5 and VP2 with wild-type 
VP7 and VP3 appears to yield slightly more outer shell proteins in the gradient fractions. 
This is particularly evident when comparing fractions 5.  
Though this experiment was not ideal due to prolonged problems with plant health, it 
can nevertheless be concluded that the combination of lower-expressing wild-type genes 
of VP3 and VP7 with codon-optimized genes for VP5 and VP2 favours the accumulation of 
more fully assembled particles when compared with the expression of exclusively codon-
optimized genes. Thus down-regulation of the expression of VP3 and VP7 relative to VP2 
and VP5 appears to be a potentially useful strategy for optimising the proportion of fully 
assembled VLP.  
6.3.5.2 Expression of four structural proteins and P19 from a single T-DNA 
It has been previously shown that co-infiltration of multiple Agrobacterium strains is 
not an efficient means of co-expressing multiple proteins in a cell (Section 3.3.6). The   
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pEAQexpress vector is a useful tool to ensure efficient co-expression of two proteins as 
well as P19 in each cell by transfer of a single T-DNA construct. Such pEAQexpress 
constructs have already been shown to successfully express BTV structural proteins by 
combining genes for the core proteins (VP3 and VP7) on one pEAQexpress construct, and 
those for the outer shell proteins (VP2 and VP5) on another (Section 6.3.5.1). However, 
successful assembly of BTV virus-like particles requires all four structural proteins to be 
expressed in every cell.  
In order to ensure efficient co-expression, and to determine whether this has an effect 
on levels of VLPs obtained, genes for all four BTV structural proteins were cloned onto a 
single T-DNA construct. Drawing from the results presented in the previous section, it was 
decided that a combination of wild-type VP3 and VP7 genes and codon-optimized VP5 
and VP2 genes would be optimal. Due to the size and similarity of the two starting 
plasmids, pEAQex-BTV8.7-BTV8.3 and pEAQex-BTV8.5co-BTV8.2co, it was necessary to 
employ a more complicated cloning strategy involving the vector backbone and 
incompatible ends (Figure 6.7). The vectors were digested with FseI or PacI, respectively, 
and incompatible ends removed / filled in. Both linearised vectors were then digested 
with NotI, cutting within the OriV origin of replication and producing sticky ends. This 
strategy ensured ligation of the two fragments in the correct orientation. The correct 
assembly of the resulting pEAQex-BTV8-52co73 (short for VP5co-VP2co-VP7-VP3) was 
confirmed by multiple restriction digests. This vector contains a T-DNA region spanning 
over 16 kb.  
In order to determine whether expression from a single T-DNA construct increases the 
relative amounts of fully assembled VLPs, leaves were infiltrated with pEAQex-BTV8-
52co73 alone, or co-infiltrated with pEAQex-BTV8.7-BTV8.3 and pEAQex-BTV8.5co-
BTV8.2co. Harvested tissue was subjected to extraction in low-salt SSB and iodixanol 
gradient centrifugation as previously described. Relevant fractions were separated on 
SDS-PAGE and the gel stained with Coomassie blue (Figure 6.8). As before (Section 
6.3.5.1), co-infiltration of the two constructs resulted in an overrepresentation of VP3, i.e. 
subcore-like particles. However, the experiment presented here yielded relatively more 
VP5 and VP2 in the particle fractions, indicating a higher proportion of assembled VLPs, 
irrespective of whether one or two constructs were infiltrated. This may be due to better 
extraction of soluble VLPs by lowering of the salt concentration of the buffer (low-salt SSB 
versus SSB).   
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Figure 6.8: Expression of all BTV-8 structural proteins from a single T-DNA reduces over-
representation of VP3. 
Leaves were agro-infiltrated with constructs to introduce codon-optimized VP5 and VP2, and 
wild-type VP7 and VP3 genes as indicated, and harvested 10 dpi. Clarified extracts were separated 
on iodixanol step gradients. Fractions were collected from the bottom, separated on 4-12% SDS-
PAGE gels and Coomassie blue- stained. Co-infiltration of pEAQexpress constructs carrying codon-
optimized genes for all four structural proteins. (A) Co-infiltration of two Agrobacterium strains 
carrying constructs for VP7-VP3 and VP5-VP2, respectively. (B) Infiltration with a single 
Agrobacterium  for expression of all four structural proteins from a single T-DNA. M = SeeBlue +2 
marker; 2-6 = gradient fraction numbers. 
 
Levels of VP5 and VP2 recovery do not appear to be greatly improved by expression 
from the pEAQex-BTV8-52co73 construct, relative to co-infiltration (Figure 6.8 B and A, 
respectively). This indicates that the relative proportion of VLP compared with CLP and 
SCLP is not significantly improved by expression of all structural proteins from a single 
construct in this configuration. However, it may be possible that changes in the relative 
positions of the gene expression cassettes on the T-DNA may produce a better effect.  
Due to the difficulties of cloning such large constructs, this possibility was not 
investigated further.  
  
CHAPTER 6 – BTV-8 
 
172 
 
6.3.5.3 Restriction of VP3 expression by targeted use of wild-type 5’UTR 
Previous attempts to limit the expression of the BTV core proteins VP3 and VP7 have 
provided an indication that this strategy might help to maximise the yield of fully 
assembled VLPs by restricting the production of CLPs (Section 6.3.5.1-2). However, these 
experiments still resulted in an over-accumulation of VP3 in the form of SCLPs. Assuming 
that outer shell proteins VP5 and VP2 are expressed to a high level, the restriction of both 
VP3 and VP7 expression may result in VP7 becoming the limiting factor in VLP assembly. 
Without an intact VP7 layer, the outer shell could not interact with the forming particles 
and would be lost in the low density fractions of a gradient upon purification. A better 
strategy may therefore be the selective and drastic limitation of VP3 expression while 
maintaining very high levels of VP2, VP5 and VP7 expression. If VP3 becomes the limiting 
factor in particle assembly, any VP3 that does form SCLPs should encounter an 
abundance of VP7, VP5 and VP2, ensuring that any particles formed will be full VLPs.  
The high expression levels achieved using the mutated leader of the CPMV-HT system 
represent a vast, ca. 10 - 25-fold improvement over those levels attained using the wild-
type 5’UTR of CPMV RNA-2 (Sainsbury and Lomonossoff, 2008). The selective use of 5’-
UTRs with and without the HyperTrans (HT) mutations may therefore provide a useful 
means of modulating relative expression levels when multiple proteins are produced.  
In order to test whether the use of a wild-type 5’UTR for the expression of VP3 would 
yield a higher ratio of fully assembled VLPs, the 5’UTR of the codon-optimized VP3 
expression cassette was replaced by a wild-type version. The new pEAQexpress vector 
was called pEAQex-BTV8co-7HT-3, to indicate that both genes are codon-optimised but 
only the VP7 gene is flanked by a HyperTrans leader. This construct was agro-infiltrated 
with pEAQex-BTV8.5co-BTV8.2co, and compared to co-infiltration with constructs 
containing entirely codon-optimized genes expressed from HyperTrans cassettes. As 
previously seen, this latter combination produced fractions whose stoichiometry was 
indicative of VLPs, but also yielded fractions with a large over-representation of VP3, 
indicating SCLPs (Figure 6.9 A, lane 5). In contrast, expression of VP3 from a wild-type 
leader construct greatly reduced the level of VP3 purified in the same fraction (lane 5), 
while boosting the yield of stoichiometrically correct BTV proteins in the other fractions 
(Figure 6.9 B). This slight increase in VLP yield may be due to the lower level of VP3 
expression allowing plant cell resources to be spent on elevated production of the other 
viral proteins.  
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Overall, the use of a wild-type CPMV 5’UTR for the expression of VP3 provides the best 
strategy (of those discussed here) for ensuring high yields of stoichiometrically sound VLP 
preparations. Thus, pEAQex-BTV8co-7HT-3 was used in conjunction with pEAQex-
BTV8.5co-BTV8.2co during the preparation of virus-like particles for immunogenicity 
studies.  
 
 
 
Figure 6.9: Expression of a VP3 construct with a wild-type CPMV RNA-2 leader increases the 
yield of stoichiometrically correct VLP fractions. 
Leaves were agro-infiltrated with codon-optimized constructs as indicated and harvested 8 dpi. 
Clarified extracts were separated on sucrose step gradients. Fractions were collected from the 
bottom, separated on 4-12% SDS-PAGE gels and Coomassie blue stained. (A) Co-infiltration of 
pEAQexpress constructs carrying HyperTrans cassettes for all four structural proteins. (B) Co-
infiltration of pEAQexpress constructs carrying HyperTrans cassettes for VP5, VP2, and VP7 a wild-
type leader cassette for VP3. M = SeeBlue +2 marker; 1-5 = gradient fraction numbers; C = empty 
vector control. 
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6.3.6 PARTICLE PURIFICATION 
Bluetongue virus-like particles, CLPs and SCLPs are large icosahedral structures with a 
higher sedimentation coefficient than most plant proteins. Hence, it is possible to achieve 
partial purification by a simple density gradient centrifugation, as shown previously. For 
analysis of protein ratios and TEM, this level of purity is sufficient. However, for the 
purpose of immunogenicity and efficacy studies in sheep, it is important to produce 
particle preparation of high purity and homogeneity. It was also important that 
preparations be devoid of detergents and other reagents commonly used in plant protein 
extraction. 
In order to optimise purification protocols for BTV-8 CLPs and VLPs, buffer protocols 
and density gradient conditions were continuously modified, taking into consideration 
past experience and information gathered from published literature and personal 
communications. Some key findings and the final optimised purification protocol are 
presented here.  
Extraction buffer compositions and purification protocols used for the isolation of BTV 
particles vary widely in the literature. The buffer recipes used during this project are 
detailed in Section 6.2.2. As a starting point, a protocol provided by Dr. Rob Noad (London 
School of Hygiene and Tropical Medicine, personal communication) was used for the 
extraction of BTV-10 and BTV-8 particles (BTV extraction buffer). This buffer works well for 
core-like particles of both serotypes. However, the apparent failure to produce BTV-10 
virus-like particles was reason to change the buffer composition. In Smith Stabilisation 
Buffer (SSB) the Good buffer Bicine was substituted for Tris-HCl as the buffering agent, 
due to its acid dissociation constant (pKa) being closer to the required pH and its 
concentration was increased from 20 mM to 50 mM to increase buffering capability.  The 
detergent NP-40 was used (French et al., 1990), and 10% glycerol added for stabilisation. 
The first successful preparations of BTV-8 VLPs from plant tissue were prepared using this 
SSB extraction buffer (Section 6.3.4). However, in hindsight, this positive result was 
probably influenced more by the change in serotype and codon-optimization than by the 
extraction buffer used.  
The extraction buffer SSB was further altered to accommodate a lower salt 
concentration of 20 mM after personal discussions with Dr. Meredith Stewart (London 
School of Hygiene and Tropical Medicine, UK), thereby yielding low-salt SSB (Section 
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6.3.5.2). The final modification of the extraction buffer took into account information 
obtained from Dr. Peter Mertens (personal communication), who suggested that the use 
of 0.1 % sodium lauroyl sarcosine (NLS) detergent is optimal for storage of VLPs to avoid 
aggregation. This gave the extraction buffer used most successfully for extraction and 
purification of VLPs , which was called “BTV VLP extraction buffer”.  
Sucrose density gradients are commonly used to analyse and purify BTV preparations 
(French et al., 1990; Martin and Zweerink, 1972). However, the iodixanol density gradient 
medium Optiprep, may have some key advantages over other gradient media. It is 
claimed that virus preparations in Optiprep retain a higher rate of infectivity, suggesting 
that they are more intact (Møller-Larsen and Christensen, 1998). Additionally, 
concentrated iodixanol fractions can be injected directly into small animals for antibody 
production, without adverse effects.  
In order to determine which of the two gradient media is optimal for plant-produced 
BTV particles, pooled clarified extract of BTV-8 CLP-expressing tissue (infiltrated with 
pEAQex-BTV8.7-BTV8.3) was applied to Optiprep and sucrose step-gradients, as shown in 
Figure 6.10 A. Gradient tubes were imaged after ultracentrifugation. Two distinct bands 
were visible in the Optiprep gradient, while the sucrose gradient did not appear to 
contain a distinct band. Both gradients were carefully fractionated by collecting drops 
from the bottom of the tube.  
Analysis of the fractions by SDS-PAGE revealed a striking difference between the two 
gradients (Figure 6.10 B). The distinct bands of the Optiprep gradient were separated in 
fractions 3 and 4. The ratio of VP3 and VP7 in fractions 1-3 was indicative of the formation 
of core-like particles. Fraction 4, however, contained far more VP3 than VP7, indicating 
that this fraction consisted mainly of subcore-like particles. These two species of particles 
were clearly separated in the Optiprep, but not the sucrose gradient. Here, subcore- and 
core-like particles were present throughout the collected fractions, with higher density 
fractions appearing to contain more CLPs, and lower density fractions having a higher 
proportion of VP3, i.e. SCLPs.  
Both Optiprep and sucrose gradients efficiently separate BTV particles from plant 
material, which is retained at the top of the gradient. However, Optiprep appears to be 
much better suited to the separation of different particle species. This was also reflected 
in a parallel experiment with BTV virus-like particles (data not shown).   
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Figure 6.10: Iodixanol gradients are more suited to the separation of BTV particle species than sucrose 
gradients. 
Leaves were infiltrated with pEAQex-BTV8.7-BTV8.3 and harvested 9 dpi. (A) Pooled clarified 
extract was distributed between two step density gradients (20 - 40% iodixanol and 30 - 50% 
sucrose) and imaged after ultracentrifugation. Fractions were collected from the bottom as 
indicated in red. (B) Fractions were separated by SDS-PAGE and Coomassie blue stained. E = 
clarified extract; M = SeeBlue +2 Marker; P = resuspended pellet. 
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Figure 6.11: VLP integrity preservation is better in TEM grids prepared from sucrose 
fractions than iodixanol fractions. 
Leaves were co-infiltrated with pEAQex-BTV8co-7HT-3 and pEAQex-BTV8.5co-BTV8.2co and 
harvested 8 dpi. Pooled clarified extract was distributed between two discontinuous density 
gradients: (A) 30 - 60% sucrose; (B) 20 - 50% iodixanol. VLP containing fractions were pooled and 
purified on a second round of density gradient centrifugation. VLP containing fractions were 
adsorbed to carbon-coated grids, rinsed with deionized water (3x), stained with 2% UA and 
imaged using TEM. 
 
Analysis of the ratio of structural proteins in a gradient fraction provides a good 
indication of the composition of the sample and the particle species therein. However, no 
method surpasses TEM in providing confidence about the integrity of a sample intended 
for such critical experiments as animal studies. When preparing virus-like particles, 
samples which had been separated on sucrose gradients consistently showed higher 
particle integrity under TEM than those prepared with iodixanol (Figure 6.11). This effect 
may be an artefact of the harsh grid preparation and staining techniques involved in TEM. 
However, the quality of the sucrose-prepared particles, as well as the widely   
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Figure 6.12: Purification of BTV-8 VLP intended for immunogenicity studies. 
(A) Schematic representation of the key steps of the followed purification protocol for BTV-8 
VLP and CLP: homogenization, clarification, sucrose gradient 1, fractionation, sucrose gradient 2, 
fractionation. (B) Leaves were co-infiltrated with pEAQex-BTV8co-7HT-3 and pEAQex-BTV8.5co-
BTV8.2co and harvested 8 dpi. Clarified extract was purified on two sequential 30 - 60% sucrose 
gradients as described. Fractions were separated by 4-12% SDS-PAGE and Coomassie stained. 
Asterisk denotes bands that were submitted for mass spectrometry. Arrows indicate samples 
pooled for TEM analysis. S = starting material for second gradient spin; M = SeeBlue +2 marker; 
asterisks = bands confirmed by mass spectrometry to be VP5. (C) TEM of pooled purified samples 
as indicated by arrows in (B). Scale bar = 100 nm. 
 
 
documented use of sucrose in preparation of BTV particle samples for immunogenicity 
trials, were reason to favour this medium for the preparation of particles intended for 
efficacy trials in sheep. 
After much optimisation, the final purification procedure for obtaining BTV particles 
from N. benthamiana leaf tissue is schematically illustrated in Figure 6.12 A. Infiltrated leaf 
tissue was homogenised with three volumes of extraction buffer (BTV CLP or BTV VLP 
extraction buffers, as required), then filtered through Miracloth before centrifugation. The 
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clarified extract was applied to a 30 – 60 % sucrose step gradient, fractions of which were 
tested for the presence and ratio of BTV proteins by Coomassie-stained SDS-PAGE. 
Fractions of high quality were pooled, diluted, and subjected to a second round of density 
gradient centrifugation, containing only buffer and salt. Fractions were again tested for 
protein presence and ratios by SDS-PAGE analysis (Figure 6.12 B). The prominent bands in 
the high MW range were identified as VP5 multimers by mass spectrometry. The shown 
gel represents 1/400th of the total fractions obtained from 24 g of leaf tissue co-infiltrated 
with pEAQex-BTV8co-7HT-3 and pEAQex-BTV8.5co-BTV8.2co. Those fractions indicated by 
red arrows represent the fractions of optimal protein ratio, which were pooled and 
imaged using TEM (Figure 6.12 C). It is thus confirmed that a majority of particles in the 
preparation resemble VLPs, with a smaller proportion of CLPs present as expected. The 
amount of total BTV particles in this pooled sample was estimated from the intensity of 
Coomassie blue staining, and was later confirmed to be approximately 1.6 mg, 
corresponding to a recovery of 67 mg purified VLPs per kg FWT. However, this represents 
only a fraction of total BTV proteins produced, as a majority of assembled and 
unassembled proteins were discarded in gradient fractions deemed to have a poorer ratio 
of structural proteins or a high contamination with plant proteins and chlorophyll. Thus, a 
conservative estimate of total particulate BTV protein yield from N. benthamiana using the 
CPMV system is 200 mg / kg FWT. Further optimisation of extraction protocols may boost 
the relative recovery of pure VLPs from this total yield.  
During TEM analysis of a purified VLP sample which had been stored at 4 °C for over 
two months, some virus-like particles were identified which appeared to interact with a 
contaminant, giving them the appearance of having another layer (Figure 6.13 A). 
Interestingly, while most of the VLPs in the sample resembled CLPs due to a loss of the 
outer VP5 and VP2 shell, the few particles found to have a ‘halo’ structure appeared to be 
remarkably intact. This suggests that these particles were protected from disassembly 
during storage and/or during TEM grid preparation. The same staining procedure and the 
same aliquot of uranyl acetate were used to stain other particle samples of BTV CLPs and 
Hepatitis B; however similar structures were not observed in these samples. This indicates 
that the ‘halo’ effect is not an artefact of staining, but specific to this BTV VLP sample.  
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Figure 6.13: Preparations of purified BTV-8 VLPs contain some particles with associated 
halos. 
BTV-8 virus-like particles were expressed in leaf tissue and subjected to two rounds of sucrose 
density gradients to purify. Particles were stored in ca. 40% sucrose fractions containing 20 mM 
Tris-HCl, 20 mM NaCl, pH 8.0. Samples were adsorbed to carbon-coated TEM grids, rinsed with 
water and stained with 2% uranyl acetate prior to imaging. Scale bars = 100 nm. (A) Sample was 
stored at 4 ˚C for 2 months prior to imaging. (B) Independently prepared sample stored for two 
days prior to imaging. 
 
In order to determine whether the halo structures were an artefact of the particular 
virus-like particle sample examined, a fresh VLP sample was prepared by following the 
same purification procedure. Having only been stored for a short period of time, the new 
sample had a higher proportion of full virus-like particles, as expected (Figure 6.13 B). 
Similar halo structures were also observed in this sample and appeared to be slightly 
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more abundant. The reproducibility of the structures indicates that there is, in fact, an 
interaction between full VLPs and these structures under the extraction and purification 
conditions employed. The thickness of approximately 8 nm is consistent with the 
thickness of the cellular membrane (Buchanan et al., 2000). Although BTV is not an 
enveloped virus, the outer shell of the particles has been shown to interact with 
membranes, both during entry and egress of the particles (Hassan et al., 2001; Hassan and 
Roy, 1999). It is conceivable, that plant-produced BTV VLPs could interact with cell 
membrane debris before or during purification. The disuse of detergents in the later 
stages of particle preparation may allow these membrane fragments to become stably 
associated with some particles. Since uranyl acetate stain was able to penetrate into these 
particles, it is clear that they are not entirely encased during grid preparation. However, 
the tight association of the structures with the particles does offer an explanation why the 
associated particles appear to be more intact than most other particles in the older 
sample (Figure 6.13 A). The time constraints of this project did not allow for these 
structures to be studied further. 
The optimisation of extraction and purification procedures for BTV particles from 
plants has yielded a protocol which allows for consistently high quality BTV VLP 
preparations to be prepared. The purification procedure from the time of harvest requires 
less than two working days, with a recovery of 67 mg of purified VLP-rich particles per 
kilogram of fresh weight tissue.  
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6.4 DISCUSSION 
Following the successful expression of BTV-10 CLPs (Chapter 5), in this chapter I have 
shown that it is possible to achieve high-level BTV-8 virus-like particle expression in plants 
using the CPMV-HT system in conjunction with the pEAQ vectors (Chapter 3). This 
provides a potentially cheaper alternative production system for an effective inherently 
safe Bluetongue vaccine against BTV-8.  
High yields of full BTV-like particles were obtained upon expression of serotype 8 
codon-optimized and wild-type genes, implying that efficiency of plant-based expression 
of BTV particles is serotype-dependent. It would, however, be interesting to determine 
whether codon-optimization of BTV-10 genes would allow recovery of full VLPs of this 
serotype as well. The high degree of variability in the outer shell proteins of BTV serotypes 
may lead to differences in protein stability. Codon usage may also affect the expression 
levels of BTV proteins. In fact, it was found that codon-optimization of BTV-8 genes for 
expression in N. benthamiana resulted in increased expression levels for all structural 
proteins, when compared with the wild-type genes. However, codon-optimization for N. 
benthamiana expression is not a universal guarantee of higher expression levels in plants, 
and ideally several codon usages should be tested for yield optimization (Maclean et al., 
2007).  
The problems encountered in the expression of complex heteromeric protein 
structures such as BTV VLPs clearly show that maximization of overall protein yield is not 
necessarily the best route to ensuring product quality. The BTV-like particle consists of 
1440 subunits composed of a complex stoichiometric ratio of four different structural 
proteins (Stuart and Grimes, 2006). Each particle contains 120 copies of VP3 and 6.5 times 
as many copies of VP7, in addition to the other two structural proteins. The situation is 
further complicated by differences in mRNA and protein stability which inevitably 
influence the relative expression levels of different proteins. Thus, to maximize the 
amount of fully assembled particles in a preparation, it is necessary to modulate the 
expression levels of these four structural proteins.  
In previous experiments, it was found that co-expression of two proteins in plant cells 
was more efficient when genes were cloned onto a single T-DNA construct, such as that 
of pEAQexpress (Section 3.3.6). Co-expression of all of the structural proteins of a virus in 
the same cell is of utmost importance for the assembly of the virus particle. Hence, the 
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genes for the structural proteins of BTV were combined in sets of two with pEAQexpress 
constructs, and later combined to form a single T-DNA for the simultaneous expression of 
four BTV genes in addition to P19 (section 6.3.5.2). Though this approach only resulted in 
a marginal improvement in protein ratios of the purified particles, it provided a great 
improvement to upstream processes such as the preparation of inoculum and the syringe 
agro-infiltration. Co-expression of four BTV genes and P19 from five separate constructs at 
an optical density of 0.3 requires the preparation of an inoculum of OD600 = 1.5, a very 
thick solution which is difficult to infiltrate and negatively impacts plant health. The 
efficient expression of all five genes from a 16 kb T-DNA region also represents the 
greatest number of genes expressed simultaneously from a single construct using the 
CPMV-HT system, and is thereby a good test of the expression system as well as the pEAQ 
vectors.  
The use of long T-DNAs for expression of multiple proteins has previously presented a 
problem when used for the recovery of transgenic plants. T-DNA transfer occurs from the 
right border to the left border. Breakage of the T-DNA resulted in recovered transformants 
lacking the genes located closer to the left border (van Engelen et al., 1995). This is not a 
problem when using Agrobacterium-mediated T-DNA transfer for transient expression, as 
any breakages will not be detected. The results presented here show that high-level 
expression of BTV-8 VP5 can be achieved even when its cassette is cloned closest to the 
left border of a 16.1 kb T-DNA. Since the employed system provides each gene in the 
context of its own promoter and terminator sequences, expression may still be possible in 
the case of T-DNA breaks.  
An efficient way of maximising the relative yield of fully assembled VLPs, as opposed 
to CLPs and SCLPs, is through the restriction of the availability of core proteins. The 
stoichiometry of structural proteins found in early BTV particle preparations was 
indicative of an overrepresentation of core-like particles (section 6.3.4). It was thought 
that a solution to this problem could be the use of the wild-type genes for VP3 and VP7 to 
limit the production of CLPs while maintaining high levels of VP5 and VP2 through the 
use of codon-optimized sequences. This approach did lead to a reduction of VP3 levels in 
particle preparations (section 6.3.5.1), showing that this strategy was valid. However, the 
ratio of proteins produced still indicated an over-representation of core- and subcore-like 
particles. It is known that the structural proteins VP2, VP5 and VP7 cannot assemble into 
particles in the absence of VP3 (Roy and Noad, 2006). Hence, the above strategy was 
refined by drastically limiting the expression of VP3 while maintaining high expression 
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levels of the other proteins to ensure that VP3 became the limiting factor in VLP assembly. 
This was achieved by cloning the codon-optimized VP3 gene behind the wild-type, rather 
than the HyperTrans CPMV RNA-2 leader (section 6.3.5.3). The results indicate that this is 
the best strategy for the preparation of VLPs as it limits the accumulation of core- and 
subcore-like particles. Virus-like particles produced in this way were deemed to be of very 
high integrity (Dr. Peter Mertens, Institute for Animal Health Pirbright, personal 
communication). The work presented here is the first use of combinations of HT and wild-
type leaders of CPMV RNA-2 to modulate relative expression levels of heterologous 
proteins in this way.  
The stoichiometry problems encountered during BTV VLP expression in plants are not 
limited to this expression system. Though the relative amounts of the four proteins are 
not discussed in great detail in publications about the insect cell-produced VLPs, close 
analysis of the literature does reveal that these problems are general. The first report of 
BTV VLP assembly presents Coomassie blue-stained gels clearly showing a lower 
proportion of VP5 than is expected of full virus preparations (French et al., 1990). The 
bands for VP3 and VP2 were not resolved, hence no conclusion can be drawn about the 
relative levels of VP2. Recently, the expression of all four structural proteins from a single 
baculovirus construct has been reported (Stewart et al., 2010). Discussions with the 
author revealed that one reason for doing this was to ensure efficient co-expression of all 
four proteins in every infected cell, a strategy that was also reported in Section 6.3.5.2. 
However, the gels and TEM images published in this article still show disproportionate 
levels of the four structural proteins in purified VLP preparations. The experiments 
reported in this chapter to modulate expression levels and achieve higher VLP 
homogeneity represent the first such attempts in the field.  
The instability of the outer shell is integral to virion function during cell entry, and is 
not a phenomenon restricted to VLP production. In fact, the elucidation of the multi-shell 
composition of BTV virions was aided by the finding of two distinct particles in virus 
preparations: BTV-D (core) and BTV-L (virus; Martin and Zweerink, 1972). It was later found 
that virus particles are more easily labelled with anti-VP7 antibody after sedimentation 
through a sucrose gradient, indicating that gradient centrifugation damages the outer 
shell of particles (Hyatt and Eaton, 1988). Thus, it might be impossible to produce pure 
VLP preparations without contaminating CLPs and SCLPs. It is likely that the 
heterogeneity observed in particle preparations throughout the published literature is an 
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indication of incomplete assembly within cells, as much as damage during downstream-
processing.  
Despite the difficulties of handling an inherently instable virus, it was possible to 
produce VLP preparations of high quality for use in other applications. Sucrose fractions 
of purified VLPs and CLPs, produced as described in Section 6.3.6, have been frozen in 
aliquots, in preparation for preliminary immunogenicity and efficacy trials in sheep. Other 
samples prepared in Optiprep have been sent to Dr. Ann Meyers (University of Cape 
Town) for the purpose of raising antibodies. The antisera obtained will be an important 
tool for any future BTV work in both groups. Some critical next experiments include the 
use of the antiserum to detect BTV-8 proteins in a sample of commercial inactivated BTV 
vaccine, and to determine whether plant-made BTV-8 VLPs are able to raise neutralizing 
antibodies against authentic BTV-8. Plant-produced BTV-8 VLPs have also been provided 
to the Division of Structural Biology at the University of Oxford, where they were frozen in 
vitreous ice ready for cryoEM analysis (performed in collaboration with Dr. Alistair Siebert 
and Dr. Robert Gilbert). Structural information obtained from CEM would provide final 
proof of the integrity of the plant-produced VLPs.  
During the purification of virus-like particles, crescent-shaped structures were 
observed to be associated with some of the particles in the final sucrose fractions (Figure 
6.13). References to such structures could not be found in the literature. The thickness and 
lack of staining of the crescents leads me to speculate that these may be membrane 
fragments. It is known that both outer shell proteins associate with membranes: VP2 has a 
receptor-binding domain and a sialic acid-binding hub and functions in cell attachment 
during infection (Hassan and Roy, 1999; Zhang et al., 2010); VP5 is associated with lipid 
rafts and is involved in membrane permeabilization (Bhattacharya and Roy, 2008; Hassan 
et al., 2001). It is therefore conceivable that some lipids may associate with the VLPs 
before or during extraction, despite the presence of a detergent in the extraction buffer 
since the final stages of purification were performed without detergent. Interestingly, 
those particles associated with the crescent structures were the most intact VLPs in a 
sample which had been stored for several months. This may be an indication of a 
stabilizing effect of these structures on the VLPs. It would be interesting to test whether 
the addition of lipids to purified VLPs might aid in stabilizing these particles during 
storage. If it were possible to maintain efficacy while stabilizing VLPs in this way, this 
could be part of a solution to the problem of vaccine stability during storage and 
shipping. 
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Recently, it has been shown that a subunit vaccine consisting of plant-produced VP6 of 
Rotavirus induces passive protection of mice when administered orally (Zhou et al., 2010).  
At a yield of 1.54 mg / kg FWT and a 125 ug dose per mouse, this approach is far from 
economical. However, the proof of efficacy of an oral Reoviridae subunit vaccine, as well as 
recent findings that BTV-8 can be transmitted orally, indicate that it may be feasible to 
achieve immunogenicity from an orally administered plant-produced BTV vaccine in the 
future (Backx et al., 2009; Calvo-Pinilla et al., 2010). The high yields of over 200 mg BTV-8 
proteins per kg FWT achieved using the CPMV-HT system certainly make this approach 
more economical.  
During expression trials, an attempt was made to express the innermost structural 
protein VP3 on its own. Publications report that it is not possible to produce subcore-like 
particles by expressing BTV VP3 alone in insect cells (Hewat et al., 1992; Loudon and Roy, 
1992). It is, however, possible to produce subcore-like particles of Broadhaven Virus, a 
related Orbivirus, in this way (Moss and Nuttall, 1994), indicating that self-assembly of BTV 
VP3 might be possible. Upon expression of VP3 alone in N. benthamiana, subcore-like 
particles could indeed be purified. These particles resemble those produced by removal 
of VP7 from baculovirus-produced CLPs (Hewat et al., 1992). This provides proof that BTV 
VP3 can, in fact, self-assemble into icosahedral particles without the need for interaction 
with other BTV proteins.  
In this chapter, I have shown that the CPMV-HT system, in conjunction with the pEAQ 
vectors, can be used for high-level expression of BTV-8 SCLP, CLP and VLP in plants. The 
high yield of 67 mg purified VLP per kg FWT, and the good stoichiometric ratio of the 
produced proteins indicates that plants could rival insect cells as a production platform 
for BTV VLPs. Evidence of the self-assembly of VP3 in plants is indicative of the excellent 
capacity of plant cells to fold foreign proteins properly. This finding, as well as the 
evidence that C-terminally His-tagged BTV-10 VP3 retains its ability to form stable 
particles (Section 5.3.2) led me to investigate whether the plant-expression system would 
enable me to produce full BTV particles encapsidating large polypeptides, such as GFP 
(Chapter 7).  
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7 EXPRESSION AND USE OF FLUORESCENT BTV-LIKE PARTICLES 
7.1 INTRODUCTION 
The discovery of green fluorescent protein in 1962 and its later development as a 
biomarker have revolutionized many areas of biology by allowing proteins to be 
visualized in vivo (Chalfie et al., 1994; Shimomura et al., 1962). Recent advances in 
microscopy have enabled researchers to track individual fluorescent molecules, thereby 
making it possible to study the dynamics of protein movement within cells (reviewed by 
Greber and Way, 2006; Patterson et al., 2010). These new technologies provide an exciting 
new approach to the study of viruses.  
Fluorescent tags and proteins have been used only relatively recently in the field of 
virology to study virus entry, movement and egress. In 1998, the report of fluorescent 
labelling of the structural proteins of a virus allowed researchers to track adenovirus cell 
attachment and internalization into tissue culture cells (Leopold et al.). Viruses can be 
labelled with fluorophores either directly by covalent bonding with the viral capsids, or 
indirectly by use of a virus-specific antibody (Bartlett and Samulski, 1998). Such labelled 
viruses have been used successfully in single molecule tracking experiments to visualize 
the infection pathway of an adeno-associated virus in real time (Seisenberger et al., 2001). 
Despite their large size, the genetic fusion of fluorescent protein sequences to viral 
genes has provided another means of labelling some viruses. As described previously, it is 
possible to fuse GFP to the immunodominant loop of Hepatitis B core antigen, while 
maintaining its ability to form stable particles (Chapter 4; Kratz et al., 1999). Though these 
fusions have been explored mainly as a proof of principle for the insertion of large 
sequences for vaccine production, the formation of fluorescent HB cores opens up the 
possibility for the further study of HB particle assembly. It has already been shown that 
some enveloped viruses are amenable to budding in the presence of a fluorescent tag. In 
fact, it has been possible to produce fluorescent enveloped viruses, such as HIV-like 
particles, for the study of viral infection processes (Müller et al., 2004). More recently, 
Klingen et al. (2008) have been able to produce infectious double-labelled Rabies virus 
particles with a green fluorescent core and red fluorescent envelope. This was achieved 
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by fusion of RFP to the transmembrane domains of rabies virus G protein, and 
simultaneous expression of a GFP-fused nucleoprotein (Finke et al., 2004).  
In the case of non-enveloped viruses, the labelling of the outside surface of the virus 
with a fluorescent protein or dye invariably alters the surface properties of the particles to 
some extent. This may impact biophysical properties, as seen in Chapter 4, and may 
influence binding, uptake and infectivity of the particle (Leopold et al., 1998). A possible 
solution to this problem is the encapsidation of a fluorophore on the inside of the particle, 
the exterior of which would resemble the authentic virus. A method for the non-covalent 
anchoring of EGFP to the inside of Cowpea Chlorotic Mottle Virus (CCMV) has recently 
been described (Minten et al., 2009). However, due to the small size of CCMV, it is 
necessary to produce mosaic particles which only contain a small number of GFP 
molecules in order to allow for efficient folding of the fluorophore and assembly of the 
particles.  
Both Bluetongue Virus and Rotavirus have been shown to accommodate 120 copies of 
EGFP on the inside of core- and virus-like particles (Charpilienne et al., 2001; Kar et al., 
2005). The Reoviridae subcore structure, with its large internal cavity encased by only 120 
subunits of the same structural protein, makes it particularly suited to the encapsidation 
of large protein extensions. In 2001, an N-terminally truncated version of rotavirus VP2 
(equivalent to BTV VP3) was fused to GFP via a flexible SRGS linker (Charpilienne et al., 
2001). Co-expression of this construct with VP6 (equivalent to BTV VP7) in insect cells 
allowed rotavirus core-like particles to assemble, which resembled authentic cores. 
Furthermore, some evidence was provided for the assembly of the outer shell proteins 
VP4 and VP7 on this core-like structure, providing particles with distinct cell-binding 
characteristics. GFP- and DsRed-containing particles were used to study the 
internalization of rotavirus by kidney cell cultures.  
GFP-tagging of Bluetongue Virus structural protein VP3 has enabled researchers to 
show that its intracellular localization changes when it is co-expressed with other 
structural proteins (Kar et al., 2005). When expressed individually in mammalian BSR cells, 
VP3 was localized to the host cell proteasome. However, co-expression with its structural 
partner VP7 and other BTV proteins caused VP3 to be concentrated in the vicinity of the 
nucleus, within virus inclusion bodies, where it assembled into stable core-like particles. 
Though it was clearly shown that GFP-VP3 is able to assemble into fluorescent CLP, no 
indication was given for the assembly into full virus-like particles in the presence of VP2 
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and VP5. Moreover, the baculovirus-produced fluorescent BTV CLPs (Kar et al., 2005) do 
not appear to have been utilized further in the study of BTV cell entry. 
7.1.1 AIMS OF THIS CHAPTER 
In order to allow the potential of fluorescent BTV particles to be exploited for the study 
of virus functions, it is essential to produce pure preparations of full fluorescent VLP (fVLP) 
resembling authentic virus. The work presented in this chapter describes the successful 
plant-based production of core-like and full virus-like particles of BTV with three different 
fluorophores contained on the inside. The modular nature of the gene construct allows 
for easy fusion of other proteins to VP3. Preliminary mammalian cell binding and entry 
study results are also presented.  
 
7.2 SPECIFIC MATERIALS AND METHODS 
7.2.1 CLONING 
To construct pEAQ-HT-GFP:BTV8.3co, three fragments were ligated: (1) The egfp gene 
of pEAQ-HT-EGFP was amplified with M13F and GFP-BspEI-rev, then digested with PacI 
and BspEI; (2) The codon-optimized BTV-8 VP3 gene of pEAQ-HT-BTV8.3co (Chapter 6) was 
amplified with BTV8.3co-BspEI-fwd and C3, then digested with BspEI and AvrII; (3) pEAQ-
HT-BTV8.3co was digested with AvrII and PacI.  
A GFP: VP3co fusion construct with a wild-type CPMV RNA-2 5’UTR was cloned and 
named pEAQ-GFP:BTV8.3co. To produce this, three fragments were ligated: (1) pEAQ-GFP 
(a version with the wild-type 5’UTR of CPMV RNA-2) was digested with XhoI-DraI to obtain 
a pEAQ vector backbone with wild-type 5’UTR; (2-3) pEAQ-HT-BTV8-GFP:VP3co was 
digested with XhoI-DraIII-EcoRI and the XhoI-DraIII and DraIII-DraIII fragments were 
purified. Due to the interrupted palindromic recognition sequence of DraIII, the two sites 
cut by this enzyme produced different sticky ends, thereby ensuring directional ligation.  
mRuby and mT-Sapphire were cloned into pEAQ-HT by amplification with respective  
end-tailoring primers (Table 7.1), digestion with AgeI and XhoI, and ligation with digested 
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vector to form pEAQ-HT-mRuby and pEAQ-HT-mT-Sapphire.  N-terminal VP3 fusions with 
mRuby and mT-Sapphire were produced by amplification of these pEAQ-HT clones with 
C1 and the respective BspEI end-tailoring primers and digestion with NruI and BspEI. The 
vector pEAQ-GFP:BTV8.3co was equally digested and the mRuby and mT-Sapphire 
fragments ligated. Constructs are listed in Appendix A. 
 
Table 7.1: Oligonucleotides used in cloning of fluorescent BTV constructs. 
Name Sequencea Function 
   
BTV8.3co-BspEI-fwd CCTCCGGA Primer for end-tailoring of BspEI site to BTV-8 VP3co; sense 
GGCatggctgctcaaaat
gagc 
C1 aacgttgtcagatcgtgcttcggcacc Universal sequencing primer from CPMV RNA-2 5’UTR; sense 
C3 ctgaagggacgacctgctaaacaggag Universal sequencing primer from CPMV RNA-2 3’UTR; antisense 
GFP-BspEI-rev agctccggatttgtatagttcatccatgccatg 
Primer for end-tailoring of BspEI site to EGFP; 
antisense 
M13-F  acgttgtaaaacgacggccag Universal sequencing primer 
mRuby_AgeI_F CGACCGGT Primer for end-tailoring of AgeI site to mRuby; sense 
atgaacagcctgatcaaa
g 
mRuby_BspEI-R AGTCCGGA Primer for end-tailoring of BspEI site to mRuby; antisense ccctccgcccaggcc 
mRuby_XhoI_R ATCTCGAG Primer for end-tailoring of XhoI site to mRuby; antisense ttaccctccgcccaggcc 
mT-Sapphire_BspEI_R ATTCCGGA Primer for end-tailoring of BspEI site to mT-Sapphire; antisense 
cttgtacagctcgtccatgc
c 
mT-Sapphire_XhoI_R ATCTCGAG Primer for end-tailoring of XhoI site to mT-Sapphire; antisense 
ttacttgtacagctcgtcca
tgc 
SEQ_BTV8_VP3co_R cctaaccttctgcataatc Sequencing primer from BTV8.3co; antisense 
 
a END-TAILORING is shown in uppercase, restriction enzyme
 
 recognition sites are underlined.  
7.2.2 PARTICLE PURIFICATION 
Optimal fluorescent particle purification was achieved with the protocols used for BTV-
8 VLP and CLP purification, as detailed in Section 6.2.2. 
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7.2.3 UPTAKE STUDIES 
Experiments to track the internalization of GFP fVLP into mammalian cells were carried 
out in collaboration with Drs. Sarah Gold and Terry Jackson at the Institute for Animal 
Health, Pirbright.  
Baby Hamster Kidney cells (BHK-21; European Cell Culture Collection) were maintained 
in Glasgow Minimum Essential Medium (GMEM) containing 10 % foetal bovine serum 
(FBS), 2 mM glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin, 5 % (v/v) tryptose 
phosphate broth solution (Sigma). Cells were plated onto 13 mm borosilicate coverslips in 
24-well tissue cultre plates and maintained at 37 °C, 5 % CO2, to be used when 40 - 60 % 
confluent.  
To bind BTV fVLP, BHK cells were kept and washed three times with cold serum-free 
medium on ice before adding 20 μg/ml BTV -8 GFP fVLP and incubating on ice for 40 
minutes. Unbound VLP was removed by washing twice with cold serum-free medium, 
then cells were warmed by washing three times with 37°C warm serum-free medium. 
Cells  were incubated at 37 °C, 5 % CO2 and replicates removed at 0, 15 , 30 and 60 minute 
time points to monitor uptake. To stop internalization, cells were placed on ice and 
washed twice with cold serum-free medium before fixing with 4% paraformaldehyde for 
40 mintues.  
To detect VP5 and prepare cells for confocal microscopy, coverslips were washed three 
times with PBS before permeabilisation with 0.1% Triton X-100 for 20 minutes. After 
washing twice with PBS, non-specific binding was blocked using block buffer (100 ml TBS 
[10 ml of 1M Tris pH 7.5 in 500 ml 0.85% saline] supplemented with 1mM CaCl2, 0.5mM 
MgCl2,10% Normal Goat Serum [Harlan Lab Sera] and 1% Teleostean Gelatin [Sigma]) for 
30 minutes. Guinea-pig anti-BTV-1 VP5 antibody was added and incubated for one hour, 
washed three times with PBS and incubated with anti-guinea pig Alexa-Fluor-labelled 
secondary antibody (Molecular Probes) for one hour. After washing three times with PBS, 
cells were stained with 4’-, 6’-Diamidino-2-Phenylindole (DAPI; Sigma) at 1:10 000 dilution 
in water for 10 minutes, then washed with PBS. Coverslips were then mounted in 
Vectashield mounting medium (Vector Laboratories) on a glass slide and sealed with clear 
nail varnish. Slides were stored at 4 °C 
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7.3 RESULTS 
7.3.1 CONSTRUCTION OF PEAQ-HT-GFP:BTV8.3CO 
A fusion of EGFP to the N-terminus of BTV-8 VP3 was prepared as described in Section 
7.2.1 (Figure 7.1). The good results achieved in expression and assembly of GFP-displaying 
Hepatitis B Tandem cores (Section 4.3.5) provided reason to design the GFP:VP3 fusion in 
such a way as to include a flexible serine-glycine-glycine linker between the GFP and VP3 
proteins. This was achieved by end-tailoring PCR, which also introduced a unique BspEI 
site between the fused GFP and VP3 sequences. The unique NruI and BspEI sites flanking 
the egfp gene in pEAQ-HT-GFP:BTV8.3co allow for a simple substitution of egfp with any 
other gene of interest to produce new VP3 fusion proteins. This was done to produce 
mRuby and mT-Sapphire fusion proteins.  
Fusion of the 27 kDa GFP protein to VP3 was designed to result in the assembly of 
particles with 120 copies of this fluorescent protein on the inside. To obtain a sense of the 
relative size of GFP and VP3, the published crystal structures of the two proteins were 
assembled into a single image using Pymol software (Figure 7.1 C). The face of each VP3 
molecule measures 135 Å by 75 Å (Stuart and Grimes, 2006), making it far larger than the 
compact β-barrel structure of GFP, measuring only 30 Å in diameter (Ormo et al., 1996). 
This illustrates the availability of sufficient space to allow GFP to fold and fluoresce from 
the inside of BTV particles.  
 
7.3.2 EXPRESSION OF GFP:VP3 AND ASSOCIATION WITH BTV STRUCTURAL PROTEINS 
The pEAQ-HT-GFP:BTV8.3co construct was co-infiltrated with other BTV structural 
protein constructs in various combinations to establish whether the GFP:VP3 fusion 
protein could be expressed in plants and to determine whether it could form particles in 
the presence of other BTV structural proteins. GFP:VP3 was co-infiltrated with VP7 to 
obtain fluorescent core-like particles (fCLP), and with VP7, VP5 and VP2 for fluorescent 
virus-like particles (fVLP). Taking into account the possibility that fluorescent particle 
formation may only be possible in the form of mosaics with untagged VP3, leaf tissue was 
infiltrated with both GFP:VP3 and VP3 constructs at half of the optical density used for 
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VP7 (½ fCLP). As a control for assembly, VP3 and VP7 (pEAQ-HT-BTV8.3co and pEAQ-HT-
BTV8.7co) without GFP tag were co-infiltrated (CLP). Leaves infiltrated with the GFP:VP3 
were found to fluoresce under UV illumination, whereas the control infiltration did not 
produce fluorescence (Figure 7.2 A). The expression of the GFP:VP3 fusion protein did not 
appear to affect tissue health when compared with VP3.  
 
Figure 7.1: Design of a GFP:VP3 fusion construct. 
(A) Schematic representation of the three fragments used in the construction of the clone. (B) 
Schematic representation of pEAQ-HT-GFP:BTV8.3co. Restriction sites and functional elements  
critical to the cloning strategy are labelled. (C) Illustration of the relative sizes of GFP and VP3. GFP 
is shown as a ribbon; VP3 dimer is shown as a space filling model. The image was produced with 
Pymol programme using published structural data.  
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Figure 7.2: GFP:VP3 fusion protein is expressed in N. benthamiana leaf tissue and sediments in 
sucrose gradients. 
Leaves were co-infiltrated with codon-optimized BTV8 constructs as indicated. 1/2 fCLP = infiltrations 
with GFP:VP3 and VP3 at half of the normal optical density each (i.e. OD600 = 0.2). (A) Leaves were 
harvested 9 dpi and imaged under white and UV light to visualize GFP fluorescence. (B) Leaf tissue was 
extracted in low-salt SSB and clarified extract separated on 15 - 45 % iodixanol step gradients. Gradient 
tubes were imaged under white and UV light illumination to visualize GFP bands.  
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Clarified leaf extracts derived from the above infiltrations were separated on iodixanol 
step gradients to determine whether particles were being formed. After 
ultracentrifugation, fluorescence was detected only in the lower part of the gradients, 
indicating that the expressed GFP was efficiently incorporated into large structures 
(Figure 7.2 B). Both samples containing untagged VP3 produced two distinct thin bands 
at the bottom of the gradient, visible in white light. Under UV illumination, these bands 
were found to fluoresce in the ½ fCLP sample. In contrast, the fCLP and fVLP samples 
produced a broader, greenish and fluorescent band spanning the same density range of 
the gradient. It was previously determined that co-expression of BTV-8 VP3 and VP7 
constructs efficiently produces core-like particles in plants, and that these sediment to the 
in the range of 30 - 40% iodixanol (Section 6.3.4). Hence, the presence of fluorescent 
bands in this part of the gradient and a lack of fluorescence in other parts of the gradient 
indicated efficient fluorescent particle formation.  
Gradients were fractionated from the bottom and the most fluorescent fractions 
separated on SDS-PAGE to determine their composition (Figure 7.3). As shown previously 
(Section 7.3.3), co-expression of VP3 and VP7 yielded both proteins in all fractions, with a 
peak in fraction 4, indicating core-like particle assembly. As seen previously (Section 
6.3.5), an excess of VP3 was present in some fractions, indicating the presence of subcore-
like particles. This fraction likely corresponds to the upper of the two distinct bands seen 
in the gradients (Figure 7.2 B). The fractions obtained from the ½ CLP gradient contained 
similar amounts and patterns of VP3 and VP7 as the CLP fractions. However, in addition to 
the 103 kDa VP3 band, there was an intense band of lower electrophoretic motility, 
corresponding to GFP:VP3 (131 kDa). This indicates the presence of fluorescent core- or 
subcore-like particles. These fractions may contain a mixture of fluorescent and not-
fluorescent particles, or mosaic particles, or both.  
The ability of GFP:VP3 to form core-like particles containing 120 copies of GFP was 
finally proven by analysis of the fCLP fractions (Figure 7.3). These contained intense bands 
for both GFP:VP3 and VP7, indicating particle assembly. Crucially, there was no evidence 
of degradation products (i.e. free GFP and VP3), showing that all of the VP3 associated 
with the sedimenting particles was attached to GFP. The first evidence of the association 
of VP5 and VP2 with fluorescent BTV CLPs was found in the fractions of the fVLP gradient. 
Though the ratio of the outer shell proteins to core proteins was not indicative of a high 
proportion of VLP, the presence of VP2 and VP5 in the gradient fractions showed that the   
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Figure 7.3: C-terminal fusion of GFP to VP3 does not significantly affect the gradient 
sedimentation pattern of co-expressed BTV-8 structural proteins. 
Leaves were co-infiltrated with codon-optimized BTV8 constructs as indicated. 1/2 fCLP = 
infiltrations with GFP:VP3 and VP3-carrying Agrobacteria at half of the normal optical density each 
(i.e. OD600 = 0.2). Leaves were harvested 9 dpi, extracted in low-salt SSB and clarified extract 
separated on 15 - 45 % iodixanol step gradients. Key fractions were separated on 4 - 12 % SDS-PAGE 
gels and Coomassie blue stained. M = SeeBlue + 2 protein marker; C = purified BTV-8 VLP 
preparation.  
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outer shell proteins can associate with fluorescent core-like particles in the absence of 
untagged VP3.  
7.3.3 OPTIMIZATION OF FVLP YIELD AND INTEGRITY 
In order to study the uptake of Bluetongue virus by mammalian cells, it was important 
to produce particle preparations with a high proportion of fluorescent virus-like particles 
and few contaminating fCLP and fSCLP. Though the result presented above (Figure 7.3) 
shows that it is possible to produce fluorescent BTV particles with VP5 and VP2 attached, 
the ratio of BTV proteins is indicative of a mixture of fVLP, fCLP and fSCLP.  
The best strategy for optimization of VLP yield has been found to be the use of a wild-
type CPMV RNA-2 5’-UTR in the VP3 construct to down-regulate its expression relative to 
the other structural proteins (Section 6.3.5.3). Following this strategy, a new vector was 
prepared to replace the HyperTrans 5’ UTR with the wild-type leader, thereby producing 
pEAQ-GFP:BTV8.3co. The effect of this change on the stoichiometry of BTV-8 protein 
expression was determined by production of fluorescent VLP with the HT and non-HT 
constructs for GFP:VP3 (Figure 7.4). As seen previously, the use of HyperTrans constructs 
results in an overproduction of VP3, resulting in an excess of GFP:VP3 and VP7 (Figure 7.4 
A, lanes 7 + 8). BTV cores have a higher sedimentation rate than full virus, which explains 
why the excess of VP7 and GFP:VP3 is seen in the denser parts of the gradient. The BTV 
structural proteins in lanes 9-11 produce bands of similar intensity, as is expected for 
preparations of intact virus-like particles. The replacement of the HyperTrans leader of the 
GFP:VP3 construct results in similarly good fractions 9-11, indicating intact fVLP in these 
fractions (Figure 7.4 B). However, the over-representation of GFP:VP3 and VP7 in fractions 
7 and 8 is greatly reduced. This indicates that, overall, leaves expressing GFP:VP3 from the 
wild-type leader construct have a higher proportion of fully assembled fVLP.  
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Figure 7.4: Lower expression levels of GFP:VP3 with a wild-type leader result in a reduced 
over-representation of fCLP in fVLP preparations. 
Leaves were co-infiltrated with codon-optimized BTV8 constructs as indicated. GFP:VP3 was 
provided either in the context of a HyperTrans leader (A) or a wild-type leader (B). Leaves were 
harvested 8 dpi, extracted using BTV VLP extraction buffer and clarified extracts sedimented through 
discontinuous Optiprep gradients. Relevant fractions were separated on 4 - 12 % SDS-PAGE. M = 
SeeBlue + 2 protein marker; E = clarified extract; -ve = empty vector control extract. 
 
 
 
In order to conclusively show that the fusion of GFP to VP3 does not inhibit the 
formation of virus-like particles, purified fVLP were imaged using negative staining and 
TEM (Figure 7.5). Images showed a high proportion of fully assembled fVLP, interspersed 
with some partially disassembled particles and fCLP. Fluorescent virus-like particles were 
morphologically indistinguishable from VLP (compare Figure 7.5 A and B). However, the 
internal cavity of fVLP did not appear to be as distinct, suggesting that the negative stain 
was less able to penetrate these particles. However, due to the variability of negative 
staining and TEM grid preparation, this distinction is not always clear.  
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Figure 7.5: Purified fluorescent VLP are morphologically indistinguishable from normal VLP. 
Virus-like particles were produced by co-expression of BTV-8 VP2, VP5 and VP7 with either VP3 to 
generate VLP (A) or GFP:VP3 to generate fVLP (B). Purified particle-containing sucrose fractions were 
imaged using negative staining (2% UA) and TEM. Arrows indicate particles which appear to have lost the 
outer shell. Scale bar = 100 nm.  
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7.3.4 INTERNALIZATION OF FLUORESCENT BTV-LIKE PARTICLES BY MAMMALIAN CELLS 
One of the many potential uses of fluorescent Bluetongue VLPs is in the study of BTV 
cell entry. To determine whether plant-produced BTV fVLP bind mammalian cells, and to 
monitor their internalization, a confocal microscopy experiment with BHK cells was 
designed and carried out in collaboration with Dr. Sarah Gold and Dr. Terry Jackson 
(Institute for Animal Health, Pirbright).  
In short, GFP fVLP were incubated with BHK cells on ice to allow binding of the virus to 
the cell membrane. After removal of unbound fVLP, uptake was initiated by incubation at 
37 °C. Cells were fixed at time points of 0, 15, 30, and 60 minutes to monitor binding and 
uptake of virus. Permeabilization of the cells allowed VP5 to be labelled with a red Alexa 
Fluor dye by immunocytochemistry. The nuclei of the cells were stained with DAPI and 
fluorescent signals were imaged using confocal microscopy (Figures 7.6 and 7.7). 
Before initiation of uptake (0 minute time point), signals for GFP:VP3 (green) and VP5 
(red) were detected around the perimeter of the cells (Figure 7.6). The merged image 
showed co-localization (yellow) of the two signals, indicating that VP5 and GFP:VP3 were 
closely associated as is the case in virus-like particles. The binding of fVLP to BHK cells 
shows that the necessary binding motifs of VP5 and VP2 are present and in the correct 
conformation to allow interaction with the cell membrane and/or receptors. 
After incubation at 37 °C for 15 mintues, the localization of GFP:VP3 and VP5 changed 
drastically. By this time, most of the fVLP had been internalized, resulting in punctate 
signals throughout the cytoplasm (Figure 7.6). The merged image showed that most of 
the GFP:VP3 and VP5 was still co-localized. This result shows that plant-produced fVLP are 
internalized efficiently by BHK cells, and that the core and outer shell of the particles is still 
in close proximity within the cells, 15 minutes after internalization. 
At later time points, the signal for GFP:VP3 was gradually lost. Thirty minutes after 
initiation of uptake, both GFP:VP3 and VP5 signals were still detected throughout the 
cytoplasm (Figure 7.7). However, the merged image revealed that only a minority of foci 
showed co-localization of the two signals. The abundance of red foci within the cells 
indicated that VP5 was detected in these locations, whereas GFP:VP3 was not. This trend 
continued, and 60 minutes after internalization the vast majority of detected foci was red.  
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The gradual loss of GFP signal was not expected, but can be explained in two ways. 
One possibility is that the internalized particles partially disassembled after 
internalization, and that the fluorescent core-like particles were released from the early 
endosomes as is expected. If the core-like particles were spread out throughout the 
cytoplasm, the signal would be very dilute and hence not clearly detected. Another 
explanation for the loss of GFP signal is the fact that GFP fluorescence is pH-sensitive. 
From pH 7, EGFP fluorescence decreases rapidly with decreasing pH and is undetectable 
below pH 4.0 (Haupts et al., 1998). The pH of the early endosome has been found to be 
approximately pH 6, lowering to pH 5 upon fusion with lysosomes (Murphy et al., 1984). 
Such a pH shift may well be the cause of the loss of GFP signal at later time points.  
The experiment presented here demonstrates the binding and internalization of plant-
produced BTV-8 fVLP by BHK cells. However, to enable further study of the uncoating and 
intracellular movement of BTV by fluorescence tracking, it is essential to fuse VP3 to a 
fluorescent protein which fluoresces strongly at low pH.  
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Figure 7.6: Plant-produced BTV-8 fVLP bind BHK cells and are internalized. 
BTV-8 GFP fVLP were labelled with PM10 anti-VP5 antibody, then bound to BHK cells on ice 40 
minutes, washed off, and uptake initiated by addition of pre-warmed medium. Uptake was 
stopped after 0 and 15 minutes and cells imaged using confocal microscopy to visualize DAPI-
stained nuclei (blue), GFP (green), anti-VP5 antibody (red), and to determine co-localization 
(merge). Experiment performed in collaboration with Dr. Sarah Gold (IAH-P).  
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Figure 7.7: Plant-produced BTV-8 fVLP bind BHK cells and are internalized (Part 2).  
BTV-8 GFP fVLP were labelled with PM10 anti-VP5 antibody, then bound to BHK cells on ice 40 
minutes, washed off, and uptake initiated by addition of pre-warmed medium. Uptake was 
stopped after 30 and 60 minutes and cells imaged using confocal microscopy to visualize DAPI-
stained nuclei (blue), GFP (green), anti-VP5 antibody (red), and to determine co-localization 
(merge). Experiment performed in collaboration with Dr. Sarah Gold (IAH-P).  
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7.3.5 RUBY + SAPPHIRE 
The most likely explanation for the loss of GFP fluorescence upon internalization of 
GFP fVLP into BHK cells is the sensitivity of GFP to low pH. To widen the toolbox of 
fluorescent BTV particles, two other fluorescent protein variants were fused to the N-
terminus of VP3 as previously described (section 6.2.1). mT-Sapphire is a green 
fluorescent protein with a pKa of 4.9, making it more suited than EGFP to use in low pH 
environments (Zapata-Hommer and Griesbeck, 2003). mRuby is a monomeric far-red 
fluorescent protein with a pKa of 4.4 and a higher fluorescence intensity than EGFP (Kredel 
et al., 2009). The constructs used for expression were called pEAQ-Sapphire:BTV8.3co and 
pEAQ-mRuby:BTV8.3co, respectively, and contained the wild-type CPMV RNA-2 leader 
sequence.  
mRuby and mT-Sapphire fCLP (and fVLP) were produced by co-infiltration of the above 
constructs with HyperTrans, codon-optimized constructs for BTV-8 VP7 (and, when VLPs 
were required, also with VP5 and VP2). Upon separation of clarified extracts on sucrose 
density gradients, the Sapphire:VP3 fusion produced fluorescent bands similar to those 
seen for GFP:VP3-containing particles (Figure 7.8 A). As expected, the mRuby:VP3 extracts 
did not fluoresce green, but gradients showed a reddish band in the same area as the 
fluorescent band of GFP:VP3 gradients. The excitation wavelength of mRuby (558 nm) is 
not covered by the UV lamp used in these experiments, explaining the lack of intense far-
red fluorescence.  
Particle-containing fractions of the gradients were easily identified using a hand-held 
UV lamp. The most intensely fluorescent fractions were separated by SDS-PAGE and 
Coomassie-stained (Figure 7.8 B). The ratios of structural proteins detected in the fCLP 
and fVLP fractions did not differ significantly between the mRuby, mT-Sapphire and GFP 
particles. Fluorescent CLP fractions contained the respective VP3 fusion protein and VP7, 
with band intensities being similar, as expected for a molar ratio of 2 : 13. In the case of 
fluorescent virus-like particle fractions, VP2 and VP5 were also present. In the case of 
mRuby and mT-Sapphire fVLP, fraction 4 of the gradient appeared to contain an excess of 
the VP3 fusion protein, indicating contaminating fSCLP.  
Fraction 3 of each gradient was deemed to contain the optimal stoichiometry of 
structural proteins for the respective species of fluorescent particle, and these fractions 
were imaged using negative staining and TEM (Figure 7.8 C). When compared with non-   
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Figure 7.8: Production of fluorescent BTV-8 CLP and VLP with three different fluorophores. 
fCLP (and fVLP) were produced by co-expression of BTV-8 VP7 ( and VP5 and VP2) with one of three 
different VP3 versions: GFP:VP3, mRuby:VP3 or mT-Sapphire:VP3. (A) Clarified extracts were separated on 
sucrose density gradients and photographed under UV illumination. (B) The most fluorescent fractions 
were separated on 4 - 12 % SDS-PAGE and Coomassie blue-stained. (C) Fraction 3 of each gradient was 
imaged using negative staining and TEM.  For comparison, CLP and VLP produced from regular VP3 are 
included. Scale bars  = 100 nm. 
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fluorescent plant-produced CLP, the fluorescent CLP looked similar, with a distinctive 
spiky appearance owing to the VP7 trimers on their surface. Likewise, the fluorescent VLP 
were indistinguishable from the non-fluorescent VLP. As usual, some partially 
disassembled particles were present in the fVLP and VLP TEM grid preparations.  
To determine whether the insertion of 120 fluorescent proteins on the inside of BTV-8 
particles influences particle size, TEM images were used to measure particle diameters 
(Figure 7.9). At first glance, it appears as though virus-like particles containing GFP or mT-
Sapphire are slightly smaller (ca. 6 nm) than either empty or mRuby-containing VLP. 
However, core-like particles derived from all four versions of VP3 have are very similar in 
size. Due to the instability of the outer shell of BTV, it is possible that the measured VLP 
size is variable and largely dependent on TEM grid preparation. Core-like particles are 
more stable and thus provide a more reliable measurement of relative particle size. In 
order to obtain more reliable data for VLP, it would be necessary to increase the sample 
number and to include data from multiple TEM grids for every particle species. Due to 
time constraints, this was not undertaken. The mRuby and mT-Sapphire particles have 
been supplied to my collaborators for use in further uptake studies to see whether they 
are less pH-sensitive, as expected.  
 
Figure 7.9: Core-like and virus-like particle size is not significantly influenced by fusion to 
fluorescent proteins. 
Box plot analysis of the size distribution of different BTV-8 particles in TEM images. At least 25 
particles were measured for each particle species using Adobe Photoshop. Data were analyzed 
with Microsoft Excel.  
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7.3.6 INTRACELLULAR LOCALIZATION OF GFP:VP3 IN PLANT CELLS 
Tagging of VP3 with a fluorescent protein makes it possible to visualize the 
intracellular localization of VP3 and associated particle structures in the plant cells in 
which they are being expressed. In order to determine whether plant-expressed GFP:VP3 
is found throughout the cytoplasm or in distinct foci, plants were infiltrated with 
combinations of GFP:VP3 and other BTV-8 structural protein constructs, and viewed using 
confocal microscopy.  
Though GFP:VP3 is likely produced throughout the cytoplasm, fluorescence signals 
were detected only in distinct areas of the cell (Figure 7.10). Tissue expressing GFP:VP3 
either on its own (fSCLP) or with VP7 (fCLP), contained large foci of fluorescence, usually 
in a single area of each cell. In contrast, tissue co-infiltrated with all four structural 
proteins of BTV contained cells with multiple, distinctly circular foci of fluorescence. As a 
control, pEAQ-HT-GFP was agroinfiltrated and tissue showed fluorescence throughout 
the cytoplasm of the cell. These preliminary results indicate that VP3 localizes to distinct 
areas of the cell upon expression, and that the presence of other BTV structural proteins 
influences the intracellular localization of VP3. 
 
 
Figure 7.10: Intracellular localization of GFP:VP3 is influenced by co-expression of other 
structural proteins. 
Plants were agro-infiltrated with constructs as indicated. GFP fluorescence in the lower 
epidermis was imaged at 8 dpi by confocal microscopy.  fSCLP = GFP:VL3; fCLP = GFP:VP3 + VP7; 
fVLP = GFP:VP3 + VP7 + VP2 + VP5.  
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Given the necessary time, this experiment could be improved in several ways. To 
determine whether GFP:VP3 is associated with specific subcellular compartments, a 
combination of different vital stains could be used to visualize the nucleus (DAPI), cellular 
membranes (FM4-64) or mitochondria (MitoTracker). When visualizing individual cells, it is 
crucial to ensure that all proteins are efficiently co-expressed in each cell. Previous 
experiments have demonstrated that co-infiltration is not an effective means of ensuring 
efficient co-expression in every cell (Section 3.3.6). Thus, it is important to repeat this 
experiment with constructs containing all BTV structural proteins on the same T-DNA, as 
done in Section 6.3.5.2.  
 
 
7.4 DISCUSSION 
During the past decade, fluorescent particles of many different viruses have been 
produced for use in the study of virus function, or as a proof of principle for the 
encapsidation or display of large epitopes (reviewed by Brandenburg and Zhuang, 2007). 
However, the compact, multimeric structure of simple icosahedral viral capsids poses the 
problem of steric hindrance for the tagging of these viruses with functional fluorescent 
proteins. For instance, a small viral capsid composed of 240 subunits of one structural 
protein, e.g. the Hepatitis B core, will display 240 copies of the fused fluorescent protein. 
In Chapter 4 I have shown how the development of tandem HBcAg has enabled the 
display of a large polypeptide on every second c/e1 loop, thereby reducing the steric 
hindrance. The display of foreign protein structures has focussed mainly on the outside of 
viral capsids where there is more space for folding.  
Bluetongue virus and other Reoviridae have internal capsid structures which allow 
relatively few (120) foreign proteins to be assembled within a relatively large central 
cavity of up to 46 nm diameter (Fauquet et al., 2005, p. 467). The encapsidation of foreign 
proteins on the inside of a virus-like particle can have several key advantages: (1) Inside 
the particle, a foreign peptide is protected from the cellular protein degradation 
machinery. (2) If the linker between the structural protein and the foreign peptide is 
unstable, the detached foreign protein will remain trapped within the assembled particle. 
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(3) With the outer surface of the particle resembling the native virus, biophysical 
properties such as surface charge and isoelectric point will be largely unchanged, thereby 
allowing these particles to be purified using established protocols. (4) Structures on the 
outer surface of the particles which play a crucial role in receptor binding, cell 
attachment, cell entry, intracellular trafficking or localization will be present in their native 
conformation and will not be obscured by the foreign polypeptide. Depending on the 
application, however, the display of polypeptides on the outside may be necessary (e.g. 
targeting, receptor-ligand interaction).  
Although the assembly of BTV particles containing GFP in insect cells was reported 
over five years ago, the huge potential of this tool for basic research of BTV and for 
biotechnological applications has not been exploited (Kar et al., 2005). The reasons for 
this may include low yield, instability of the linker between GFP and VP3, and most 
crucially the inability to form stable full virus-like particles with a complement of VP2 and 
VP5.  
Here, an attempt was made to express GFP-tagged BTV-8 VP3 in plants, and to purify 
fluorescent BTV particles as was previously done using the baculovirus system (Kar et al., 
2005). The instability of the GFP:VP3 fusion protein reported in the latter publication was 
addressed by the insertion of a flexible SGG linker between the two proteins, based on 
the good results achieved with such a linker during the expression of GFP-tagged tandem 
HBcAg (Chapter 4). This GFP:VP3 fusion protein was successfully expressed in leaf tissue 
on its own allowing assembly of fluorescent subcore-like particles (data not shown) and 
was found to assemble into fluorescent core-like particles when co-expressed with VP7 
(Figure 7.2). The presence of a high proportion of untagged VP3 in fluorescent particles 
prepared using the baculovirus expression system (Kar et al., 2005) led authors to 
speculate that GFP-tagged VP3 can only assemble into chimaeric particles containing a 
proportion of untagged VP3 (Kar et al., 2005). This was disproved by the finding that fCLP 
produced from GFP:VP3 in plants contain only the fusion protein, with cleaved VP3 
undetectable in these preparation. This shows that all 120 copies of VP3 in a particle can 
accommodate a large N-terminal extension.  
While fluorescent BTV core-like particles have been produced previously, fluorescent 
virus-like particles have not been reported. However, similar experiments with GFP-
tagged VP2 of the closely related rotavirus have resulted in virus-like particles consisting 
of all four structural proteins (Charpilienne et al., 2001). Though this publication did not 
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provide direct proof in the form of TEM images or SDS-PAGE gels, the indirect evidence of 
the assembly of the outer shell provides a good indication that it may be possible to 
produce full Bluetongue virus-like particles. In this chapter I have shown that GFP:VP3 
does, in fact, assemble into fVLP when co-expressed with VP7, VP5 and VP2. Though the 
first attempts provided only a poor recovery of outer shell proteins, the stoichiometry was 
greatly improved by limiting of GFP:VP3 expression through the use of a wild-type 5’UTR 
as described in Chapter 6. Transmission electron microscopy confirmed that the 
fluorescent virus-like particles closely resembled normal VLP. To my knowledge, no TEM 
images of fluorescent Reoviridae particles have been published.  
Purified plant-produced fluorescent BTV particles have already been supplied to 
several research groups for use in their experiments. At the John Innes Centre, an attempt 
has been made by Dr. Allister Crow to crystallize fCLP in order to obtain structural data for 
the encapsidated fluorescent protein. A positive outcome of this proof of principle 
experiment would open the door to the crystallization of other “difficult” proteins by 
proxy. The BTV particle scaffold would ensure solubility of the cargo protein and should 
allow standardized crystallization conditions to be employed. The design of the VP3 
fusion construct allows for easy substitution of the gfp gene with any other gene of 
interest. It is questionable, however, whether the flexible linker inserted between VP3 and 
the cargo protein would allow for good crystallographic data to be obtained. Another 
possibility to obtain structural data for a cargo protein is provided by cryo electron 
microscopy. A sample of fVLP has been frozen in vitreous ice at the Division of Structural 
Biology, University of Oxford, and is awaiting CEM analysis by the research group of Dr. 
Robert Gilbert. These structural studies would also provide evidence for the structural 
integrity of plant-produced BTV VLP.  
The most obvious application for fluorescent BTV particles is in the study of viral 
movement into and within cells. Purified fCLP have been supplied to Dr. Tom Wileman 
(University of East Anglia) for use in microinjection studies to track the movement of virus 
structures within cells. A collaborative project has been set up with Drs. Terry Jackson and 
Sarah Gold at the Institute for Animal Health, Pirbright, to study the binding and 
internalization of BTV in mammalian and insect cells. The results of preliminary 
experiments have been presented here. Plant-produced fVLP were shown to bind BHK 
cells in vitro, and the particles were internalized efficiently. In these experiments, the BTV 
core was visualized by excitation of the encapsidated GFP, while the outer shell was 
detected by immunocytochemistry using an antibody against VP5. This allowed 
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visualization of the co-localization of the inner and outer shells of the virus-like particles. It 
was expected that the signals for VP3 and VP5 would separate upon release of the core-
like particle into the cytoplasm, thereby providing proof of the uncoating of the VLP upon 
endocytosis. However, the signal for GFP was lost unexpectedly, soon after uptake of the 
fVLP. This result mirrors the finding that trypsinized fluorescent rotavirus VLP are not 
detectable after uptake by MA104 cells (Charpilienne et al., 2001). The most logical 
explanation for this would be the quenching of fluorescence due to a rapid lowering of 
pH in the early endosome (Murphy et al., 1984; Patterson et al., 1997). 
In an attempt to produce fluorescent BTV particles which are not quenched by the low 
pH of the endosome, GFP was replaced by two pH-stable fluorescent proteins, mRuby 
and mT-Sapphire (Kredel et al., 2009; Zapata-Hommer and Griesbeck, 2003). Expression 
and purification of these new fluorescent particles was done using the same protocols 
optimized for non-fluorescent BTV VLP (Chapter 6), and resulted in a similar yield. The 
transferability of purification methods to particles encapsidating foreign proteins 
provides an indication that expression of a foreign sequence on the inside of a particle 
leaves the biophysical surface properties of the particle largely unchanged. This is in stark 
contrast to the insertion of GFP on the outside of tandem Hepatitis B core-like particles, 
which were thereby rendered completely insoluble and required many changes to 
extraction conditions to allow recovery of even a small proportion of soluble particles 
(Chapter 4).  
TEM analysis of the size and shape of fluorescent and non-fluorescent BTV CLP and VLP 
revealed that the presence of a foreign polypeptide on the inside of the BTV particles 
does not significantly affect their morphology. The four species of core-like particle (GFP-, 
mT-Sapphire-, mRuby-fused or wild-type) were similar in size, with fluorescent particles, if 
anything, appearing to be slightly smaller than wild-type particles. Though this finding 
was not statistically significant, it is consistent with the observation that empty BTV core-
like particles are slightly larger than dsRNA-containing authentic core particles (Hewat et 
al., 1992). It would be interesting to compare structural data for authentic cores, core-like 
and fluorescent core-like particles to determine whether the packing of density on the 
inside of the particles causes subtle changes in particle structure.  
In addition to the applications in structural studies and virus uptake discussed above, 
fluorescent BTV particles have the potential to be exploited for several other purposes. 
The functional cell attachment domains of the outer shell proteins could be studied by 
CHAPTER 7 – FLUORESCENT BTV 
 
212 
 
co-expression of mutant versions of these proteins with fluorescent cores, followed by 
analyses of the effects on binding and uptake efficiency. It might be possible to co-
express the mRuby fluorescent cores with a mT-Sapphire-tagged VP2, thereby producing 
dual-labelled VLP for real-time detection of the dissociation of BTV protein shells during 
infection (Bhattacharya et al., 2007). The GFP:VP3 fusion protein has already been used to 
study the localization of virus assembly, and this could be expanded upon (Kar et al., 
2005). Fluorescent, fully assembled virus-like particles could also be used to shed light on 
the non-lytic virus egress by interaction with the cell membrane-associated non-structural 
protein NS3 in insect cells. It could also be possible to feed Culicoides species with 
fluorescent VLP in an effort to elucidate the viral infection process in the insect host.  
During the many rounds of expression and particle purification performed as part of 
this project, the fluorescence of the particles was found to greatly facilitate the tracking of 
particles throughout the purification process. By simply shining UV light onto gradients, 
gel filtration columns and buffer exchange columns, it was possible to monitor which 
fractions contained BTV particles and to see whether significant loss of particles had 
occurred due to aggregation. If Bluetongue VLPs are to be developed as a vaccine, 
extraction and purification conditions will have to be further optimized for large-scale 
production. For these purposes, fluorescent particles may provide the ideal tool for the 
rapid analysis of the effect of changes to the established protocols. Furthermore, particle 
stability in a variety of pH, salt and temperature conditions as well as after long-term 
storage could be easily assessed using fluorescent particles.  
The design of the developed GFP:VP3 construct allows other genes to be substituted 
for gfp through use of unique restriction sites. Thus, other proteins can be easily fused and 
tested for particle assembly within several days by transient expression using the CPMV-
HT system. This provides a great advantage over the slower baculovirus expression 
system. It has been shown that immunization with BTV and rotavirus particles displaying 
an antigenic sequence on the inside induces an immune response against the inserted 
foreign peptide (Charpilienne et al., 2001; Tanaka et al., 1995). The apparent superior 
stability of the GFP:VP3 fusion protein seen here opens up the possibility for using plant-
produced BTV particles as epitope carriers in the development of vaccines against other 
agents. It would be interesting to attempt the production of chimeric BTV CLP containing 
several different VP3 fusion proteins. As a proof of principle, this could be achieved by co-
expression of GFP:VP3 and mRuby:VP3, followed by confocal microscopy of a dilute 
solution of purified particles to show co-localization of the green and red signals. Another 
CHAPTER 7 – FLUORESCENT BTV 
 
213 
 
possibility would be the insertion of peptides with an affinity for certain drugs or metals. 
The large pores of the BTV CLP should allow the particles to be loaded with drug 
molecules, enabling the use of BTV as a vehicle for drug delivery, as envisaged for other 
viruses (Franzen and Lommel, 2009; Lee and Wang, 2006).  
In conclusion, the work presented here shows that it is possible to produce high yields 
of fully assembled fluorescent Bluetongue Virus-like particles in plants which may find 
uses in basic research, downstream processing optimization, biotechnological and 
biomedical applications in the future.  
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8 DISCUSSION AND OUTLOOK 
The overall aim of this thesis was to push the boundaries of virus-like particle 
production in plants by making use of recent advances in transient expression 
technology. Two of the main applications of VLPs, i.e. their use as vaccines in their own 
right, and their function as carriers of foreign epitopes, have been addressed by the 
expression of Bluetongue and Hepatitis B particles. Furthermore, a toolbox of small binary 
vectors has been created, which are uniquely suited to exploit the benefits of the CPMV-
HT system for the transient expression of complex, heteromeric BTV-like particles – the 
largest and most complex biopharmaceutical protein structures to have been expressed 
in plants to date.  
The CPMV-HT system achieves high expression levels by enhanced translation, not 
replication, and it has been shown to be ideally suited to the co-expression of up to three 
GOI by co-infiltration (Sainsbury and Lomonossoff, 2008). However, for the efficient 
cloning and co-expression of four BTV structural proteins as well as P19 within the same 
cell, the existing, outdated vector system had to be changed. In fact, I have shown that co-
infiltration is not an efficient means of ensuring consistent cellular co-expression of as few 
as two foreign proteins, let alone five. The pEAQ vector series was developed to bring the 
CPMV-HT cloning system up to date and to allow for consistent co-expression of multiple 
proteins from a single T-DNA construct (Sainsbury et al., 2009). The pEAQ vectors are the 
first binary vectors to include an expression cassette for a suppressor of gene silencing, 
ideal for transient expression. Gateway-compatible versions of the vectors allow the 
CPMV-HT system to be used for high-throughput screening of new constructs, and allow 
it to be tested in parallel with other Gateway-compatible expression systems. In fact, 
Gateway cloning has allowed me to test the CPMV-HT leader sequences for expression of 
GFP in insect cells using the baculovirus system, which has provided a first indication of 
the functionality of CPMV-HT in heterologous systems (data not shown here). To date, in 
excess of 100 research groups and companies have used the pEAQ vectors, and they are 
one of the main expression platforms of the EU Framework 7 PLAPROVA project, showing 
that they are a widely used toolbox for various protein expression projects beyond the 
scope of this thesis. In particular, these vectors have been supplied to Medicago Inc., a 
company which is using the CPMV-HT system to produce influenza vaccines for human 
clinical trials.  
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For the purposes of my project, the pEAQ vectors were first used to express a relatively 
simple VLP, the hepatitis B tandem core. While wild type HBcAg particles have been 
produced successfully in many expression systems, including the CPMV system in plants 
(Mechtcheriakova et al., 2006; Sainsbury and Lomonossoff, 2008), tandem HBcAg particles 
have proved difficult to produce. Collaborators at the University of Leeds and Iqur Ltd, 
who developed the tandem core technology to overcome steric hindrance limitations in 
the use of wild type HBcAg as an epitope display platform, have expressed tHBcAg in E. 
coli and yeast systems. While empty tandem core particles can be produced efficiently 
using these systems, the attachment of GFP as a model epitope yielded a heterogeneous 
mixture of particle sizes which were not amenable to purification and structural analyses. 
This irregularity in particle structure presents a major hurdle in the adoption of tandem 
core technology for the development of human vaccines, due to strict quality assurance 
guidelines associated with regulatory approval of biopharmaceuticals. The challenge to 
produce more homogeneous tandem core particles with large inserts in a plant system 
was taken up. 
In Chapter 4 I have shown that tHBcAg particles presenting active GFP on the outer 
surface can be expressed efficiently in plants using the pEAQ vectors. These particles are 
very regular in size and shape, allowing them to be used in structural studies using cryo-
electron microscopy. The three-dimensional reconstruction obtained by CEM clearly 
shows the regular shape of the hepatitis B tandem core particle with a surrounding layer 
of density corresponding to the displayed GFP.  
This proof of concept opens the door to allow the tandem core technology to be used 
for the display of other, more medically relevant epitopes and proteins. In fact, I have 
shown that a range of other tHBcAg constructs can be expressed using the CPMV-HT 
system. Constructs for the display of two model epitopes, namely GFP and a 40 aa 
fragment of the Hepatitis B surface antigen, exploit the unique propensity of tHBcAg to 
accommodate two different foreign sequences. Such particles could be used as bivalent 
vaccines, as first suggested by Brown et al (1991), or could include a targeting peptide to 
allow for targeted delivery of the tHBcAg particles to specific cell types. However, the 
display of foreign peptides on the outside of VLPs profoundly changes their surface 
properties, and this has led to the problem of aggregation of most of the tHBcAg 
constructs expressed during the work reported in this thesis. If tandem core technology is 
to be exploited commercially, it will be important to invest in the development of 
downstream processing protocols and buffers that are tailored for every new construct.  
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The finding that tHBcAg particles displaying GFP assemble more reliably in plant cells 
than they do in E. coli or yeast is another indication that plant-based pharmaceutical 
production systems have some key benefits over other traditional systems. As discussed 
previously, plants have the benefits of other eukaryotic systems, allowing for superior 
folding with the help of chaperones, and post-translational processing such as 
glycosylation and disulfide bond formation. In fact, transgenic plant systems are being 
developed which allow for near-human glycosylation patterns of antibodies and other 
biopharmaceuticals (Gomord et al., 2010). In comparison with mammalian cell production 
systems, plants have the added advantages of no risk of contamination with animal 
viruses and potentially far lower production costs. In fact, even the cost of cGMP plant 
production facilities are 3-4 times lower than the cost of mammalian cell culture facilities 
(Gleba, 2009). The development of new products using viral vector-based transient 
expression is also extremely fast, as demonstrated recently by the development of a 
plant-based VLP vaccine against the new H1N1 “swine flu” strain of influenza within three 
weeks of the release of the genetic sequence (D'Aoust et al., 2010). However, with big 
pharma slow to adopt this new technology, acceptance of plant-based expression 
systems may be raised by the development of a veterinary vaccine, such as Bluetongue 
virus-like particles, as a less tightly regulated stepping stone.  
The pEAQ vectors have been a particularly useful and essential tool in the production 
of BTV-like particles. I have shown that it is possible to produce assembled virus-, core- 
and subcore-like particles of two BTV serotypes in plants, making this the second 
production platform successfully used for this purpose (after insect cells). Interestingly, it 
has been possible to produce SCLP by expression and self-assembly of VP3 alone, 
contradicting previous reports that SCLP can only be produced by removal of the outer 
layers of CLPs and VLPs (Hewat et al., 1992; Loudon and Roy, 1992). This is another 
indication of the superior ability of plants to produce the correct tertiary and quaternary 
structures of heterologous proteins.  
The complexity of the BTV VLP arises from the stoichiometry of the structural proteins, 
the multi-layered structure, and the differing stabilities of the layers. The ratio of the four 
structural proteins comprising each BTV particle is 2 : 13 : 4 : 6 (VP3 : VP7 : VP2 : VP5), in 
stark contrast to the simple tHBcAg particle consisting of only one structural protein, or 
even CPMV or FMDV particles which have two or three structural proteins, respectively, at 
equimolar ratios. Expression of these four proteins at the required ratios is further 
complicated by the fact that expression levels attained for any given protein are 
CHAPTER 8 – DISCUSSION AND OUTLOOK 
 
217 
 
dependent on many factors such as mRNA stability, codon-usage, protein stability, 
protein toxicity, etc. Since BTV particles can exist in at least three different forms (SCLP, 
CLP, VLP), it is inevitable that particle preparations will contain a mixture of different 
particles. Close scrutiny of TEM images of Bluetongue virions and virus-like particles in 
published literature reveals a mixed population in most cases (French et al., 1990; Hewat 
et al., 1994; Roy et al., 1992). However, for the purposes of vaccine production, it is 
essential to produce the most homogeneous preparation of full VLPs possible, since the 
outer shell proteins VP5 and VP2 are the main immunogenicity determinants of BTV and 
are essential for vaccine efficacy. In Chapter 6, three strategies were employed to tackle 
the stoichiometry problem: (1) reduced relative expression of core proteins from non-
codon-optimized constructs; (2) cloning of all four BTV genes and P19 onto the same T-
DNA to ensure efficient co-expression; (3) reduced expression levels of the innermost 
protein (VP3) by selective combinatorial use of delRNA-2 with CPMV-HT. The third, and 
most effective approach made VP3 expression the limiting factor in particle assembly, 
allowing any VP3 particles the highest chance of acquiring a full complement of VP7, VP5 
and VP2. Optimization of extraction and purification conditions enabled the recovery of 
highly pure and homogeneous VLP preparations using this approach.  
The ability to modulate the relative expression levels of multiple proteins may have 
implications for other biotechnological applications. In the case of metabolic pathway 
engineering, individual enzymes may be needed at lower levels than others to ensure 
efficient conversion of a substrate to a desired product. The CPMV expression system is 
already being used for metabolic pathway engineering, for instance for production of the 
plant defense compound avenacin (Mugford et al., 2009). Another example would be the 
production of multiple proteins from a polyprotein by co-expression of a protease, where 
only relatively low levels of the protease enzyme may be needed. Proteases are often 
toxic when expressed at high levels, hence a lower expression level may be essential. In 
the case of the work presented here, it would be good to attempt the expression of 
relatively low levels of BTV-8 NS3 together with the structural proteins in order to reduce 
the necrosis associated with NS3 and to allow assembled VLPs to egress from the cells.  
The pEAQ vectors can be used for simultaneous co-expression of at least five different 
genes of interest by transient expression. Though such a construct has not so far been 
tested for the regeneration of stable transformants, it is likely to make the recovery of 
homozygous lines for the expression of multiple proteins much easier.  
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Work on the expression of BTV particles was complicated by the lack of commercially 
available antibody and positive controls. Obtaining functional antibodies would allow 
several key experiments to be performed in the future, including Western blots, 
immunogold labelling of VP2 and VP5 to prove that VLP contain both outer shell proteins, 
and ELISA to quantify the produced proteins and particles. Antibody production in sheep 
is underway using the plant-produced VLP described in Chapter 6. I hope that the 
resulting antisera will be used to show production of virus-neutralizing antibodies, a key 
indication of efficacy as a vaccine. These will also be an invaluable tool for further BTV 
research by collaborators in South Africa. Furthermore, an efficacy trial using sheep has 
been planned by a company in South Africa to test both the plant-produced VLP and CLP 
for induction of protective immunity against Bluetongue disease. Particle aliquots are 
ready and awaiting shipping permit approval. The particles produced here are 
morphologically and stoichiometrically equivalent to insect cell-produced VLP, and I 
expect them to be just as effective. It may be worth investigating a possible oral 
vaccination strategy which would greatly facilitate immunization of large animal herds.  
The ability to produce relatively homogeneous BTV VLP preparations using the CPMV-
HT system led me to consider other applications for these particles, in addition to their 
use as a vaccine. It had already been shown that fluorescent CLPs of BTV could be 
produced in insect cells by way of fusing GFP to the N-terminus of VP3 (Kar et al., 2005). 
This fusion protein was used to track the intracellular localization of VP3 in insect cells 
expressing other BTV proteins. However, the fluorescent particles have not been used in 
basic research into the infection cycle of BTV. This is likely due to the instability of these 
particles and the inability to produce full fVLP with an intact VP2 and VP5 layer. Using the 
CPMV-HT system, it has been possible to produce such fluorescent VLP, which resemble 
the wild type VLPs in size and appearance under the TEM. Particles which contain the pH 
stable fluorescent proteins T-Sapphire and mRuby have also been produced. These 
particles are being used in a collaborative project with Drs. Terry Jackson and Sarah Gold 
at the Institute for Animal Health (Pirbright, UK) to study BTV cell attachment, 
internalization and disassembly in mammalian cells. By labelling the outer shell with a 
fluorescent dye, it should be possible to track virus entry as well as the disassembly of the 
outer shell and egress of the core particle into the cytoplasm of the infected cell. Such a 
system would allow easy monitoring of any effects of selective mutation of host or virus 
factors playing a role in internalization, thereby providing new insight into the process of 
BTV infection. This may also be applied to the insect vector. In the plant system, it would 
also be interesting to co-express a tonoplast-targeted BTV NS3 protein with the 
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fluorescent particles, which may allow the particles to “egress” into the plant cell vacuole. 
If this were possible, it could be used as a model system to study the factors involved in 
viral egress. 
Encapsidation of epitopes on the inside of BTV core-like particles has been shown to 
elicit an immune response against these foreign peptides (Tanaka et al., 1995). The design 
of the GFP:VP3 fusion construct used here allows the gfp sequence to be easily replaced 
by other genes. Therefore, it should be straightforward to produce BTV particles with 
other foreign epitopes or whole proteins encapsidated on the inside, for use as vaccines. 
Such chimaeric virus-like particles with a full complement of VP5 and VP2 would likely be 
stronger immunogens than the core-like particles produced previously, due to their 
ability to bind mammalian cells and to be internalized. With the recent publication of 
detailed structural data for VP2 and VP5 (Zhang et al., 2010), it may be possible to design 
fusion proteins for the display of targeting peptides on the outer surface of BTV particles, 
further increasing their versatility.  
The experiments with GFP-tagged VP3 presented here show that the display of GFP on 
the inside of BTV does not greatly alter the BTV particle surface properties, allowing them 
to be purified using the established protocols for untagged particles. This is in stark 
contrast to the GFP-displaying tHBcAg particles which required protocol optimization to 
allow recovery of even a small fraction of the particles. The ability to use a universal 
downstream-processing procedure for the purification of an array of different epitope-
displaying VLPs is a great advantage. Assuming that BTV-like particles can elicit a strong, 
protective immune response against a foreign peptide displayed on their inside, I would 
argue that these particles could rival hepatitis B cores in their use as a versatile epitope 
carrier.  
The work presented in this thesis provides a significant step forward in the 
establishment of plants as an alternative platform for VLP production. VLPs are a newly 
established vaccine technology, and though their efficacy and superior safety are widely 
accepted, the high cost of production associated with the cell culture systems used in 
their production has limited their use to economically important human diseases. Here, I 
have shown that the CPMV-HT system in conjunction with the newly developed pEAQ 
vectors is the ideal system for the production of highly complex heteromeric VLPs in plant 
tissue, showing that the system can rival traditionally used insect cell systems in its 
versatility. If acceptance of plant-based expression systems as a cheaper alternative can 
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be raised, the presented system has the potential to make VLP technology a more widely 
viable vaccine strategy to combat other human and veterinary diseases.  
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APPENDIX A: TABLE OF CONSTRUCTS 
 Name Encoded proteins GW Binary 5’-UTR Notes 
Ch
ap
te
r 3
 
pENTR-ET2 GFP x  HT  
pDEST-BINPLUS none x x n/a  
pDEST-BINPLUS-GFP GFP x x wt Co-infiltrate 
pBIN61-P19 
pDEST-BINPLUS-GFP-HT GFP x x HT Co-infiltrate 
pBIN61-P19 
pBINPLUS-GFP GFP  x wt Co-infiltrate 
pBIN61-P19 
pBINPLUS-GFP-HT GFP  x HT Co-infiltrate 
pBIN61-P19 
pBD-FSC2-GFP-HT GFP  x HT Co-infiltrate 
pBIN61-P19 
pEAQbeta GFP  x HT Co-infiltrate 
pBIN61-P19 
pEAQ-GFP-HT GFP  x HT Co-infiltrate 
pBIN61-P19 
pEAQ-HT (NPTII, P19)  x HT  
pEAQexpress-GFP-HT GFP (P19)  x HT “pEAQex” 
pEAQselectK-GFP-HT GFP (NPTII)  x HT Co-infiltrate 
pBIN61-P19 
pEAQspecialK-GFP-HT GFP (NPTII, P19)  x HT  
pEAQ-HT-DEST-1 (NPTII, P19) x x HT untagged 
pEAQ-HT-DEST-2 (NPTII, P19) x x HT N-term His 
pEAQ-HT-DEST-3 (NPTII, P19) x x HT C-term His 
pEAQ-GW-GFP GFP (NPTII, P19) x x HT  
pEAQ-GW-HisGFP His-GFP (NPTII, P19) x x HT  
pEAQ-GW-GFPHis GFP-His (NPTII, P19) x x HT  
pEAQ-GW-GFP-Stop GFP (NPTII, P19) x x HT  
pEAQ-HT-EYFP YFP (NPTII, P19)  x HT  
pEAQ-HT-ECFP CFP (NPTII, P19)  x HT  
pEAQex-EYFP-ECFP YFP, CFP (P19)  x HT  
Ch
ap
te
r 4
 
pEAQ-HT-HBcΔ176 HBcΔ176 (NPTII, P19)  x HT  
pEAQ-HT-CoHe7e-empty CoHe7e-empty (NPTII, 
P19) 
 x HT  
pEAQ-GW-CoHo7e-empty CoHo7e-empty (NPTII, 
P19) 
x x HT  
pEAQ-GW-CoHe7e-sAg CoHe7e-sAg (NPTII, 
P19) 
x x HT  
pEAQ-HT-CoHo7e-sAg CoHo7e-sAg (NPTII, 
P19) 
 x HT  
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 Name Encoded proteins GW Binary 5’-UTR Notes 
Ch
ap
te
r 4
 –
 H
ep
at
it
is
 B
 
pEAQ-GW-CoHe7e-sAg,eGFP CoHe7e-sAg,eGFP 
(NPTII, P19) 
x x HT  
pEAQ-GW-CoHo7e-sAg,eGFP CoHo7e- sAg,eGFP 
(NPTII, P19) 
x x HT  
pEAQ-HT-CoHe7e-eGFPs CoHe7e-eGFPs (NPTII, 
P19) 
 x HT  
pEAQ-HT-CoHe7e-eGFPs CoHe7e-eGFPs (NPTII, 
P19) 
 x HT  
pDEST-BD-CoHe7e-eGFPL CoHe7e-eGFPL (NPTII) x x HT Co-infiltrate 
pBIN61-P19 
pDEST-BD-CoHo7e-HAVP1 CoHo7e-HAVP1 (NPTII) x x HT Co-infiltrate 
pBIN61-P19 
Ch
ap
te
r 5
 –
 B
TV
-1
0 
pDEST-BD-BTV10.3 BTV-10 VP3 (NPTII) x x HT Co-infiltrate 
pBIN61-P19 
pDEST-BD-BTV10.7 BTV-10 VP7 (NPTII) x x HT Co-infiltrate 
pBIN61-P19 
pDEST-BD-BTV10.3-His BTV-10 VP3-His (NPTII) x x HT Co-infiltrate 
pBIN61-P19 
pDEST-BD-BTV10.7-His BTV-10 VP7-His (NPTII) x x HT Co-infiltrate 
pBIN61-P19 
pEAQ-HT-BTV10.2 BTV-10 VP2 (NPTII, P19)  x HT  
pEAQ-HT-BTV10.2-His BTV-10 VP2-His (NPTII, 
P19) 
 x HT  
pEAQ-HT-BTV10.5 BTV-10 VP5 (NPTII, P19)  x HT  
pEAQ-HT-BTV10.5-His BTV-10 VP5-His (NPTII, 
P19) 
 x HT  
pEAQ-HT-BTV10.NS1 BTV-10 NS1 (NPTII, P19)  x HT  
pEAQ-HT-BTV10.NS1-His BTV-10 NS1-His (NPTII, 
P19) 
 x HT  
Ch
ap
te
r 6
 –
 B
TV
-8
 
pEAQ-HT-BTV8.2 BTV-8 VP2 (NPTII, P19)  x HT  
pEAQ-HT-BTV8.2co BTV-8 VP2co (NPTII, 
P19) 
 x HT codon optimized 
pEAQ-HT-BTV8.3 BTV-8 VP3 (NPTII, P19)  x HT  
pEAQ-HT-BTV8.3co BTV-8 VP3co (NPTII, 
P19) 
 x HT codon optimized 
pEAQ-HT-BTV8.5 BTV-8 VP5 (NPTII, P19)  x HT  
pEAQ-HT-BTV8.5co BTV-8 VP5co (NPTII, 
P19) 
 x HT codon optimized 
pEAQ-HT-BTV8.7co BTV-8 VP7co (NPTII, 
P19) 
 x HT codon optimized 
pEAQ-GW-BTV8.NS3 BTV-8 NS3 (NPTII, P19) x x HT  
pEAQex-BTV8.5co-BTV8.2co BTV-8 VP5co, BTV-8 
VP2co (P19) 
 x HT codon optimized 
pEAQex-BTV8.7co-BTV8.3co BTV-8 VP7co, BTV-8 
VP3co (P19) 
 x HT codon optimized 
pEAQex-BTV8.7-BTV8.3 BTV-8 VP7, BTV-8 VP3 
(P19) 
 x HT  
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 Name Encoded proteins GW Binary 5’-UTR Notes 
Ch
ap
te
r 6
 pEAQex-BTV8-52co73 BTV-8 VP5co, BTV-8 
VP2co, BTV-8 VP7, BTV-
8 VP3 (P19) 
 x HT ½ codon 
optimized, ½ 
wild-type 
pEAQex-BTV8co-7HT-3 BTV-8 VP7co, BTV-8 
VP3co (P19) 
 x  VP7 is HT, VP3 is 
wt 
Ch
ap
te
r 7
 –
 fl
uo
re
sc
en
t B
TV
 
pEAQ-HT-GFP:BTV8.3co BTV8 GFP:VP3co fusion 
(NPTII, P19) 
 x HT  
pEAQ-GFP:BTV8.3co BTV8 GFP:VP3co fusion 
(NPTII, P19) 
 x wt  
pEAQ-mRuby:BTV8.3co BTV8 mRuby:VP3co 
fusion (NPTII, P19) 
 x wt  
pEAQ-Sapphire:BTV8.3co BTV8 mT-
Sapphire:VP3co fusion 
(NPTII, P19) 
 x wt  
pEAQ-GFP GFP (NPTII, P19)  x wt  
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APPENDIX B: SEQUENCES OF CODON-OPTIMIZED BTV8 GENES 
The following sequences were codon-optimized for expression in N. benthamiana and 
synthesized by GeneArt AG. Start codons are highlighted in green, stop codons are 
highlighted in red. The restriction sites used for cloning into pEAQ-HT, namely AgeI and 
XhoI
 
, are underlined in orange and blue, respectively. 
BTV-8 VP2co 
 
       1 TTAATTAATC GCGACCGGT
      51 ACGTTTTCCC AGCTGAGCTT CTTGATGGAT ACGATTACAT CATCGATGTT 
A TGGAAGAACT CGCTATCCCA ATCTACACTA 
     101 TCTTCTAGGG TTGAAGAAGA AGGCGACGAG CCAGTTAAGA GGCATGATGT 
     151 GACTGAGATT CCTAGGAACT CCATGTTCGA TATCAAGGAT GAGCACATCA 
     201 GGGATGCTAT TATCTACAAG CCAGTGAACA ACGATGGATA CGTTTTGCCA 
     251 AGGGTGCTCG ATATTACTCT CAAGGCTTTC GATGATAGGA AGCGTGTTGT 
     301 TCTTAACGAT GGACACTCTG AGTTTCACAC TAAGACTAAC TGGGTGCAGT 
     351 GGATGATTGA TGATGCTATG GATGTGCAGC CACTCAAAGT TGATATTGCT 
     401 CACACTAGGT CTAGGATTTC TCACGCTCTC TTCAATTGCA CTGTGAGGCT 
     451 TCATTCTAAG AAGGCTGATA CTGCTTCTTA TCACGTTGAG CCAGTGGAAA 
     501 TTGAATCTTG GGGATGCAAT CACACTTGGC TTTCTAGGAT TCACCACCTT 
     551 GTTAACGTTG AGCTTTTCCA CTGTTCTCAA GAGGCTGCTT ACACTCTTAA 
     601 GCCAACTTAC AAGATCATTT CCAACGCTGA AAGGGCTTCT ACTTCCGATT 
     651 CTTTCAACGG AACTATGATC GAGCTTGGTA GGAATCATCA GATCCAGATG 
     701 GGAGATCAAG GATACCAGAA GCTTAAAGAG GGACTTGTTC AGGTTAGAAT 
     751 CGAGGGAAAG ACTCCACTTG TTATCCAGGA AGAGATCACT GCTCTCAACA 
     801 AGATTCGTGA GCAATGGATT GCTAGGAATT TCGATCAGCG TGAGATTAAG 
     851 GTTTTGGATT TGTGCAGGCT TCTTTCAACT ATCGGTAGGA AGATGTGCAA 
     901 TACTGAAGAG GAACCTAAGA ACGAGGCTGA TCTTTCTGTT AAGTTCCAGA 
     951 TGGAACTCGA TGAGATTTTC AGGCCAGGAA ATAACGAGAG GACTAACATT 
    1001 ATGGGAGGTG GAGTTCATAG AAAGAACGAG GACAGGTTCT ACGTGCTCAT 
    1051 TATGATTGCT GCTTCCGATA CAAACAAGGG AAGGATTTGG TGGTCTAATC 
    1101 CATATCCATG TCTTAGGGGT GCTCTTATTG CTGCTGAGGT TCAGCTTGGA 
    1151 GATGTGTACA ACCTTCTCCG TAATTGGTTC CAATGGTCTG TTAGGCCAAC 
    1201 TTACGTTCCA TACGATAGGA ACAGAGAGTC CGATAAGTAC ATCTACTCCA 
    1251 GGATCAACCT TTTCGATTCT ACTCTTAGGC CAGGTGATAA GATTGTGCAC 
    1301 TGGGAGTACA AGCTTTTGAA CGAGGTTAGA GAGGTGTCAA TCAACAAGGG 
    1351 AAACGAGTGT GATTTGTTCC CAGAGGATGA AGAGTTCACT ACTAAGTTCC 
    1401 ATGAGGCTAG GTATACTGAG ATGAAGAACC AGATTATTCA GTCTGGATGG 
    1451 AACCAGAGGG ATTTCAAGAT GCACAAGATC CTTGAGGATG GTGCTAACGT 
    1501 GCTCACAATC GATTTTGAGA AGGATGCTCA CATTGGAACT GGATCTGCTC 
    1551 TTTCTCTCCC TGATTACTAC AACAAGTGGA TTATCGCTCC AATGTTCAAC 
    1601 GCTAAGCTCA GGATTACTGA GGTTGTGATT GGAACTGCTC ACACTGATGA 
    1651 TCCAGCTGTT GGAAGATCTG CTAAGGCTTT CACTCACGAT CCATTCGATC 
    1701 TTCAAAGGTA CTGTCTCGCT AGGTATTATG ATGTTAGGCC AGGAATGATG 
    1751 GGTAGAGCTT TGTCTAAGCA GCAGAATATG TCCTCCATGA CTGATAAGCT 
    1801 TTCCAAGCAA GAGGATTACG CTGGAATTGT GTCAAGAAGG CTTGAGTACA 
    1851 AAGAGAGAGA GAACCGTTGT CTTACTGAGA CTGCTCAGTA CGTTTTCGAA 
    1901 AAGACTTGCC TCTACGTTTT GGAGCTTCTT TCTAGGCATA CAATGCCATC 
    1951 TGAGGATTCT GAAGTGACTT TCGAGCACCC AACTATTGAT CCATCTGTGG 
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    2001 ATATCGAGAC TTGGAAGATC ATTGATGTGT CCCAGCTCAT TATCTTCGTG 
    2051 TTCGATTACC TTTTCGAGAA CCGTAAGATC GTTAGGGATA CAACTGAAGC 
    2101 TAGGTGGACT CTTTTCAAGA TTAGGTCTGA GGTTGGAAGG GCTAGGATTG 
    2151 ATGCTATCGA GATGACTTTT CCAAGGTTCG GAAGGATGCT TAGGAATGCT 
    2201 TCTCAGGCTA AGATCAACCA GGATATCGCT TGCCTTAACT TCCTTCCACT 
    2251 CCTCTTCATT ATCGGTGATA ACATCTCTTA CGCTCATAGG CAATGGTCTA 
    2301 TTCCAGTGCT TCTTTACGCT CACGATATCA GGATTATCCC ACTTGAGGTT 
    2351 GGAGCTTACA ATAACAGGTT CGGACTTACT TCTTACCTTG AGTACATGGC 
    2401 TTTCTTCCCA TCTTATGCTA CTAGGGTGGC AAAGATTGAT GAGTCCATCA 
    2451 AAGAGTGCGC TATTGCTATG GCTGAGTTCT ACATGAACAC TGATATTCAC 
    2501 TCTGGATCCG TGATGTCTAA CGTGATCACT ACTAAGAGGC TTCTCTACGA 
    2551 GACTTACCTT GCTTCTCTTT GCGGTGGATA CTCTGATGGA CTTCTCTGGT 
    2601 ACTTGCCAAT TACTCACCCA TCTAAGTGCC TTGTTGCTTT CGAAGTTGCT 
    2651 GATGATGTTG TGCCACTTTC TGTTAGAAGA GAGAGGATTC TTTCTAGGTT 
    2701 CCCACTTTCT TCAAGGCACG TGAAGGGAAT TGCTCTTATT TCCGTGGATA 
    2751 GGAACCAGAA AGTTTCTGTT CAGACTGAGG GAATTGTGAC TCATAGGCTC 
    2801 TGCAAGAAGA ACCTTCTCAA GTACGTTTGT GATGTGATCC TCTTCAAGTT 
    2851 CTCTGGTCAC GTTTTCGGAA ACGATGAGAT GCTTACTAAG CTCCTCAACG 
    2901 TTTGACTCGA G
 
GCCTGGCGC GCC 
 
BTV-8 VP3co 
 
       1 TTAATTAATC GCGACCGGT
      51 GGATTAAGAC TACTCCATAC CTTGAGGGTG ATGTGCTTTC TTCTGATTCT 
A TGGCTGCTCA AAATGAGCAA AGGCCAGAGA 
     101 GGACCACTTC TTTCTGTTTT CGCTCTCCAA GAGATTATGC AGAAGGTTAG 
     151 GCAAGTTCAG GCTGATTACA TGACTGCTAC TAGGGAAGTT GATTTCACTG 
     201 TTCCAGATGT GCAGAAAATC CTCGATGATA TCAAGGCTCT TGCTGCTGAG 
     251 CAAGTGTACA AGATTGTGAA GGTGCCATCC ATTTCTTTCA GGCACATTGT 
     301 GATGCAATCT AGGGATAGGG TTCTCAGAGT GGATACTTAC TACGAAGAGA 
     351 TGTCTCAGGT TGGAGATGTG ATTACTGAAG ATGAGCCAGA GAAGTTCTAC 
     401 TCCACTATCA TCAAGAAGGT GAGATTCATT AGGGGAAAGG GATCTTTCAT 
     451 TCTCCACGAT ATCCCAACTA GAGATCACAG AGGAATGGAA GTTGCTGAGC 
     501 CAGAAGTTCT TGGAGTTGAG TTCAAGAATG TGCTTCCAGT TCTTACTGCT 
     551 GAACACAGGG CTATGATTCA GAATGCTCTC GATGGATCTA TTATCGAGAA 
     601 CGGAAACGTT GCAACTAGGG ATGTGGATGT GTTTATTGGA GCTTGCTCTG 
     651 AGCCAATCTA CAGGATCTAC AACAGGCTTC AGGGATATAT TGAGGCTGTT 
     701 CAGCTTCAAG AACTCAGGAA CTCTATTGGT TGGCTTGAAA GGCTTGGACA 
     751 GAGGAAGAGG ATTACTTACT CTCAAGAGGT GCTCACTGAT TTTAGAAGGC 
     801 AGGATACAAT TTGGGTTTTG GCTCTCCAGC TTCCAGTTAA CCCACAAGTT 
     851 GTTTGGGATG TTCCAAGGTC CTCTATTGCT AACCTCATCA TGAACATTGC 
     901 TACTTGCCTT CCAACTGGTG AGTACATTGC TCCAAACCCA AGGATTTCTT 
     951 CCATTACTCT CACTCAGAGG ATCACTACTA CTGGACCATT CGCTATTCTT 
    1001 ACTGGATCTA CTCCAACTGC TCAGCAGCTT AACGATGTGA GGAAGATCTA 
    1051 CCTTGCTCTT ATGTTCCCAG GACAGATTAT TCTCGATCTC AAGATCGATC 
    1101 CAGGTGAAAG AATGGATCCA GCTGTTAGAA TGGTTGCTGG TGTTGTTGGA 
    1151 CACCTTCTTT TTACTGCTGG TGGAAGGTTC ACTAACCTCA CACAGAATAT 
    1201 GGCTAGGCAG CTTGATATTG CTCTCAACGA TTACCTCCTC TATATGTACA 
    1251 ACACTAGGGT TCAGGTTAAC TATGGACCAA CTGGTGAACC ACTCGATTTT 
    1301 CAGATTGGTA GGAACCAGTA CGATTGCAAT GTTTTCAGGG CTGATTTCGC 
    1351 TACTGGAACT GGATACAATG GATGGGCTAC TATTGATGTG GAGTACAGAG 
    1401 ATCCAGCTCC ATATGTTCAT GCTCAGCGTT ACATTAGGTA CTGCGGAATT 
    1451 GATTCTAGGG AACTCATCAA CCCAACTACT TACGGAATCG GAATGACTTA 
    1501 CCACTGCTAC AATGAGATGC TTAGGATGCT TGTTGCTGCT GGAAAGGATT 
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    1551 CTGAGGCTGC TTACTTCAGA TCTATGCTCC CATTCCACAT GGTTAGGTTC 
    1601 GCTAGGATTA ACCAGATCAT CAACGAGGAT CTTCACTCTG TTTTCTCCCT 
    1651 CCCTGATGAT ATGTTCAACG CTCTCCTTCC TGATCTTATT GCTGGTGCTC 
    1701 ATCAGAATGC TGATCCAGTT GTGCTTGATG TGTCTTGGAT TTCTCTCTGG 
    1751 TTCGCTTTCA ACAGATCTTT CGAGCCAACT CATAGGAATG AGATGTTGGA 
    1801 GATTGCTCCA CTTATTGAGT CTGTGTACGC TTCTGAGCTT TCTGTTATGA 
    1851 AGGTGGACAT GAGGCACCTT TCACTTATGC AAAGGCGTTT CCCAGATGTT 
    1901 CTTATTCAAG CTAGGCCATC CCATTTTTGG AAGGCTGTGC TTAATGATTC 
    1951 TCCAGAGGCT GTTAAGGCTG TGATGAACCT TTCTCACTCC CACAACTTCA 
    2001 TCAACATCAG GGATATGATG AGATGGGTTC TCCTTCCATC TCTTCAACCA 
    2051 TCTCTTAAGC TTGCTCTTGA AGAAGAAGCT TGGGCTGCTG CTAATGATTT 
    2101 CGAGGATCTC ATGCTTACTG ATCAGGTTTA CATGCACAGG GATATGCTTC 
    2151 CAGAACCTAG GCTTGATGAT ATTGAGAGGT TCAGGCAAGA GGGATTCTAC 
    2201 TACACTAACA TGCTTGAAGC TCCACCAGAA ATTGATAGGG TGGTGCAGTA 
    2251 CACTTATGAG ATTGCTAGGC TCCAAGCTAA TATGGGACAA TTCAGGGCTG 
    2301 CTCTTAGGCG TATTATGGAT GATGATGATT GGGTTAGGTT CGGAGGTGTT 
    2351 CTTAGAACTG TGAGGGTGAA GTTTTTTGAT GCTAGGCCAC CAGATGATAT 
    2401 TCTTCAGGGA CTCCCATTCT CTTACGATAC AAACGAGAAG GGTGGACTTT 
    2451 CTTACGCTAC TATCAAGTAC GCTACTGAGA CTACTATCTT CTACCTCATC 
    2501 TACAACGTGG AGTTCTCTAA CACTCCAGAT TCTCTCGTGC TCATCAACCC 
    2551 TACTTACACT ATGACTAAGG TGTTCATCAA CAAGAGAATT GTGGAGAGAG 
    2601 TTAGGGTTGG ACAGATTCTT GCTGTGCTTA ACAGGCGTTT CGTTGCTTAT 
    2651 AAGGGAAAGA TGAGGATCAT GGATATTACT CAGTCCCTCA AGATGGGAAC 
    2701 TAAGCTTGCT GCTCCAACTG TTTAACTCGA G
 
GCCTGGCGC GCC 
 
BTV-8 VP5co 
 
       1 TTAATTAATC GCGACCGGT
      51 TCGGAAAGAA GGTTGGAAAC GCTCTTACTT CCAACACTGC TAAGAAGATC 
A TGGGAAAGAT TATTAAGTCC CTCTCAAGGT 
     101 TACTCCACTA TTGGAAAGGC TGCTGAGAGA TTTGCTGAGT CTGAGATTGG 
     151 ATCCGCTGCT ATTGATGGAC TTGTTCAGGG ATCTGTGCAC TCTCTTATGA 
     201 CTGGTGAGTC TTACGGTGAG TCTGTTAAGC AAGCTGTGCT TCTTAACGTT 
     251 ATGGGATCTG GTGAAGAACT TCCAGATCCA CTTTCTCCAG GTGAAAGGGG 
     301 AATGCAGACT AAGATTCGTG AACTTGAGGA TGAACAGAGG AACGAGCTTA 
     351 TTAGGCTCAA GTACAACGAT AAGATCAAGC AGAAGTTCGG AAAAGAGCTT 
     401 GAAGAGGTTT ACGAGTTCAT GAACGGTGTT GCTAAGCAAG AGGAAGATGA 
     451 AGAGAAGCAC TACGATGTGC TTAAGAAGGC TGTTAACTCC TACGATAAGA 
     501 TCCTTACTGA GGAAGAGAAG CAGATGAGGA TTCTTGCTAC TGCTCTCCAG 
     551 AAAGAGGTGA AAGAAAGGAC TGGAACTGAG GCTGTTATGG TGAAAGAGTA 
     601 CAGGAACAAG ATCGACGCTC TCAAAGAGGC TATTGAGGTT GAAAGGGATG 
     651 GAATGCAGGA AGAAGCTATC CAAGAGATCG CTGGAATGAC TGCTGATGTT 
     701 CTTGAAGCTG CTTCTGAAGA GGTTCCACTT ATTGGAGCTG GAATGGCTAC 
     751 TGCTGTTGCT ACTGGAAGGG CTATTGAGGG AGCTTACAAG CTTAAGAAGG 
     801 TGATCAACGC TCTTTCTGGA ATTGATCTCA CTCACCTCAG GACTCCAAAG 
     851 ATTGAGCCAA CTATCGTGTC TACTGTGCTC GATCACAAGT TCAAGGATAT 
     901 CCCAGATGAG ATGCTTGCTG TGTCTGTGCT TTCTAAGAAT AGGGCTATCG 
     951 AAGAGAACCA CAAAGAGATC ATCCACCTCA AGAACGAAAT TCTCCCAAGG 
    1001 TTCAAGAAAG CTATGGATGA AGAGAAAGAG ATTTGCGGAA TCGAGGATAA 
    1051 GAAGATCCAC CCAAAGGTTA TGATGAAGTT CAAGATCCCA AGGACTCAAC 
    1101 AACCACAGAT TCACATCTAT TCCGCACCTT GGGATTCTGA TGATGTGTTC 
    1151 TTCTTCCACT GCATTTCTCA TCATCACGCT AACGAGTCTT TCTTCATCGG 
    1201 ATTCGATCTT GGAATTGATT TGGTGCACTA CGAGGATCTT ACTGCTCATT 
    1251 GGCATGCTCT TGGAGCTGCT CAAGCTGCTG TTGGAAGATC TCTTAACGAG 
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    1301 GTGTACAAAG AGTTCCTTAA CCTCGCTATC AACAACACTT ACTCCTCTCA 
    1351 AATGCACGCT AGAAGGATGA TTAGGTCCAA GACTGTTCAC CCAATCTACC 
    1401 TTGGATCTCT CCACTACGAT ATCTCATTCT CTACTCTCAG GTCTAATGCT 
    1451 CAGAGGATTG TGTACGATGA GGAACTTCAG ATGCACATTC TTAGGGGACC 
    1501 ACTTCATTTT CAGAGAAGGG CTATTCTCGG AGCTATTAAG CACGGTGTGA 
    1551 AGATTCTTGG AACTGAAGTG GATATTCCAC TCTTCCTTAG GAACGCTTGA 
    1601 CTCGAG
 
GCCT GGCGCGCC 
 
BTV-8 VP7co 
 
       1 TTAATTAATC GCGACCGGT
      51 TTATGAGAGC TTGCGCTACT CTTCAAGAGG CTAGGATTGT GCTTGAGGCT 
A TGGATACAAT TGCTGCTAGG GCTCTTACTG 
     101 AACGTGATGG AAATTCTCGG AATCGCTATC AATAGGTACA ACGGACTTAC 
     151 TCTTAGGGGT GTTACTATGA GGCCAACTTC TCTTGCTCAG AGGAACGAGA 
     201 TGTTCTTCAT GTGCCTCGAT ATGATGCTTT CTGCTGCTGG TATTAACGTG 
     251 GGACCAATCT CTCCAGATTA CACTCAGCAC ATGGCTACTA TTGGAGTTCT 
     301 TGCTACTCCA GAGATCCCTT TTACTACTGA GGCTGCTAAT GAGATTGCTA 
     351 GGGTGACAGG TGAAACTTCT ACTTGGGGAC CAGCTAGACA ACCATACGGA 
     401 TTTTTCTTGG AGACTGAAGA GACTTTTCAA CCAGGACGTT GGTTTATGAG 
     451 AGCTGCTCAA GCTGTTACTG CTGTTGTTTG CGGACCAGAT ATGATTCAGG 
     501 TGTCCCTTAA TGCTGGTGCT AGAGGTGATG TTCAGCAGAT TTTCCAGGGT 
     551 AGGAACGATC CAATGATGAT CTACCTTGTG TGGAGAAGGA TTGAGAATTT 
     601 CGCTATGGCT CAGGGAAATT CTCAACAAAC TCAGGCTGGT GTTACTGTTT 
     651 CTGTTGGAGG TGTTGATATG AGAGCTGGAA GGATTATTGC TTGGGATGGA 
     701 CAAGCTGCAC TTCATGTTCA TAACCCAACT CAGCAGAATG CTATGGTTCA 
     751 GATTCAGGTG GTGTTCTACA TCTCTATGGA TAAGACTCTC AACCAGTACC 
     801 CAGCTCTTAC TGCTGAGATC TTCAACGTTT ACTCCTTCAG GGATCATACT 
     851 TGGCATGGAC TCAGGACTGC TATTCTCAAC AGGACTACTC TTCCAAATAT 
     901 GCTCCCACCA ATCTTCCCAC CAAACGATAG GGATTCTATC CTTACTTTGC 
     951 TCCTTCTTAG CACTCTTGCT GATGTGTACA CTGTTCTTAG GCCAGAGTTC 
    1001 GCTATTCATG GTGTTAATCC AATGCCAGGA CCACTTACTA GAGCTATTGC 
    1051 TAGGGCTGCT TATGTGTGAC TCGAG
 
GCCTG GCGCGCC 
APPENDIX C 
 
245 
 
APPENDIX C: PUBLICATION OF PEAQ VECTORS 
The pEAQ vector series developed as part of this thesis has been published: 
Sainsbury, F.*, Thuenemann, E.C.*, and Lomonossoff, G.P. (2009). pEAQ: versatile 
expression vectors for easy and quick transient expression of heterologous proteins in 
plants. Plant Biotechnology Journal 7, 682-693. 
* These authors contributed equally to the work. 
